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Growth Hormone (GH), a major regulator of normal growth and metabolism, regulates 
diverse physiological processes through regulation of specific target genes. A key 
activator of GH-regulated genes is Signal Transducer and Activator of Transcription 
(Stat) 5.  However, mechanisms by which GH regulates transcriptional repression are 
poorly understood. A profile of GH-regulated genes in 3T3-F442A adipocytes identified 
the potent transcriptional repressor Bcl6 (B-cell lymphoma 6) as a novel GH-responsive 
molecule.  Further, the gene for Socs2 (Suppressor Of Cytokine Signaling 2) is strongly 
inhibited by Bcl6, while Socs2 activation by GH is mediated by Stat5. Chromatin 
immunoprecipitation (ChIP) showed that endogenous Bcl6 occupies the Socs2 promoter 
in the absence of GH, and occupancy decreases with GH treatment, while Stat5 
occupancy increases reciprocally.   
 
To examine the reciprocal relationship between the repressor Bcl6 and the activator 
Stat5, we evaluated their genome-wide occupancy by ChIP-Sequencing in GH-
responsive 3T3-F442A adipocytes, revealing over 3000 regions of occupancy for Bcl6 
and over 900 for Stat5. Among these, gene ontology analysis of potential Bcl6 target 
genes identified genes involved in growth, differentiation, metabolism, and signaling.  
 
Reciprocal occupancy of Bcl6 and Stat5 was observed not only on the Socs2 promoter, 
but also on the Cish (Cytokine-inducible SH2-containing protein) and Bcl6 gene 
promoters.  However, Socs2 and Cish are stimulated by GH while Bcl6 is inhibited by 
GH.  Analysis of transcription co-regulators suggests regulatory differences among these 
genes:  p300 and Hdac3 (Histone deacetylase 3) occupied the Bcl6/Stat5 regulatory 
sequences of Socs2, Cish and Bcl6 constitutively.  Promoter activation assays show that 
p300 co-activates Stat5-mediated induction of Socs2 and Cish expression, while Hdac3  
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functions as a co-repressor.  In contrast, both p300 and Hdac3 may function as co-
repressors when regulating Bcl6 expression.   
 
This work provides insight into novel roles for Bcl6 in GH action, and mechanisms of 
transcriptional regulation involving reciprocal relationships by activating and repressing 






Transcription and transcription factors: Activation and repression of gene 
expression 
 
Transcription is the synthesis of RNA from DNA, and is the first step leading towards 
gene expression. Regulation of this process by various mechanisms is what allows cells 
to respond specifically to internal and environmental cues. The activation or repression of 
specific sets of target genes at the right time or in the right location allows the cells to 
adapt, counter, change, or develop as needed for the survival of the cell or the organism. 
Over the years, it has become clear that the important biological process of transcription 
is regulated at multiple levels, such as by the location of the gene on the chromosome (1, 
2), the structure of the nearby chromatin (3), the availability and functional state of the 
transcription factors and their associated coregulatory proteins (4-6), to the structure, 
sequence, or export of the transcribed RNA sequence itself (7, 8). However, much of 
gene expression is controlled at the level of transcription initiation. For the process of 
transcription initiation, expression of a gene is mostly dependent on the cis-regulatory 
elements comprised of the regulatory DNA sequences of the gene and the trans-acting 
protein factors that interact with specific cis-acting elements to initiate or inhibit 
transcription. 
 
Transcription factors are proteins that bind to specific DNA sequences to regulate 
transcription of a gene (9-11). These proteins contain one or more DNA binding domains 
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and a transactivating (transcription activation) domain. Transcription factors often also 
contain one or more regulatory domains, which can interact with other proteins to convey 
regulatory signals. DNA binding domains recognize and associate with specific DNA 
sequences, usually near the genes they regulate, and serve to locate the transcription 
factor in a position from which the activation domain can regulate transcription. Recent 
work has also shown that DNA sequences regulating gene transcription can be located 
quite far from the target gene, in the case of enhancer elements (12, 13), and in some 
cases can be located on a different chromosome altogether (14). Often, a gene will have 
multiple regulatory sequences for different transcription factors, and transcription of the 
gene depends on the net effects of several transcription factors and their associated 
proteins. Transcription activation domains interact with the transcriptional machinery, 
consisting of general transcription factors and RNA polymerase II (RNA pol II) (15), and 
stimulate the initiation and elongation steps of transcription (16). Transcription factors 
that activate expression of a gene are known as transcription activators, while 
transcription factors that serve to inhibit gene expression are transcription repressors.  
 
Transcription factors can use various mechanisms to regulate expression of a target gene 
(17, 18). These mechanisms include stabilizing or inhibiting the binding of RNA pol II to 
DNA, and the recruitment of coregulatory protein factors to the transcriptional regulatory 
protein complex. Coregulatory proteins can aid in the activation or repression of 
transcription by modifying the activity of associated transcription factors, mediating the 
further recruitment of nuclear regulatory proteins, stabilizing or destabilizing associations 
with the general transcriptional machinery, or modifying the structure and accessibility of 
the surrounding chromatin. 
 
The activity of transcription factors can also be regulated by multiple mechanisms. Some 
of these include the synthesis of the transcription factor, cellular localization of the 
transcription factor, and activation of the transcription factor by ligand binding, post-
translational modification, or interaction with other transcription factors or coregulatory 
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proteins. The activity of many transcription factors is regulated by a combination of 
several mechanisms. For example, the activity of the growth hormone (GH)-regulated 
transcription factor C/EBP! (CCAAT/enhancer binding protein beta) can be regulated by 
both activating and repressive phosphorylation events, protein acetylation, cellular 
localization, and interactions with C/EBP!-associated nuclear proteins (19). 
 
This thesis describes the novel growth hormone (GH)-regulated transcriptional repressor 
Bcl6 (B cell lymphoma 6), its reciprocal relationship with the GH-activated transcription 
factor Stat5, and the associated coregulatory proteins that interact with Bcl6 and Stat5 to 
regulate gene expression in response to GH.  Through the work in this thesis, we have 
identified novel GH-responsive transcriptional complexes, and started to identify 
mechanisms by which these nuclear protein complexes participate in GH action to 
orchestrate the proper expression of several essential GH target genes. Teasing out 
potential downstream physiological effects of these newly-discovered alliances between 
known and newly-discovered GH regulatory factors in the nucleus using both cell culture 
and relevant animal models will add to our understanding of the molecular mechanisms 
regulating normal and aberrant growth and metabolism. 
 
GH and the regulation of transcription 
 
A useful system to study the many mechanisms of transcription and downstream effects 
of transcriptional regulation is the study of the regulation of growth hormone (GH) target 
genes. GH, a peptide hormone secreted by the pituitary gland, regulates a wide variety of 
physiological effects. In particular, GH has long been known as a major regulator of 
normal growth and carbohydrate, lipid, and protein metabolism (20, 21). In conjunction 
with insulin-like growth factor 1 (IGF1), GH promotes longitudinal growth by 
stimulating the proliferation and differentiation of osteoblasts and chondrocytes in long 
bone (22-25). GH also promotes a relative increase in lean body mass and decrease in 
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body lipid through its effects on targets such as the liver, muscle, and adipose tissue (26, 
27). GH excess can result in diseases such as acromegaly or insulin resistance (26, 28, 
29), while GH deficiency in children can result in growth failure and short stature, and 
GH deficiency in adults can result in a variety of non-specific problems, including truncal 
obesity and decrease in muscle mass (30, 31). 
 
Many functions of GH occur through regulation of specific target genes. These responses 
are usually initiated by binding of GH to the GH receptor (32, 33). The GH receptor is a 
member of the cytokine receptor superfamily and is classified as a type I cytokine 
receptor. Other members include the prolactin receptor and leukemia inhibitory factor 
receptor. In the case of GH, a single molecule of GH binds to a GH receptor dimer and 
activates Jak2 (Janus kinase 2), a non-receptor tyrosine kinase that binds to the GH 
receptor. Jak2 phosphorylates itself and the cytoplasmic domain of the GH receptor to 
initiate downstream signaling (34). Signaling molecules, including signal transducers and 
activators of transcription (Stats), and proteins involved in the mitogen activated protein 
kinases (MAPKs) and phosphatidyl inositol 3’ kinase (PI3K) signaling pathways, are 
among the messengers recruited to relay GH signals to the nucleus in order to modulate 
gene transcription (32, 33, 35, 36). 
 
GH is secreted in a sex-dependent pulsatile manner throughout the day (37), and different 
genes are activated or repressed in time-dependent waves of expression (38). Regulation 
of gene expression by GH is often related to secretion patterns and hormone 
concentration, making genes that show changes in expression in response to GH (GH 
target genes) an ideal and versatile system for studying a wide variety of transcriptional 
regulatory networks and the downstream physiological effects of gene regulation. 
Regulation of gene transcription in response to GH occurs at multiple levels in the cell, 
including cellular localization of rate-limiting protein factors, post-translational 
modification of transcription factors and other nuclear proteins, chromatin modification, 
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and the formation, composition, and recruitment of transcriptional regulatory complexes 
(19). 
 
Bcl6 as a newly recognized GH-regulated transcriptional repressor  
 
Previous work on GH-mediated transcriptional regulation has mostly focused on 
mechanisms by which GH activates transcription. Therefore, it was of intense interest to 
identify mechanisms by which GH could inhibit or downregulate transcription, as proper 
balance between gene activation and repression is essential to the proper function of 
biological processes and survival of the cell. The identification of the eight twenty-one 
(ETO) protein as a potential C/EBP!-interacting corepressor offered one of the first clues 
into potential mechanisms by which a GH-regulated transcription factor could interact 
with other proteins to downmodulate activity and achieve transcriptional repression (39, 
40). The identification of Bcl6 (B cell lymphoma 6) as a GH-regulated transcriptional 
repressor and the study of how it regulates expression of GH target genes gave added 
insight into how GH mediates transcriptional repression and coordinates the activation 
and repression of a subset of GH-responsive genes (41) (Chapter 2).  
 
To learn more about mechanisms by which GH regulates transcription, a gene expression 
profiling microarray analysis was carried out using GH-responsive 3T3-F442A 
adipocytes treated with GH for both short (30 min) and long time periods (4 h and 48 h). 
Analysis of the gene expression profiles revealed about 500 GH-regulated genes that 
were either activated or repressed in time-dependent waves of GH-regulated gene 
expression (38). Analysis of GH early response genes have revealed that many different 
regulatory mechanisms coordinate to regulate the transcription of genes in response to 
GH. Analysis of a subset of C/EBP!-regulated genes among the GH early response genes 
revealed that even genes regulated by the same transcription factor are subjected to 
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further levels of transcriptional regulatory control to diversify responses mediated by the 
same transcription factor, and ensure specific regulation of gene expression (42).  
 
As described in Chapter 2, further analysis of the profile of GH-regulated genes using the 
CRC (Chinese restaurant clustering) algorithm (43) grouped the genes in clusters based 
on the extent of expression change in response to GH regardless of the direction of gene 
expression. This analysis revealed a cluster of genes strongly regulated by GH at later 
time points (4 h and 48 h), with 48 h of GH treatment corresponding to a time point of 
chronic GH treatment where adipocytes show phenotypes of GH-induced insulin 
resistance (41). Among the genes in the cluster were known GH target genes, such as 
Igf1, Socs2 (suppressor of cytokine signaling 2), Cish (cytokine inducible SH2-
containing protein), and Pik3r1 (phosphatidylinositol 3-kinase regulatory subunit alpha) 
(44-47). Pik3r1, in particular, has been implicated in GH-induced insulin resistance (47). 
This cluster of genes also included genes not previously recognized as GH target genes, 
such as Atf3, Klf5, and Bcl6. In particular, Bcl6 was found to be strongly repressed by 
GH, in contrast to the other genes in the cluster, and was the gene found to be the most 
highly repressed by GH in the entire profile. Strong repression of Bcl6 expression in 
response to GH was verified by quantitative real-time PCR experiments carried out in 
adipocytes and preadipocytes. Time course and dose response experiments showed that 
Bcl6 expression was repressed by GH concentrations as low as 5 ng/ml and as early as 30 
minutes after treatment (41). As the Bcl6 gene codes for a transcriptional repressor, it was 
of interest as a gene candidate for further study. It was hypothesized that Bcl6 would be a 
new link in understanding how GH regulates, and especially how GH represses, the 
expression of its target genes. More recently, GH-regulated expression of Bcl6 has also 
been demonstrated in liver (48) and the C2C12 muscle cell line (49), and prolactin was 
shown to be a potent inhibitor of Bcl6 expression in human breast cancer cell lines (50). 
These results all suggest a broader role for Bcl6 outside of its previously known functions 
in the immune system, and hint, in particular, at novel roles for Bcl6 in GH physiology. 
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Bcl6: Master regulator of B cell differentiation 
 
Bcl6 is a sequence-specific transcriptional repressor of the POZ/BTB (Pox virus and zinc 
finger/Bric-a-brac Tramtrack Broad complex)-zinc finger family (Figure 1.1) (51-54). 
The protein is localized to the nucleus and contains six Kruppel-type zinc fingers at the 
C- terminal and an N-terminal POZ-BTB domain. Each of the zinc fingers carries out 
specific interactions with either the target DNA or other Bcl6-associated proteins, with 
the four C-terminus zinc fingers required for DNA binding and recognition (55). 
Maximal repressive activity of Bcl6 requires the full POZ/BTB domain, as well as a 
repressive domain in the middle region of the protein (51). Bcl6 is known to associate 
with a variety of coregulatory proteins in order to carry out its repressive effects on 
transcription, and different coregulators are involved in modulating the transcription of 
different subsets of Bcl6 target genes. Examples of Bcl6-interacting corepressors include 
NCoR (nuclear receptor corepressor), SMRT (silencing mediator of retinoic acid and 
thyroid hormone receptor), various HDACs (histone deacetylases), ETO, CtBP (C-
terminal binding protein), and the Bcl6-specific corepressor BCoR (Bcl6 corepressor) 
(56-65). Recently, the lysine acetyltransferase p300, best known for interacting with 
transcriptional activators as a coactivator molecule, was also shown to associate with 
Bcl6 (66). Acetylation of Bcl6 at a KKYK motif in the middle region of the protein 
inhibits Bcl6 activity by disrupting its ability to recruit HDACs and other corepressors, 
resulting in derepression of target genes inhibited by Bcl6 (66). Bcl6 is also 
phosphorylated at multiple sites by mitogen-activated protein kinases (MAPKs) (67). In 
particular, phosphorylation of Bcl6 at serines 333 and 343 by Erk (extracellular signal 
regulated kinase) 1 and Erk2 results in proteasome degradation of Bcl6 in B cells (67). 
Interestingly, a recent report suggests that Bcl6 may activate expression of the Oat1 
(organic anion transporter 1) and Oat3 (organic anion transporter 3) genes in rat kidney 
proximal tubule cells (68). The mechanisms by which Bcl6 may be activating expression 










Figure 1.1  
Schematic representation of Bcl6 domain structure. The Bcl6 protein contains an N-
terminal POZ/BTB domain and a second repressive domain located in the middle of the 
protein (shaded boxes). The repressive domain in the middle region of the protein also 
contains the KKYK acetylation motif and PEST sequence phosphorylation motifs. 
Acetylation of Bcl6 inhibits its repressive activity by disrupting interaction with 
corepressive molecules. Phosphorylation of Bcl6 targets the protein for proteasomal 
degradation. Six Kruppel-type zinc fingers, represented by vertical ovals, are located at 
the C-terminus of the protein. Amino acid numbers are labeled as indicated, and Bcl6-
interacting proteins are listed in ovals depicted above known or predicted interaction 





Bcl6 is best known for its functions in the immune system, particularly its role as a 
master regulator of B cell differentiation (53, 69-71). Expression of Bcl6 in the B cell 
lineage is regulated so that high levels of Bcl6 are only expressed in the germinal center. 
Germinal centers are specialized structures where B cells undergo class switch 
recombination and somatic hypermutation to produce a diverse array of antibodies. The 
high expression levels of Bcl6 in germinal centers functions to maintain the germinal 
center gene expression program and inhibit expression of genes involved in B cell 
activation, DNA damage response, or terminal differentiation. A ChIP (chromatin 
immunoprecipitation) on chip analysis to identify direct Bcl6 target genes in immune 
cells has also revealed that Bcl6 target genes are enriched for functions such as regulators 
of transcription, chromatin structure, protein ubiquitylation, cell cycle regulation, and 
DNA damage responses (72). As such, terminal differentiation of B cells cannot be 
initiated until expression of Bcl6 has been downregulated. Due to the anti-apoptotic 
functions of Bcl6 during B cell development, dysregulation of Bcl6 expression is a 
frequent cause of B cell lymphomas (53, 69).  
 
New and novel functions of Bcl6 outside the immune system 
 
Recent studies have shown that Bcl6 plays physiological roles outside of the immune 
system. Bcl6 has been identified as playing a role in protecting testicular germ cells from 
apoptosis (73, 74), repressing proliferation of pancreatic beta cells (75), and mediating 
sexual dimorphism in liver (48, 76). Bcl6 has also been shown to mediate inflammatory 
responses in the pancreas (77), and a role has been demonstrated for Bcl6 in regulating 
left-right patterning in Xenopus embryos by competing with the coactivator Mastermind-
like 1 for the Notch1 intracellular domain, thereby restricting Notch-activated 
transcription to specific cell types (78). Roles for Bcl6 in muscle and bone differentiation 
have also been proposed (79), and its expression pattern during development suggests a 
potential role for Bcl6 in patterning visual and somatosensory pathways as well (80). The 
identification of Bcl6 as a GH target gene therefore suggests intriguing and novel 
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functions for Bcl6 in growth, metabolism, circadian rhythm, adipose differentiation, or 
adipose immune functions. As Bcl6 is a newly identified GH target gene, it was of 
interest to investigate whether or not Bcl6 was also a GH-regulated transcription 
repressor, and if it had GH-specific functions in adipocytes. These goals were the focus 
of Chapter 2 of this thesis. Identifying the physiological roles of Bcl6 in response to GH 
and the underlying transcriptional mechanisms by which Bcl6 target genes are regulated 
by GH may provide insight into how Bcl6 regulates the network of functions it has been 
found to participate in in other tissues. Of particular interest as a future project would be 
the identification of Bcl6 target genes in different tissues followed by analysis of 
similarities or differences in the subsets of genes targeted by Bcl6 in different cell types. 
 
Stat5:  GH-regulated transcription factor and major mediator of GH responses 
 
Stat5 (signal transducer and activator of transcription 5) belongs to the Stat family of 
latent transcription factors, of which there are seven members (Stat1, Stat2, Stat3, Stat4, 
Stat5a, Stat5b, Stat6) in mammalian cells. Stats are essential regulators of a subset of 
cytokine, growth factor, and hormone responses (81-84). It has been shown that Stat5a 
and Stat5b are crucial mediators for GH signaling to the nucleus (Figure 1.2) (85-88).  
 
Stat5a and Stat5b are encoded by two separate genes, and the proteins share 91% identity 
in amino acid sequence (89). Knock out mouse studies have shown that the two proteins 
have both redundant and distinct functions (90-92). Stat5b has been shown to be the 
essential transducer of GH-stimulated Igf1 expression and a key mediator for GH-
stimulated somatic growth and regulation of sexual dimorphism genes in the liver (85, 
86, 88, 93). In this thesis, the function of Stat5 in regulation of the candidate target genes 
was examined without distinction between the isoforms, using antibodies that recognize 








Figure 1.2  
Activation of Stat5 by GH. (Left) The growth hormone receptor (GHR) is a constitutive 
dimer. A molecule of Jak2 is bound to the intracellular domain of each monomer. 
(Middle) Binding of GH to its receptor induces conformational changes in the GHR 
dimer, which stimulate the kinase activity of Jak2, leading to phosphorylation of tyrosine 
residues on Jak2, and phosphorylation of multiple tyrosine residues (Y-P) in the 
intracellular domain of the GHR. (Right) Many of the phospho-tyrosine sites on the GHR 
can bind Stat5, which is then phosphorylated on a single tyrosine residue by Jak2. This 
promotes the dissociation of Stat5 from the GHR, Stat5 dimerization, translocation to the 
nucleus, and activation of Stat5-regulated gene transcription. Adapted from (88). 
!
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In the absence of stimulus, Stat5 mostly resides in the cytoplasm as latent monomers. 
When a GH molecule binds to the GH receptor heterodimer, conformational changes in 
the receptor dimer are followed by recruitment, activation, and autophosphorylation of 
the receptor-associated tyrosine kinase, Jak2, and phosphorylation of multiple tyrosine 
residues in the intracellular domain of the GH receptor (85, 94, 95). Stat5 is recruited to 
the receptor through interactions between the Stat5 SH2 domain and specific receptor 
phosphotyrosine residues, and recruitment of Stat5 to the GH receptor induces the 
phosphorylation of Stat5 by Jak2 on a conserved carboxy-terminal tyrosine (Stat5a/b, 
Y694/Y699) (96-98). Phosphorylated Stat5 enables the formation of Stat5 dimers and 
dissociation of Stat5 from the GH receptor. Stat5 dimers translocate to and are retained in 
the nucleus, where they bind specific DNA sequences to regulate the expression of target 
genes (99, 100).  
 
Stat5 is best known as a transcriptional activator, and is known to interact with a variety 
of coregulatory molecules, including p300, CBP (cyclic AMP response element binding 
protein binding protein), and NCoA1 (nuclear receptor coactivator 1) (101-103). Stat5 is 
also known to repress transcription, and has been shown to interact with corepressor 
molecules such as SMRT and HDACs (104-106). Paradoxically, other studies suggest 
that Stat5-dependent gene activation might require the recruitment and activity of 
HDACs as well (106, 107). Stat5b has been shown to play a critical role in inhibition of 
insulin-like growth factor binding protein 1 (Igfbp1) gene transcription by impairing the 
actions of the transcription factor FoxO1 (Forkhead box protein O1) on the Igfbp1 
promoter (108). More recently, it has been postulated that Stat5 may form tetrameric 
complexes on target DNA when repressing transcription; these tetrameric Stat5 
complexes interact with members of the Polycomb repressor family, which generates a 





Reciprocal regulation of target gene transcription by Bcl6 and Stat5 
 
Bcl6 binds to a DNA consensus similar to that for Stat5, with Bcl6 having a core motif of 
5’-TTC CT(A/C) GAA-3’, and Stat5 having a core motif of 5’-TTC C(A>T)G GAA-3’ 
(51, 55, 110, 111). As Bcl6 and Stat5 share similar DNA binding motifs, it would be 
predicted that a subset of Bcl6 or Stat5 target genes could be dual-regulated by both 
transcription factors.  
 
Examples of Bcl6 and Stat transcription factors both regulating a target gene using the 
same DNA regulatory region have been described previously. The consensus sequence 
for Stat transcription factors is highly similar among all family members, sharing the 
same core motif of 5’-TTC (N)2-4 GAA-3’ (112). Despite the high structural 
conservation among Stat family members and the similarity in their DNA binding 
consensus sequences, each Stat member has its own distinct target genes and functions 
(81). Bcl6 and various Stat proteins have been shown to bind the same DNA sequences in 
vitro (113), and Bcl6 and Stat6 both regulate expression of the I epsilon promoter that 
controls immunoglobulin heavy chain class switching to IgE in B cells (114). The 
discovery of the reciprocal regulation of Socs2 by Bcl6 and Stat5 in response to GH 
(Chapter 2) was the first example of an in vivo system where a gene is regulated by both 
Bcl6 and Stat5 using the same DNA regulatory sequence. This was soon followed by 
other examples showing cooperation between Bcl6 and Stat5 in regulating a common 
target gene. Interplay between Bcl6 and Stat5 was identified in regulation of sex-specific 
genes in liver, with Bcl6 functioning to repress female-biased Stat5 target genes in male 
liver (48, 76). Common targets of Bcl6 and Stat5 in the liver showed enrichment for 
genes involved in lipid and drug metabolism, suggesting potential functional regulation 
of dual Bcl6 and Stat5 target genes outside the immune system (76). Bcl6 and Stat5 
occupancy patterns across the genome in the presence and absence of GH have also been 
examined in adipocytes (Chapter 3). Analysis of Bcl6 occupancy patterns and gene 
expression data suggest that multiple genes strongly regulated by GH may also be Bcl6 
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target genes. Bcl6 has been found to occupy the Stat5 regulatory region of the Cish gene 
in liver (115), and results in this thesis suggest that Bcl6 and Stat5 regulate the expression 
of Cish and Bcl6 using the same DNA regulatory sequence in adipocytes as well (Chapter 
4). 
 
Recently, the Bcl6 ortholog in Drosophila has been described (116). Ken and Barbie 
(ken), the Drosophila ortholog of Bcl6, was shown to promote somatic stem cell renewal 
in the testis niche (74). Ken carries out some of its functions by functioning as a negative 
regulator of the Jak/Stat pathway, and recognizes a DNA consensus sequence that 
overlaps with the recognition sequence of the Drosophila Stat homolog Stat92E (116). 
Ken is thought to negatively regulate the Jak/Stat pathway by competing for a subset of 
Stat targets in vivo and repressing Stat-dependent expression of these genes, including vvl 
(ventral veins lacking) (116). Interestingly, Ken was not found to repress the expression 
of the Drosophila SOCS homolog, Socs36e (116). Socs36e is both a target and negative 
regulator of Jak/Stat signaling. It shows the closest homology to the mammalian Socs5, 
which has not been shown to be a Bcl6 target gene in mammalian cells (117). 
Nevertheless, it appears that dual regulation of target genes by Bcl6 and Stat5 is a 
transcriptional regulatory mechanism that has been conserved over evolution. Future 
work elucidating binding requirements for each transcription factor, and analysis of the 
subsets of genes regulated specifically by either Bcl6 or Stat5 compared to genes 
regulated by both factors in different organisms and different tissues, will shed light on 
the implications and functions of this conserved regulatory mechanism.  
 
Transcriptional coactivator p300 
 
Coregulatory proteins are protein factors that interact with transcription factors to activate 
or repress transcription (6, 118, 119). Coregulators do not directly bind to DNA, and 
often carry out their actions by modifying the activity of transcription factors or the 
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structure of the surrounding chromatin (118, 120, 121). Coregulators that enhance 
transcription are known as coactivators, while coregulators that function to repress 
transcription are known as corepressors. As expression of genes dually regulated by Bcl6 
and Stat5 identified in Chapter 4 showed different responses to GH treatment, the role of 
several coregulatory proteins in mediating these different responses was also investigated 
in Chapter 4. 
 
P300 was first identified as an adenovirus E1A binding protein (122). It is structurally 
and functionally similar to the CBP (CREB binding protein) coregulatory molecule. P300 
is best known as a transcriptional coactivator, and is required for a wide array of cellular 
processes, including cell cycle progression and cellular differentiation (123-125). It 
contains an intrinsic lysine acetyltransferase activity, and known substrate proteins 
include histones and transcriptional regulatory proteins (126, 127). P300 is thought to 
regulate gene transcription by serving as an acetyltransferase and regulating the activity 
of transcription factors and the recruitment of RNA pol II, relaxing the chromatin 
structure to facilitate transcription, or functioning as a scaffold protein. A role for 
cytoplasmic p300 as an E4 ubiquitin ligase has also been described (128).  
 
Activity of p300 itself can be regulated through a variety of post-translational 
modifications. Autoacetylation of p300 at multiple lysine residues appears to act as a 
switch to increase its acetyltransferase catalytic activity (129, 130). Phosphorylation of 
p300 by Akt promotes metabolic stability of p300 protein along with augmenting p300 
acetyltransferase activity and its recruitment to target promoters (131-133). In contrast, 
phosphorylation of p300 by the MAP kinase p38 targets the protein for degradation by 
the proteasome (134). Ubiquitination of p300 is associated with the unphosphorylated 
form of p300, and targets the protein for degradation by the proteasome (135, 136), while 
sumoylation of p300 correlates with transcriptional repression (137).  
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Bcl6 and p300 
 
P300 has been shown to bind and acetylate Bcl6 in immune cells. Acetylation of Bcl6 by 
p300 inhibits Bcl6 function by disrupting the ability of Bcl6 to recruit HDACs and other 
corepressive molecules (66). Bcl6 also regulates expression of p300 in immune cells. 
Bcl6 functions as a transcriptional repressor of p300 expression. The overexpression of 
Bcl6 and subsequent repression of p300 expression is thought to contribute to the 
development and maintenance of some B cell lymphomas due to loss of p300-mediated 
acetylation of p53 and Hsp90 (138). Supporting the importance of this inhibitory 
feedback loop between Bcl6 and p300 is the observation that 39% of diffuse large B-cell 
lymphoma and 41% of follicular lymphoma cases display genomic deletions and/or 
somatic mutations that remove or inactivate the lysine acetyltransferase coding domain of 
either p300 or CBP (139). 
 
Stat5 and p300 
 
The role of p300 as a coregulator of Stat proteins in various cell types has long been 
established (101, 103, 140-143). Recruitment of p300 by Stat1, Stat2, Stat3, Stat5, and 
Stat6 has all been demonstrated. Stat6 recruits p300 to carry out transcriptional activation 
of target genes in response to interleukin 4 stimulation (143), and p300 and CBP have 
been shown to bind to STAT5 and coactivate STAT5-mediated transactivation of !-
casein  expression (101). A role for p300 as a coactivator in Stat5b-mediated transcription 
of Igf1 in response to GH in liver has also been demonstrated (115). Stat5 squelching of 
limited pools of p300 has also been implicated in the Stat5b-mediated repression of 
nuclear factor kappa B (NF-kB) signaling in response to prolactin. This squelching 
demonstrates a mechanism by which Stat5 can indirectly function as a transcriptional 
repressor without binding to target gene DNA (144). 
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The histone deacetylase (HDAC) family and Hdac3 
 
Potential roles for the coregulator Hdac3 in modulating Bcl6- and Stat5-mediated 
transcription of Socs2, Cish, and Bcl6 were also examined in Chapter 4. Hdac3 is a 
member of the histone deacetylase (HDAC) family of proteins. HDACs are a group of 
lysine deacetylases which catalyze the deacetylation of lysine residues on histones and 
other protein targets, including p53, CBP, and Stat1 (145-150). Removal of acetyl groups 
from histone tails by HDAC molecules typically correlates with condensed DNA 
structure and repression of transcription. Due to the key role HDACs play in regulating 
gene transcription, they have been implicated in a variety of biological pathways, 
including cell cycle, cellular differentiation, and signal transduction (121, 151, 152).   
 
To date, eighteen HDAC family members have been identified in higher eukaryotes. 
They are separated into four classes based on homology to yeast histone deacetylases 
(152-156). Class I HDACs include Hdac1, 2, 3, and 8 and are related to yeast Rpd3 
(reduced potassium deficiency 3). Class II HDACs are homologs of the yeast Hdac1 
protein and this group is further divided into two subgroups based on sequence homology 
and domain organization. Class IIa HDACs include Hdac4, 5, 7, and 9. These molecules 
all contain a highly conserved C-terminal catalytic domain homologous to yeast Hda1, 
but their N-terminal domains bear no similarity to HDACs of other classes. Class IIb 
HDACs include Hdac6 and Hdac10. Hdac6 possesses an additional acetylase domain and 
a zinc finger motif, and participates in cytoplasmic functions such tubulin deacetylation 
and protein degradation, in addition to its function as a histone deacetylase. Class III 
HDACs are homologous to yeast Sir2 (silent information regulator 2) and are comprised 
of the seven silent information regulator proteins, or sirtuins (Sirt1-7). Hdac11 is a class 
IV HDAC due to its distinct structure, and shares homology with yeast Hos3 (high 
osmolarity sensitive protein 3). Class I, II, and IV comprise the classical family of zinc-
dependent HDACs, while class III HDACs are nicotinamide adenine dinucleotide 
(NAD+)-dependent. Due to the diverse functions HDACs participate in and their roles in 
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transcriptional regulation, HDACs are key targets for drug development, and HDAC 
inhibitors are currently being explored as pharmaceutical agents for diseases ranging 
from neurodegeneration to cancer. Older HDAC inhibitors include the general class I and 
class II HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid (SAHA) 
(152). More recently, class selective and member specific inhibitory molecules have been 
developed for targeted inhibition of specific HDAC activity (154, 157, 158). Sirtuin 
activity has traditionally been inhibited by nicotinamide, although new small molecules 
have been developed for selective inhibition for use as pharmaceutical drugs (159, 160). 
Sirtuins have been proposed as therapeutic targets for type II diabetes due to the links 
between their enzymatic activity and the energy status of the cell (159, 161). 
 
Hdac3 is a class I HDAC that is found in many tissues in the body, and is primarily 
localized to the nucleus, although it can also be detected in the cytoplasm and at the 
plasma membrane (162, 163). It has been found in complexes with corepressive 
molecules such as SMRT, NCoR, the Bcl6 corepressor BCoR, and other HDACs (155, 
164-166). It regulates the expression of a variety of genes through its interaction with 
both histones and non-histone protein targets, and has been implicated in long term 
memory formation and NF-kB signaling (155, 167). 
 
Hdac3 catalytic activity can be regulated by phosphorylation at serine 424 in the C-
terminal domain, and phosphorylation at this site has been shown to increase enzymatic 
activity (168). Phosphorylation of this residue was not found to alter Hdac3 subcellular 
localization, and Hdac3 must be bound to the corepressors NCoR (nuclear receptor 
corepressor) or SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) 
to form an active enzyme complex (165, 169, 170). Hdac3 is the primary HDAC enzyme 
in NCoR/SMRT complexes; however, other HDAC molecules can be recruited to this 
complex in a transcription factor or promoter dependent-manner. In particular, the class 
IIa HDACs, Hdac4 and Hdac5, have been shown to interact with NCoR/SMRT at a site 
independent from the interaction site of Hdac3, and Hdacs 4, 5, 7, and 10 have been 
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shown to interact with Hdac3 but not Hdacs 1 and 2 (164, 165, 169, 171). It has been 
suggested that activity of several of these class II HDACs is dependent on their 
interactions with Hdac3 and NCoR/SMRT as part of a corepressor protein complex, and 
cellular localization of Hdac4 and Hdac5 is regulated by their phosphorylation state.  
Intriguingly, Hdac4, 5, and likely 7, are regulated through subcellular 
compartmentalization controlled by site-specific phosphorylation and binding of 14-3-3 
proteins. The regulation of these HDACs is thus linked via 14-3-3 to cellular signaling 
networks (164), and suggests a mechanism by which GH signaling can regulate Hdac3-
interacting transcription factors and their target genes. Future work to evaluate the 
contribution of other HDACs to Bcl6 and Stat5 target gene expression in response to GH 
will provide insight into this potential mechanism. 
 
Hdac3 has been shown to mediate transcriptional repression in several ways (121, 151, 
155). Deacetylation of histones results in a closed chromatin conformation that is 
inhibitory for transcription. Histone deacetylation also reduces recruitment of bromo-
domain coactivators, such as p300 and CBP, to the chromatin. Hdac3 complexes can also 
interact with transcription factors to repress expression of a target gene. In some of these 
cases, Hdac3 repression is lost when binding of a ligand induces a conformational change 
in the complex, allowing disassociation of Hdac3 and recruitment and binding of a 
coactivator. Hdac3 histone deacetylation often occurs in concert with the activity of other 
repressive chromatin remodeling enzymes, such as methyltransferases, and Hdac3 is an 
essential component for the coordination and establishment of specific epigenetic profiles 
in the cell (172-174). Hdac3 has also been implicated in the maintenance of circadian 
rhythm and hepatic lipid homeostasis (175, 176), suggesting a role for Hdac3 in the 
regulation of metabolism and energy storage. A role for Hdacs 1, 2, and 3 as inhibitors of 





Bcl6 and Hdac3 
 
Hdac3 has been identified as a Bcl6 interacting protein, and has also been detected in 
complexes with the Bcl6 corepressor BCoR (59, 179). As Hdac3 is predicted to carry out 
many of its functions in association with NCoR or SMRT as part of a multi-protein 
complex (165), and Bcl6 in turn has been shown to recruit NCoR and SMRT when 
repressing transcription (63), it would not be unexpected for Hdac3 to play a role in 
regulating expression of Bcl6 and GH target genes in adipocytes as well. Hdac3 is 
recruited by Bcl6 to repress expression of DNA damage response genes such as ATR and 
TP53 (180, 181), and Hdac3 is also a drug target for B cell lymphoma therapy (152). 
More recently, Hdac3 was found to be recruited to a subset of dual Bcl6 and NF-kB 
regulatory regions in a Bcl6 dependent manner in macrophages to restrain inflammation 
and counter the activation of inflammatory genes by NF-kB and p300 in response to LPS 
stimulation (62). Bcl6/NCoR/SMRT complexes have also been implicated in repressing 
inflammation and preventing atherosclerosis (182). As hyperinflammation and 
atherosclerosis are both pathologies in which GH may play a role (183, 184), 
understanding the role of Bcl6 and Hdac3 in the regulation of GH target genes could shed 
insight on the pathogenesis of these diseases.  
 
Stat5 and Hdac3 
 
Studies on direct interactions between Stat5 and Hdac3 or the participation of Hdac3 in 
Stat5-mediated transcription are sparse. However, Stat5 is known to interact with other 
class I HDACs, and it has been demonstrated that HDAC activity may be required for 
Stat5-mediated induction of some target genes, including Cish (106, 107, 185). Stat5 has 
also been shown to interact with the Hdac3-interacting corepressor SMRT (170); this 
interaction may be a potential mechanism by which Stat5 mediates transcriptional 
repression, or a method by which a cell downregulates Stat5 activity (104). 
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Histone modifications and their role in transcriptional regulation 
 
One of the potential mechanisms by which p300 and Hdac3 may be carrying out their 
regulatory effects on gene expression is through the post-translational modification of 
histones. Histones are small, basic proteins found in eukaryotic nuclei that package and 
order the DNA into subunits known as nucleosomes. Nucleosomes, which consist of 
about 146 base pairs of DNA wrapped around an octamer of core histone proteins, form 
the basic repeating unit of eukaryotic chromatin. Histones are one of the major 
components of chromatin, and histones, histone post-translational modifications, and the 
chromatin structure all play roles in gene regulation. Histones are grouped into five major 
families: H1/H5, H2A, H2B, H3, and H4. Histones H2A, H2B, H3, and H4 are known as 
the core histones, as two H2A/H2B dimers and an H3/H4 tetramer comprise the 
nucleosome core. Histones H1 and H5 are considered linker histones. The structure of 
histone proteins is highly evolutionarily conserved, and all histones have highly 
unstructured positively charged N-terminal domains known as histone tails where the 
bulk of histone post-translational modifications occur (186-190). 
 
Histones have been postulated to regulate gene expression in several ways. First, histone 
density plays a role, as active genes tend to have less bound histone, while inactive genes 
are highly associated with histones. Secondly, post-translational modifications on histone 
tails are associated with both higher order chromatin structure, which is generated from 
folding and packaging of nucleosomes, and regulation of gene transcription. Alteration of 
chromatin structure and compaction can regulate the accessibility of a DNA sequence to 
transcriptional regulatory proteins. Histone modifications can also serve as binding sites 
for recruitment of transcription factors and transcriptional machinery, including other 
histone modification enzymes, which further remodel the chromatin to promote or inhibit 
transcription. More recently, specific histone modifications have come to be associated 
with particular gene regulatory regions, such as promoter elements or enhancers. It has 
been proposed that these histone modifications form a “histone code”, wherein “multiple 
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histone modifications, acting in a combinatorial or sequential fashion on one or multiple 
histone tails, specify unique downstream functions” (187, 191). Functional understanding 
of most histone modifications is currently still lacking, and most experimental data are 
focused on the functional consequences of specific prominent histone modifications with 
known catalyzing enzymes that can be experimentally manipulated.  
 
Histone modifications participate in processes such as regulation of transcription, DNA 
damage, and cell division. Most of the well-studied histone modifications have been 
associated with regulation of transcription. Acetylation of histones H3 and H4, 
trimethylation of histone H3 lysine 4 (H3K4me3), and trimethylation of histone H3 
lysine 36 (H3K36me3) in particular, are associated with active transcription. Aceytlation 
of histone tails by lysine acetylases neutralizes the positive charge on histone tails, 
reducing the interactions between histones and negatively charged DNA. This results in a 
more relaxed chromatin structure, which is more accessible to the transcriptional 
machinery. Similarly, deacetylation of histones H3 and H4 by lysine deacetylases such as 
HDACs correlate with a more condensed and inaccessible chromatin state, and is 
associated with transcriptional repression. H3K4me3 is associated with the promoters of 
active genes, although the precise function of this histone modification at the promoter 
region is unclear (192-194). H3K36me3 is associated with the gene body of actively 
transcribed genes. In yeast, the methyltransferase Set2 (SET domain containing 2) 
associates with elongating RNA pol II and deposits H3K36me3 marks on histones as the 
gene is transcribed. H3K36me3 marks then recruit the Rpd3 histone deacetylase complex 
to remove acetyl marks from surrounding histones to repress spurious transcription (195-
197). 
 
Histone modifications strongly correlative with transcriptional repression include 
trimethylated histone H3 lysine 27 (H3K27me3) and trimethylated histone H3 lysine 9 
(H3K9me3). H3K27me3 is deposited by PRC2 (polycomb repressive complex 2), and is 
a clear mark of transcriptionally silent chromatin (198, 199). H3K27me3 is further 
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recognized by other repressive chromatin remodeling factors, which aid chromatin 
compaction in the genomic vicinity. H3K9me3 is catalyzed by the histone-lysine N-
methyltransferase SUV39H1 in humans (200, 201). It is a well-characterized marker of 
heterochromatin and strongly associated with gene repression. Similar to H3K27me3, 
H3K9me3 also serves as a binding site for further recruitment of repressive chromatin 
remodeling proteins. 
 
Summary and aims 
 
As a major regulator of normal growth and metabolism, GH carries out many of its 
diverse physiological functions by the specific and coordinated expression and repression 
of a multitude of target genes (19). One of the mechanisms by which GH regulates the 
expression of these target genes is the regulation of GH-responsive transcription factors. 
Much of the work on how GH regulates transcription has focused on how GH induces 
gene expression through the activity of GH-regulated transcription factors such as Stat5. 
As a careful balance of gene activation and repression needs to be maintained to ensure 
proper function of biological processes, the goal of this thesis was to investigate 
mechanisms by which GH could repress or downregulate gene expression in order to fill 
in this gap in understanding.  
 
In Chapter 2, the identification of the transcription repressor Bcl6 as a novel GH target 
gene (41) opened up new avenues for understanding mechanisms by which GH could 
inhibit gene expression. As Bcl6 is a novel GH target gene, it was of interest to 
investigate whether or not Bcl6 was also a novel GH-regulated transcription repressor, 
and if it had GH-specific functions in adipocytes. In Chapter 3, high-throughput 
sequencing techniques and genome-wide bioinformatics analyses were utilized to identify 
candidate Bcl6 target genes in adipocytes. Intriguingly, the GH-regulated transcription 
factors Bcl6 and Stat5 share a similar DNA binding consensus sequence, suggesting that 
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they may function as reciprocal regulators of GH-mediated gene transcription. Chapter 4 
describes the identification and characterization of GH target genes regulated by both 
Bcl6 and Stat5 using the same DNA regulatory region using genome-wide Bcl6 and Stat5 
occupancy profiles generated in Chapter 3. The molecular mechanisms involved in 
regulation of dual Bcl6 and Stat5 target genes in response to GH was also investigated, 
with a focus on the functional contributions of the coregulators p300 and Hdac3 on Bcl6- 
and Stat5-mediated transcriptional regulation of these dual Bcl6/Stat5 target genes. 
Chapter 5 discusses a proposed integrated model of transcription regulation for dual Bcl6 
and Stat5 target genes in response to GH, and speculates on other GH-regulated 
transcription factors and nuclear proteins that may also participate in this process. 
Together, these studies describe a novel repressor-activator relationship in GH-regulated 
gene transcription, and provide insight into molecular mechanisms by which target genes 
can be differentially regulated by the same transcription factors in response to the same 


















1. Schotta, G., Ebert, A., Dorn, R., and Reuter, G. (2003) Position-effect variegation 
and the genetic dissection of chromatin regulation in Drosophila. Semin Cell Dev 
Biol 14, 67-75 
 
2. Cremer, T., and Cremer, C. (2001) Chromosome territories, nuclear architecture 
and gene regulation in mammalian cells. Nat Rev Genet 2, 292-301 
 
3. Jaenisch, R., and Bird, A. (2003) Epigenetic regulation of gene expression: how 
the genome integrates intrinsic and environmental signals. Nat Genet 33, 245-254 
 
4. Lee, T. I., and Young, R. A. (2000) Transcription of eukaryotic protein-coding 
genes. Annu Rev Genet 34, 77-137 
 
5. Casamassimi, A., and Napoli, C. (2007) Mediator complexes and eukaryotic 
transcription regulation: an overview. Biochimie 89, 1439-1446 
 
6. Roeder, R. G. (2005) Transcriptional regulation and the role of diverse 
coactivators in animal cells. FEBS Lett 579, 909-915 
 
7. Proudfoot, N. J., Furger, A., and Dye, M. J. (2002) Integrating mRNA processing 
with transcription. Cell 108, 501-512 
 
8. Chen, K., and Rajewsky, N. (2007) The evolution of gene regulation by 
transcription factors and microRNAs. Nat Rev Genet 8, 93-103 
 
9. Roeder, R. G. (1996) The role of general initiation factors in transcription by 
RNA polymerase II. Trends Biochem Sci 21, 327-335 
 
10. Karin, M. (1990) Too many transcription factors: positive and negative 
interactions. New Biol 2, 126-131 
 
11. Latchman, D. S. (1997) Transcription factors: an overview. Int J Biochem Cell 
Biol 29, 1305-1312 
 
12. Bulger, M., and Groudine, M. (2011) Functional and mechanistic diversity of 
distal transcription enhancers. Cell 144, 327-339 
 
13. Nolis, I. K., McKay, D. J., Mantouvalou, E., Lomvardas, S., Merika, M., and 
Thanos, D. (2009) Transcription factors mediate long-range enhancer-promoter 
interactions. Proc Natl Acad Sci U S A. 106, 20222-20227 
 
 26 
14. Spilianakis, C. G., Lalioti, M. D., Town, T., Lee, G. R., and Flavell, R. A. (2005) 
Interchromosomal associations between alternatively expressed loci. Nature 435, 
637-645 
 
15. Orphanides, G., Lagrange, T., and Reinberg, D. (1996) The general transcription 
factors of RNA polymerase II. Genes Dev 10, 2657-2683 
 
16. Blau, J., Xiao, H., McCracken, S., O'Hare, P., Greenblatt, J., and Bentley, D. 
(1996) Three functional classes of transcriptional activation domain. Mol Cell 
Biol 16, 2044-2055 
 
17. Orphanides, G., and Reinberg, D. (2002) A unified theory of gene expression. 
Cell 108, 439-451 
 
18. Zawel, L., and Reinberg, D. (1995) Common themes in assembly and function of 
eukaryotic transcription complexes. Annu. Rev. Biochem. 64, 533-561 
 
19. Cesena, T. I., Cui, T. X., Piwien-Pilipuk, G., Kaplani, J. I., Calinescu, A. A., Huo, 
J. S., Iniguez-Lluhi, J. A., Kwok, R., and Schwartz, J. (2007) Multiple 
mechanisms of growth hormone-regulated gene transcription. Mol. Genet. Metab. 
90, 126-133 
 
20. Smith Jr., R. W., Gaebler, O. H., and Long, C. N. H. (1955) The Hypophyseal 
Growth Hormone, Nature and Actions, McGraw-Hill, NY 
 
21. Kaplan, S. L. (1999) Hormonal regulation of growth and metabolic effects of 
growth hormone. In Handbook of Physiology (Kostyo, I. L., ed) Vol. V pp. 129-
144, Oxford University Press, New York 
 
22. Isaksson, O. G., Lindahl, A., Nilsson, A., and Isgaard, J. (1987) Mechanism of the 
stimulatory effect of growth hormone on longitudinal bone growth. Endocr. Rev. 
8, 426-438 
 
23. Daughaday, W. H., and Rotwein, P. (1989) Insulin-like growth factors I and II.  
Peptide, messenger ribonucleic acid and gene structures, serum, and tissue 
concentrations. Endocr. Rev. 10, 68-91 
 
24. Green, H. (1985) A dual effector theory of growth hormone action. 
Differentiation 29, 195-198 
 
25. Rosenfeld, R. G., and Hwa, V. (2004) Toward a molecular basis for idiopathic 
short stature. J. Clin. Endocrinol. Metab. 89, 1066-1067 
 
26. Davidson, M. B. (1987) Effect of growth hormone on carbohydrate and lipid 
metabolism. Endocr. Rev. 8, 115-131 
 
 27 
27. Kostyo, J. L., and Nutting, D. F. (1974) Growth hormone and protein metabolism. 
In Handbook of Physiology.  Sec 7.  Endocrinology (Knobil, E., and Sawyer, W. 
H., eds) Vol. IV pp. 187-210, American Physiological Soc., Washington, D.C. 
 
28. Drange, M. R., and Melmed, S. (1999) Molecular pathogenesis of acromegaly. 
Pituitary 2, 43-50 
 
29. Rizza, R. A., Mandarino, J. L., and Gerich, J. E. (1982) Effects of growth 
hormone on insulin action in man: Mechanisms of insulin resistance, impaired 
suppression of glucose production, and impaired stimulation of glucose 
utilization. Diabetes 31, 663-669 
 
30. Dattani, M., and Preece, M. (2004) Growth hormone deficiency and related 
disorders: insights into causation, diagnosis, and treatment. Lancet 363, 1977-
1987 
 
31. Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., Shalet, S. M., 
and Vance, M. L. (2006) Evaluation and treatment of adult growth hormone 
deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol 
Metab 91, 1621-1634 
 
32. Smit, L. S., Meyer, D. J., Argetsinger, L. S., Schwartz, J., and Carter-Su, C. 
(1999) Molecular events in growth hormone-receptor interaction and signaling. In 
Handbook of Physiology (Kostyo, J. L., ed) Vol. V pp. 445-480, Oxford 
University Press, New York 
 
33. Herrington, J., and Carter-Su, C. (2001) Signaling pathways activated by the 
growth hormone receptor. Trends Endocrinol Metab 12, 252-257 
 
34. Argetsinger, L. S., Campbell, G. S., Yang, X., Wittuhn, B. A., Silvennoinen, O., 
Ihle, J. N., and Carter-Su, C. (1993) Identification of JAK2 as a growth hormone 
receptor-associated tyrosine kinase. Cell 74, 237-244 
 
35. Herrington, J., Smit, L. S., Schwartz, J., and Carter-Su, C. (2000) The role of 
STAT proteins in growth hormone signaling. Oncogene 19, 2585-2597 
 
36. Piwien-Pilipuk, G., Huo, J. S., and Schwartz, J. (2002) Growth hormone signal 
transduction. J. Pediat. Endo. Metab. 15, 771-786 
 
37. Daughaday, W. H. (1989) Growth Hormone: normal synthesis, secretion, control 
and mechanism of action. In Endocrinology (de Groot, L. J., ed) Vol. 1, W. B. 
Saunders Company 
 
38. Huo, J. S., McEachin, R. C., Cui, T. X., Duggal, N. K., Hai, T., States, D. J., and 
Schwartz, J. (2006) Profiles of Growth Hormone (GH)-regulated Genes Reveal 
 28 
Time-dependent Responses and Identify a Mechanism for Regulation of 
Activating Transcription Factor 3 By GH. J. Biol. Chem. 281, 4132-4141 
 
39. Rochford, J. J., Semple, R. K., Laudes, M., Boyle, K. B., Christodoulides, C., 
Mulligan, C., Lelliott, C. J., Schinner, S., Hadaschik, D., Mahadevan, M., Sethi, J. 
K., Vidal-Puig, A., and O'Rahilly, S. (2004) ETO/MTG8 is an inhibitor of 
C/EBPb activity and a regulator of early adipogenesis. Mol. Cell. Biol. 24, 9863-
9872 
 
40. Payne, V. A., Au, W. S., Lowe, C. E., Rahman, S. M., Friedman, J. E., O'Rahilly, 
S., and Rochford, J. J. (2009) C/EBP transcription factors regulate SREBP1c gene 
expression during adipogenesis. Biochem. J.  
 
41. Chen, Y., Lin, G., Huo, J. S., Barney, D., Wang, Z., Livshiz, T., States, D. J., Qin, 
Z. S., and Schwartz, J. (2009) Computational and functional analysis of growth 
hormone (GH)-regulated genes identifies the transcriptional repressor B-cell 
lymphoma 6 (Bc16) as a participant in GH-regulated transcription. Endocrinology 
150, 3645-3654 
 
42. Cui, T. X., Lin, G., LaPensee, C. R., Calinescu, A. A., Rathore, M., Streeter, C., 
Piwien-Pilipuk, G., Lanning, N., Jin, H., Carter-Su, C., Qin, Z. S., and Schwartz, 
J. (2011) C/EBP! mediates growth hormone-regulated expression of multiple 
target genes. Mol Endocrinol 25, 681-693 
 
43. Qin, Z. S. (2006) Clustering microarray gene expression data using weighted 
Chinese restaurant process. Bioinformatics 22, 1988-1997 
 
44. Woelfle, J., Billiard, J., and Rotwein, P. (2003) Acute control of insulin-like 
growth factor-I gene transcription by growth hormone through Stat5b. J. Biol.  
Chem. 278, 22696-22702 
 
45. Vidal, O. M., Merino, R., Rico-Bautista, E., Fernandez-Perez, L., Chia, D. J., 
Woelfle, J., Ono, M., Lenhard, B., Norstedt, G., Rotwein, P., and Flores-Morales, 
A. (2007) In vivo transcript profiling and phylogenetic analysis identifies 
suppressor of cytokine signaling 2 as a direct signal transducer and activator of 
transcription 5b target in liver. Mol. Endocrinol. 21, 293-311 
 
46. Cui, Y., Hosui, A., Sun, R., Shen, K., Gavrilova, O., Chen, W., Cam, M. C., Gao, 
B., Robinson, G. W., and Hennighausen, L. (2007) Loss of signal transducer and 
activator of transcription 5 leads to hepatosteatosis and impaired liver 
regeneration. Hepatology 46, 504-513 
 
47. del Rincon, J. P., Iida, K., Gaylinn, B. D., McCurdy, C. E., Leitner, J. W., 
Barbour, L. A., Kopchick, J. J., Friedman, J. E., Draznin, B., and Thorner, M. O. 
(2007) Growth hormone regulation of p85" expression and phosphoinositide 3-
 29 
kinase activity in adipose tissue: mechanism for growth hormone-mediated 
insulin resistance. Diabetes 56, 1638-1646 
 
48. Meyer, R. D., Laz, E. V., Su, T., and Waxman, D. J. (2009) Male-specific hepatic 
Bcl6: growth hormone-induced block of transcription elongation in females and 
binding to target genes inversely coordinated with STAT5. Mol. Endocrinol. 23, 
1914-1926 
 
49. Resmini, E., Morte, B., Sorianello, E., Gallardo, E., de Luna, N., Illa, I., Zorzano, 
A., Bernal, J., and Webb, S. M. (2012) Identification of novel GH-regulated genes 
in C2C12 cells. Horm Metab Res 43, 919-930 
 
50. Tran, T. H., Utama, F. E., Lin, J., Yang, N., Sjolund, A. B., Ryder, A., Johnson, 
K., Neilson, L. M., C, L., Brill, K., Rosenberg, A., Witkiewicz, A., and Rui, H. 
(2010) Prolactin inhibits Bcl6 expression in breast cancer through a Stat5a-
dependent mechanism. Cancer Res 70, 1171-1121 
 
51. Chang, C. C., Ye, B. H., Chaganti, R. S., and Dalla-Favera, R. (1996) BCL-6, a 
POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc.  
Nat. Acad. Sci. USA 93, 6947-6952 
 
52. Jardin, F., Ruminy, P., Bastard, C., and Tilly, H. (2007) The BCL6 proto-
oncogene: a leading role during germinal center development and 
lymphomagenesis. Pathol. Biol. (Paris) 55, 73-83 
 
53. Basso, K., and Dalla-Favera, R. (2010) BCL6: master regulator of the germinal 
center reaction and key oncogene in B cell lymphomagenesis. Adv. Immunol. 105, 
193-210 
 
54. Ye, B. H., Lista, F., Lo Coco, F., Knowles, D. M., Offit, K., Chaganti, R. S., and 
Dalla-Favera, R. (1993) Alterations of a zinc finger-encoding gene, BCL-6, in 
diffuse large-cell lymphoma. Science 262, 747-750 
 
55. Mascle, X., Albagli, O., and Lemercier, C. (2003) Point mutations in BCL6 DNA-
binding domain reveal distinct roles for the six zinc fingers. Biochem. Biophys. 
Res. Commun. 300, 391-396 
 
56. Mendez, L. M., Polo, J. M., Yu, J. J., Krupski, M., Ding, B. B., Melnick, A., and 
Ye, B. H. (2008) CtBP is an essential corepressor for BCL6 autoregulation. Mol. 
Cell. Biol. 28, 2175-2186 
 
57. Ahmad, K. F., Melnick, A., Lax, S., Bouchard, D., Liu, J., Kiang, C. L., Mayer, 
S., Takahashi, S., Licht, J. D., and Prive, G. G. (2003) Mechanism of SMRT 
corepressor recruitment by the BCL6 BTB domain. Mol. Cell 12, 1551-1564 
 
 30 
58. Cerchietti, L. C., Yang, S. N., Shaknovich, R., Hatzi, K., Polo, J. M., Chadburn, 
A., Dowdy, S. F., and Melnick, A. (2009) A peptomimetic inhibitor of BCL6 with 
potent anti-lymphoma effects in vitro and in vivo. Blood 113, 3397-3405 
 
59. Huynh, K. D., Fischle, W., Verdin, E., and Bardwell, V. J. (2000) BCoR, a novel 
corepressor involved in BCL-6 repression. Genes Dev. 14, 1810-1823 
 
60. Chevallier, N., Corcoran, C. M., Lennon, C., Hyjek, E., Chadburn, A., Bardwell, 
V. J., Licht, J. D., and Melnick, A. (2004) ETO protein of t(8;21) AML is a 
corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood 103, 1454-1463 
 
61. Ghetu, A. F., Corcoran, C. M., Cerchietti, L., Bardwell, V. J., Melnick, A., and 
Prive, G. G. (2008) Structure of a BCOR corepressor peptide in complex with the 
BCL6 BTB domain dimer. Mol. Cell 29, 384-391 
 
62. Barish, G. D., Yu, R. T., Karunasiri, M., Ocampo, C. B., Dixon, J., Benner, C., 
Dent, A. L., Tangirala, R. K., and Evans, R. M. (2010) Bcl-6 and NF-kappaB 
cistromes mediate opposing regulation of the innate immune response. Genes Dev 
24, 2760-2765 
 
63. Polo, J. M., Dell'Oso, T., Ranuncolo, S. M., Cerchietti, L., Beck, D., Da Silva, G. 
F., Prive, G. G., Licht, J. D., and Melnick, A. (2004) Specific peptide interference 
reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma 
cells. Nat. Med. 10, 1329-1335 
 
64. Dhordain, P., Albagli, O., Lin, R. J., Ansieau, S., Quief, S., Leutz, A., Kerckaert, 
J. P., Evans, R. M., and Leprince, D. (1997) Corepressor SMRT binds the 
BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc.  Nat. Acad. 
Sci. USA 94, 10762-10767 
 
65. Dhordain, P., Lin, R. J., Quief, S., Lantoine, D., Kerckaert, J. P., Evans, R. M., 
and Albagli, O. (1998) The LAZ3(BCL-6) oncoprotein recruits a 
SMRT/mSIN3A/histone deacetylase containing complex to mediate 
transcriptional repression. Nucleic Acids Res. 26, 4645-4651 
 
66. Bereshchenko, O. R., Gu, W., and Dalla-Favera, R. (2002) Acetylation inactivates 
the transcriptional repressor BCL6. Nature Genet. 32, 606-613 
 
67. Niu, H., Ye, B. H., and Dalla-Favera, R. (1998) Antigen receptor signaling 
induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 
transcription factor. Genes Dev. 12, 1953-1961 
 
68. Wegner, W., Burckhardt, B. C., Burckhardt, G., and Henjakovic, M. (2012) Male-
dominant activation of rat renal organic anion transporter 1 (Oat1) and 3 (Oat3) 
expression by transcription factor BCL6. PLoS One 7, e35556 
 
 31 
69. Staudt, L. M., Dent, A. L., Shaffer, A. L., and Yu, X. (1999) Regulation of 
lymphocyte cell fate decisions and lymphomagenesis by BCL-6. Int. Rev. 
Immunol. 18, 381-403 
 
70. Dent, A. L., Shaffer, A. L., Yu, X., Allman, D., and Staudt, L. M. (1997) Control 
of inflammation, cytokine expression, and germinal center formation by BCL-6. 
Science 276, 589-592 
 
71. Schebesta, M., Heavey, B., and Busslinger, M. (2002) Transcriptional control of 
B-cell development. Curr. Op. Immunol. 14, 216-223 
 
72. Polo, J. M., Juszczynski, P., Monti, S., Cerchietti, L., Ye, K., Greally, J. M., 
Shipp, M., and Melnick, A. (2007) Transcriptional signature with differential 
expression of BCL6 target genes accurately identifies BCL6-dependent diffuse 
large B cell lymphomas. Proc.  Nat. Acad. Sci. USA 104, 3207-3212 
 
73. Kojima, S., Hatano, M., Okada, S., Fukuda, T., Toyama, Y., Yuasa, S., Ito, H., 
and Tokuhisa, T. (2001) Testicular germ cell apoptosis in Bcl6-deficient mice. 
Development 128, 57-65 
 
74. Issigonis, M., and Matunis, E. (2012) The Drosophila BCL6 homolog ken and 
barbie promotes somatic stem cell self-renewal in the testis niche. Dev Biol 368, 
181-192 
 
75. Glauser, D. A., and Schlegel, W. (2009) The FoxO/Bcl-6/cyclin D2 pathway 
mediates metabolic and growth factor stimulation of proliferation in Min6 
pancreatic !-cells. J. Recept. Signal Transduct. Res. 29, 293-298 
 
76. Zhang, Y., Laz, E. V., and Waxman, D. J. (2012) Dynamic, Sex-Differential 
STAT5 and BCL6 Binding to Sex-Biased, Growth Hormone-Regulated Genes in 
Adult Mouse Liver. Mol. Cell. Biol. 32, 880-896 
 
77. Igoillo-Esteve, M., Gurzov, E. N., Eizirik, D. L., and Cnop, M. (2011) The 
transcription factor B-cell lymphoma (BCL)-6  modulates pancreatic {beta}-cell 
inflammatory responses. Endocrinology 152, 447-456 
 
78. Sakano, D., Kato, A., Parikh, N., McKnight, K., Terry, D., Stefanovic, B., and 
Kato, Y. (2010) BCL6 canalizes Notch-dependent transcription, excluding 
Mastermind-like1 from selected target genes during left-right patterning. Dev Cell 
18, 450-462 
 
79. Miyauchi, Y., Ninomiya, K., Miyamoto, H., Sakamoto, A., Iwasaki, R., Hoshi, 
H., Miyamoto, K., Hao, W., Yoshida, S., Morioka, H., Chiba, K., Kato, S., 
Tokuhisa, T., Saitou, M., Toyama, Y., Suda, T., and Miyamoto, T. (2010) The 
Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone 
homeostasis. J Exp Med 207, 751-762 
 32 
 
80. Leamey, C. A., Glendining, K. A., Kreiman, G., Kang, N. D., Wang, K. H., 
Fassler, R., Sawatari, A., Tonegawa, S., and Sur, M. (2008) Differential gene 
expression between sensory neocortical areas: potential roles for Ten_m3 and 
Bcl6 in patterning visual and somatosensory pathways. Cereb Cortex 18, 53-66 
 
81. Darnell, J. E. J. (1997) STATs and gene regulation. Science 277, 1630-1635 
 
82. Li, W. X. (2008) Canonical and non-canonical JAK-STAT signaling. Trends Cell 
Biol. 18, 545-551 
 
83. Levy, D. E., and Darnell, J. E. J. (2002) Stats: transcriptional control and 
biological impact. Nat Rev Mol Cell Biol 3, 651-662 
 
84. Ihle, J. N. (2001) The Stat family in cytokine signaling. Curr Opin Cell Biol 13, 
211-217 
 
85. Waters, M. J., Hoang, H. N., Fairlie, D. P., Pelekanos, R. A., and Brown, R. J. 
(2006) New insights into growth hormone action. J. Mol. Endocrinol. 36, 1-7 
 
86. Hosui, A., and Hennighausen, L. (2008) Genomic dissection of the cytokine-
controlled STAT5 signaling network in liver. Physiol. Genomics 34, 135-143 
 
87. Yoo, K. H., Baik, M., and Hennighausen, L. (2011) Context-Specific Growth 
Hormone Signaling through the Transcription Factor STAT5: Implications for the 
Etiology of Hepatosteatosis and Hepatocellular Carcinoma. Genes Cancer 2, 3-9 
 
88. Rotwein, P. (2012) Mapping the growth hormone--Stat5b--IGF-I transcriptional 
circuit. Trends Endocrinol Metab 23, 186-193 
 
89. Grimley, P. M., Dong, F., and Rui, H. (1999) Stat5a and Stat5b: fraternal twins of 
signal transduction and transcriptional activation. Cytokine Growth Factor Rev 
10, 131-157 
 
90. Hennighausen, L., and Robinson, G. W. (2008) Interpretation of cytokine 
signaling through the transcription factors STAT5A and STAT5B. Genes Dev. 22, 
711-721 
 
91. Teglund, S., McKay, C., Schuetz, E., van Deursen, J. M., Stravopodis, D., Wang, 
D., Brown, M., Bodner, S., Grosveld, G., and Ihle, J. N. (1998) Stat5a and Stat5b 
proteins have essential and nonessential, or redundant, roles in cytokine 
responses. Cell 93, 841-850 
 
92. Hwa, V., Nadeau, K., Wit, J. M., and Rosenfeld, R. G. (2011) STAT5b 
deficiency: lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol 
Metab. 25, 61-75 
 33 
 
93. Udy, G. B., Towers, R. P., Snell, R. G., Wilkins, R. J., Park, S. H., Ram, P. A., 
Waxman, D. J., and Davey, H. W. (1997) Requirement of STAT5b for sexual 
dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. 
Sci. USA 94, 7239-7244 
 
94. Lanning, N. J., and Carter-Su, C. (2006) Recent advances in growth hormone 
signaling. Rev. Endocr. Metab. Disord. 7, 225-235 
 
95. Brooks, A. J., and Waters, M. J. (2010) The growth hormone receptor: 
mechanism of activation and clinical implications. Nat Rev Endocrinol 6, 515-525 
 
96. Paukku, K., and Silvennoinen, O. (2004) STATs as critical mediators of signal 
transduction and transcription: lessons learned from STAT5. Cytokine Growth 
Factor Rev. 15, 435-455 
 
97. Hansen, L. H., Wang, X., Kopchick, J. J., Bouchelouche, P., Nielsen, J. H., 
Galsgaard, E. D., and Billestrup, N. (1996) Identification of tyrosine residues in 
the intracellular domain of the growth hormone receptor required for 
transcriptional signaling and Stat5 activation. J. Biol. Chem. 271, 12669-12673 
 
98. Calo, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., 
and Russo, A. (2003) STAT proteins: from normal control of cellular events to 
tumorigenesis. J. Cell Physiol. 197, 157-168 
 
99. Meyer, T., Hendry, L., Begitt, A., John, S., and Vinkemeier, U. (2004) A single 
residue modulates tyrosine dephosphorylation, oligomerization, and nuclear 
accumulation of stat transcription factors. J Biol Chem 279, 18998-19007 
 
100. Meyer, T., and Vinkemeier, U. (2004) Nucleocytoplasmic shuttling of STAT 
transcription factors. Eur J Biochem 271, 4606-4612 
 
101. Litterst, C. M., Kliem, S., Marilley, D., and Pfitzner, E. (2003) NCoA-1/SRC-1 is 
an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical 
region of the STAT5 transactivation domain. J. Biol.  Chem. 278, 45340-45351 
 
102. Pfitzner, E., Jahne, R., Wissler, M., Stoecklin, E., and Groner, B. (1998) 
p300/CREB-binding protein enhances the prolactin-mediated transcriptional 
induction through direct interaction with the transactivation domain of Stat5, but 
does not participate in the Stat5-mediated suppression of the glucocorticoid 
response. Mol. Endocrinol. 12, 1582-1593 
 
103. Paulson, M., Pisharody, S., Pan, L., Guadagno, S., Mui, A. L., and Levy, D. E. 
(1999) Stat protein transactivation domains recruit p300/CBP through widely 
divergent sequences. J. Biol. Chem. 274, 25343-25349 
 
 34 
104. Nakajima, H., Brindle, P. K., Handa, M., and Ihle, J. N. (2001) Functional 
interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in 
negative regulation of STAT5-dependent transcription. EMBO J. 20, 6836-6844 
 
105. Shuai, K. (2000) Modulation of STAT signaling by STAT-interacting proteins. 
Oncogene 19, 2638-2644 
 
106. Xu, M., Nie, L., Kim, S. H., and Sun, X. H. (2003) STAT5-induced Id-1 
transcription involves recruitment of HDAC1 and deacetylation of C/EBP! 
EMBO J. 22, 893-904 
 
107. Rascle, A., Johnston, J. A., and Amati, B. (2003) Deacetylase activity is required 
for recruitment of the basal transcription machinery and transactivation by 
STAT5. Mol.  Cell. Biol. 23, 4162-4173 
 
108. Ono, M., Chia, D. J., Merino-Martinez, R., Flores-Morales, A., Unterman, T. G., 
and Rotwein, P. (2007) Signal transducer and activator of transcription (Stat) 5b-
mediated inhibition of insulin-like growth factor binding protein-1 gene 
transcription: a mechanism for repression of gene expression by growth hormone. 
Mol. Endocrinol. 21, 1443-1457 
 
109. Mandal, M., Powers, S. E., Maienschein-Cline, M., Bartom, E. T., Hamel, K. M., 
Kee, B. L., Dinner, A. R., and Clark, M. R. (2011) Epigenetic repression of the 
Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. 
Nat Immunol 12, 1212-1220 
 
110. Dent, A. L., Vasanwala, F. H., and Toney, L. M. (2002) Regulation of gene 
expression by the proto-oncogene BCL-6. Crit. Rev. Oncol. Hematol. 41, 1-9 
 
111. Seyfert, V. L., Allman, D., He, Y., and Staudt, L. M. (1996) Transcriptional 
repression by the proto-oncogene BCL-6. Oncogene 12, 2331-2342 
 
112. Kraus, J., Borner, C., and Hollt, V. (2003) Distinct palindromic extensions of the 
5'-TTC...GAA-3' motif allow STAT6 binding in vivo. FASEB J 17, 304-306 
 
113. Harris, M. B., Chang, C. C., Berton, M. T., Danial, N. N., Zhang, J., Kuehner, D., 
Ye, B. H., Kvatyuk, M., Pandolfi, P. P., Cattoretti, G., Dalla-Favera, R., and 
Rothman, P. B. (1999) Transcriptional repression of Stat6-dependent interleukin-
4-induced genes by BCL-6: specific regulation of iepsilon transcription and 
immunoglobulin E switching. Mol.  Cell. Biol. 19, 7264-7275 
 
114. Harris, M. B., Mostecki, J., and Rothman, P. B. (2005) Repression of an 
interleukin-4-responsive promoter requires cooperative BCL-6 function. J Biol 
Chem 280, 13114-13121 
 
 35 
115. Chia, D. J., and Rotwein, P. (2010) Defining the epigenetic actions of growth 
hormone: acute chromatin changes accompany GH-activated gene transcription. 
Mol. Endocrinol. 24, 2038-2049 
 
116. Arbouzova, N. I., Bach, E. A., and Zeidler, M. P. (2006) Ken & Barbie selectively 
regulates the expression of a subset of Jak/STAT pathway target genes. Curr. 
Biol. 16, 80-88 
 
117. Stec, W. J., and Zeidler, M. P. (2011) Drosophila SOCS Proteins. J Signal 
Transduct 2011, 894510 
 
118. Rosenfeld, M. G., Lunyak, V. V., and Glass, C. K. (2006) Sensors and signals: a 
coactivator/corepressor/epigenetic code for integrating signal-dependent programs 
of transcriptional response. Genes Dev. 20, 1405-1428 
 
119. Perissi, V., Aggarwal, A., Glass, C. K., Rose, D. W., and Rosenfeld, M. G. (2004) 
A corepressor/coactivator exchange complex required for transcriptional 
activation by nuclear receptors and other regulated transcription factors. Cell 116, 
511-526 
 
120. Kumar, R., Wang, R. A., and Barnes, C. J. (2004) Coregulators and chromatin 
remodeling in transcriptional control. Mol Carcinog 41, 221-230 
 
121. Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms. 
Genes Dev. 12, 599-606 
 
122. Eckner, R., Ewen, M. E., Newsome, D., Gerdes, M., DeCaprio, J. A., Lawrence, 
J. B., and Livingston, D. M. (1994) Molecular cloning and functional analysis of 
the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with 
properties of a transcriptional adaptor. Genes Dev 8, 869-884 
 
123. Stein, R. W., Corrigan, M., Yaciuk, P., Whelan, J., and Moran, E. (1990) Analysis 
of E1A-mediated growth regulation functions: binding of the 300-kilodalton 
cellular product correlates with E1A enhancer repression function and DNA 
synthesis-inducing activity. J. Virology 64, 4421-4427 
 
124. Whyte, P., Williamson, N. M., and Harlow, E. (1989) Cellular targets for 
transformation by the adenovirus E1A proteins. Cell 56, 67-75 
 
125. Yao, T. P., Oh, S. P., Fuchs, M., Zhou, N. D., Ch'ng, L. E., Newsome, D., 
Bronson, R. T., Li, E., Livingston, D. M., and Eckner, R. (1998) Gene dosage-
dependent embryonic development and proliferation defects in mice lacking the 
transcriptional integrator p300. Cell 93, 361-372 
 
 36 
126. Ogryzko, V. V., Schlitz, R. L., Russanova, V., Howard, B. H., and Nakatani, Y. 
(1996) The transcriptional coactivators p300 and CBP are histone 
acetyltransferases. Cell 87, 953-959 
 
127. Soutoglou, E., Katrakili, N., and Talianidis, I. (2000) Acetylation regulates 
transcription factor activity at multiple levels. Mol Cell 5, 745-751 
 
128. Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, 
H., Nakatani, Y., and Livingston, D. M. (2003) Polyubiquitination of p53 by a 
ubiquitin ligase  activity of p300. Science 300, 342-344 
 
129. Thompson, P. R., Wang, D., Wang, L., Fulco, M., Pediconi, N., Zhang, D., An, 
W., Ge, Q., Roeder, R. G., Wong, J., Levrero, M., Sartorelli, V., Cotter, R. J., and 
Cole, P. A. (2004) Regulation of the p300 HAT domain via a novel activation 
loop. Nat. Struct. Mol. Biol. 11, 308-315 
 
130. Stiehl, D. P., Fath, D. M., Liang, D., Jiang, Y., and Sang, N. (2007) Histone 
deacetylase inhibitors synergize p300 autoacetylation that regulates its 
transactivation activity and complex formation. Cancer Res 67, 2256-2264 
 
131. Chen, J., Halappanavar, S. S., St-Germain, J. R., Tsang, B. K., and Li, Q. (2004) 
Role of Akt/protein kinase B in the activity of transcriptional coactivator p300. 
Cell Mol Life Sci 61, 1675-1683 
 
132. Huang, W. C., and Chen, C. C. (2005) Akt phosphorylation of p300 at Ser-1834 is 
essential for its histone acetyltransferase and transcriptional activity. Mol Cell 
Biol 25, 6592-6602 
 
133. Ji, M., Zhang, Q., Ye, J., Wang, X., Yang, W., and Zhu, D. (2008) Myostatin 
induces p300 degradation to silence cyclin D1 expression through the 
PI3K/PTEN/Akt pathway. Cell Signal 20, 1452-1458 
 
134. Poizat, C., Puri, P. L., Bai, Y., and Kedes, L. (2005) Phosphorylation-dependent 
degradation of p300 by doxorubicin-activated p38 mitogen-activated protein 
kinase in cardiac cells. Mol Cell Biol 25, 2673-2687 
 
135. Avantaggiati, M. L., Carbone, M., Graessman, A., Nakatani, Y., Howard, B., and 
Levine, A. S. (1996) The SV40 large T antigen and adenovirus E1a oncoproteins 
interact with distinct isoforms of the transcriptional co-activator, p300. EMBO J. 
15, 2236-2248 
 
136. Chen, J., Halappanavar, S., Th' ng, J. P., and Li, Q. (2007) Ubiquitin-dependent 
distribution of the transcriptional coactivator p300 in cytoplasmic inclusion 
bodies. Epigenetics 2, 92-99 
 
 37 
137. Girdwood, D., Bumpass, D., Vaughan, O. A., Thain, A., Anderson, L. A., 
Snowden, A. W., Garcia-Wilson, E., Perkins, N. D., and Hay, R. T. (2003) P300 
transcriptional repression is mediated by SUMO modification. Mol. Cell 11, 
1043-1054 
 
138. Cerchietti, L. C., Hatzi, K., Caldas-Lopes, E., Yang, S. N., Figueroa, M. E., 
Morin, R. D., Hirst, M., Mendez, L., Shaknovich, R., Cole, P. A., Bhalla, K., 
Gascoyne, R. D., Marra, M., Chiosis, G., and Melnick, A. (2010) BCL6 
repression of EP300 in human diffuse large B cell lymphoma cells provides a 
basis for rational combinatorial therapy. J Clin Invest 120, 4569-4582 
 
139. Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., 
Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., Rossi, D., Chadburn, A., 
Murty, V. V., Mullighan, C. G., Gaidano, G., Rabadan, R., Brindle, P. K., and 
Dalla-Favera, R. (2011) Inactivating mutations of acetyltransferase genes in B-
cell lymphoma. Nature 471, 189-195 
 
140. Horvai, A. E., Xu, L., Korzus, E., Brard, G., Kalafus, D., Mullen, T.-M., Rose, D. 
W., Rosenfeld, M. G., and Glass, C. K. (1997) Nuclear integration of JAK/STAT 
and Ras/AP-1 signaling by CBP and p300. Proc. Natl. Acad. Sci. USA 94, 1074-
1079 
 
141. Zhang, J. J., Vinkemeier, U., Gu, W., Chakravarti, D., Horvath, C. M., and 
Darnell Jr., J. E. (1996) Two contact regions between Stat1 and CBP/p300 in 
interferon ! signaling. Proc. Natl. Acad. Sci. USA 93, 15092-15096 
 
142. Bhattacharya, S., Eckner, R., Grossman, S., Oldread, E., Arany, Z., D'Andrea, A., 
and Livingston, D. M. (1996) Cooperation of Stat2 and p300/CBP in signalling 
induced by interferon-a. Nature 383, 344-347 
 
143. Gingras, S., Simard, J., Groner, B., and Pfitzner, E. (1999) p300/CBP is required 
for transcriptional induction by interleukin-4 and interacts with Stat6. Nucleic 
Acids Res 27, 2722-2729 
 
144. Luo, G., and Yu-Lee, L. (2000) Stat5b inhibits NFkappaB-mediated signaling. 
Mol Endocrinol 14, 114-123 
 
145. Vigushin, D. M., and Coombes, R. C. (2002) Histone deacetylase inhibitors in 
cancer treatment. Anticancer Drugs 13, 1-13 
 
146. Kim, H. S., and Lee, M. S. (2007) STAT1 as a key modulator of cell death. Cell 
Signal 19, 454-465 
 
147. Kramer, O. H., Knauer, S. K., Greiner, G., Jandt, E., Reichardt, S., Guhrs, K. H., 
Stauber, R. H., Bohmer, F. D., and Heinzel, T. (2009) A phosphorylation-
acetylation switch regulates STAT1 signaling. Genes Dev 23, 223-235 
 38 
 
148. Glozak, M. A., Sengupta, N., Zhang, X., and Seto, E. (2005) Acetylation and 
deacetylation of non-histone proteins. Gene 363, 15-23 
 
149. Cowger, J. J., and Torchia, J. (2006) Direct association between the CREB-
binding protein (CBP) and nuclear receptor corepressor (N-CoR). Biochemistry 
45, 13150-13162 
 
150. Gregoire, S., Xiao, L., Nie, J., Zhang, X., Xu, M., Li, J., Wong, J., Seto, E., and 
Yang, X. J. (2007) Histone deacetylase 3 interacts with and deacetylates myocyte 
enhancer factor 2. Mol. Cell. Biol. 27, 1280-1295 
 
151. Peserico, A., and Simone, C. (2011) Physical and functional HAT/HDAC 
interplay regulates protein acetylation balance. J Biomed Biotechnol. 2011, 
371832 
 
152. Witt, O., Deubzer, H. E., Milde, T., and Oehme, I. (2009) HDAC family: What 
are the cancer relevant targets? Cancer Lett 277, 8-21 
 
153. Yang, X. J., and Gregoire, S. (2005) Class II histone deacetylases: from sequence 
to function, regulation, and clinical implication. Mol Cell Biol 25, 2873-2884 
 
154. Bertrand, P. (2010) Inside HDAC with HDAC inhibitors. Eur J Med Chem 45, 
2095-2116 
 
155. McQuown, S. C., and Wood, M. A. (2011) HDAC3 and the molecular brake pad 
hypothesis. Neurobiol Learn Mem 96, 27-34 
 
156. Li, G., Jiang, H., Chang, M., Xie, H., and Hu, L. (2011) HDAC6 !-tubulin 
deacetylase: a potential therapeutic target in neurodegenerative diseases. J Neurol 
Sci 304, 1-8 
 
157. Itoh, Y., Suzuki, T., and Miyata, N. (2008) Isoform-selective histone deacetylase 
inhibitors. Curr Pharm Des 14, 529-544 
 
158. Carey, N., and La Thangue, N. B. (2006) Histone deacetylase inhibitors: 
gathering pace. Curr Opin Pharmacol 6, 369-375 
 
159. Chen, L. (2011) Medicinal chemistry of sirtuin  inhibitors. Curr Med Chem 18, 
1936-1946 
 
160. Alcaín, F. J., and Villalba, J. M. (2009) Sirtuin inhibitors. Expert Opin Ther Pat 
19, 283-294 
 
161. Houtkooper, R. H., Pirinen, E., and Auwerx, J. (2012) Sirtuins as regulators of 
metabolism and healthspan. Nat Rev Mol Cell Biol 13, 225-238 
 39 
 
162. Longworth, M. S., and Laimins, L. A. (2006) Histone deacetylase 3 localizes to 
the plasma membrane and is a substrate of Src. Oncogene 25, 4495-4500 
 
163. Takami, Y., and Nakayama, T. (2000) N-terminal region, C-terminal region, 
nuclear export signal, and deacetylation activity of histone deacetylase-3 are 
essential for the viability of the DT40 chicken B cell line. J Biol Chem 275, 
16191-16201 
 
164. Bertos, N. R., Wang, A. H., and Yang, X. J. (2001) Class II histone deacetylases: 
structure, function, and regulation. Biochem Cell Biol 79, 243-252 
 
165. Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, 
W., and Verdin, E. (2002) Enzymatic activity associated with class II HDACs is 
dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol 
Cell 9, 45-57 
 
166. Yin, L., and Lazar, M. A. (2005) The orphan nuclear receptor Rev-erbalpha 
recruits the N-CoR/histone deacetylase 3 corepressor to regulate the circadian 
Bmal1 gene. Mol Endocrinol 19, 1452-1459 
 
167. Chen, L., Fischle, W., Verdin, E., and Greene, W. C. (2001) Duration of nuclear 
NF-kB action regulated by reversible acetylation. Science. 293, 1653-1657 
 
168. Zhang, X., Ozawa, Y., Lee, H., Wen, Y. D., Tan, T. H., Wadzinski, B. E., and 
Seto, E. (2005) Histone deacetylase 3 (HDAC3) activity is regulated by 
interaction with protein serine/threonine phosphatase 4. Genes Dev 19, 827-839 
 
169. Grozinger, C. M., and Schreiber, S. L. (2000) Regulation of histone deacetylase 4 
and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc.  
Nat. Acad. Sci. USA 97, 7835-7840 
 
170. Guenther, M. G., Barak, O., and Lazar, M. A. (2001) The SMRT and N-CoR 
corepressors are activating cofactors for histone deacetylase 3. Mol. Cell. Biol. 21, 
6091-6101 
 
171. Fischle, W., Dequiedt, F., Fillion, M., Hendzel, M. J., Voelter, W., and Verdin, E. 
(2001) Human HDAC7 histone deacetylase activity is associated with HDAC3 in 
vivo. J Biol Chem. 276, 35826-35835 
 
172. Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., 
Zheng, S., Yenamandra, A., Locke, K., Yuan, J. L., Bonine-Summers, A. R., 
Wells, C. E., Kaiser, J. F., Washington, M. K., Zhao, Z., Wagner, F. F., Sun, Z. 
W., Xia, F., Holson, E. B., Khabele, D., and Hiebert, S. W. (2010) Hdac3 is 
essential for the maintenance of chromatin structure and genome stability. Cancer 
Cell 18, 436-447 
 40 
 
173. Eot-Houllier, G., Fulcrand, G., Watanabe, Y., Magnaghi-Jaulin, L., and Jaulin, C. 
(2008) Histone deacetylase 3 is required for centromeric H3K4 deacetylation and 
sister chromatid cohesion. Genes Dev 22, 2639-2644 
 
174. Yoo, J. Y., Choi, K. C., Kang, H., Kim, Y. J., Lee, J., Jun, W. J., Kim, M. J., Lee, 
Y. H., Lee, O. H., and Yoon, H. G. (2010) Histone deacetylase 3 is selectively 
involved in L3MBTL2-mediated transcriptional repression. FEBS Lett 584, 2225-
2230 
 
175. Feng, D., Liu, T., Sun, Z., Bugge, A., Mullican, S. E., Alenghat, T., Liu, X. S., 
and Lazar, M. A. (2011) A circadian rhythm orchestrated by histone deacetylase 3 
controls hepatic lipid metabolism. Science 331, 1315-1319 
 
176. Knutson, S. K., Chyla, B. J., Amann, J. M., Bhaskara, S., Huppert, S. S., and 
Hiebert, S. W. (2008) Liver-specific deletion of histone deacetylase 3 disrupts 
metabolic transcriptional networks. EMBO J 27, 1017-1028 
177. Haberland, M., Carrer, M., Mokalled, M. H., Montgomery, R. L., and Olson, E. 
N. (2010) Redundant control of adipogenesis  by histone deacetylases 1 and 2. J 
Biol Chem 285, 14663-14670 
 
178. Fajas, L., Egler, V., Reiter, R., Hansen, J., Kristiansen, K., Debril, M. B., Miard, 
S., and Auwerx, J. (2002) The retinoblastoma-histone deacetylase 3 complex 
inhibits PPARg and adipocyte differentiation. Dev. Cell 3, 903-910 
 
179. Polo, J. M., Ci, W., Licht, J. D., and Melnick, A. (2008) Reversible disruption of 
BCL6 repression complexes by CD40 signaling in normal and malignant B-cells. 
Blood 112, 644-651 
 
180. Ranuncolo, S. M., Polo, J. M., Dierov, J., Singer, M., Kuo, T., Greally, J., Green, 
R., Carroll, M., and Melnick, A. (2007) Bcl-6 mediates the germinal center B cell 
phenotype and lymphomagenesis through transcriptional repression of the DNA-
damage sensor ATR. Nat Immunol. 8, 705-714 
 
181. Ranuncolo, S. M., Wang, L., Polo, J. M., Dell'Oso, T., Dierov, J., Gaymes, T. J., 
Rassool, F., Carroll, M., and Melnick, A. (2008) BCL6-mediated attenuation of 
DNA damage sensing triggers growth arrest and senescence through a p53-
dependent pathway in a cell context-dependent manner. J. Biol. Chem. 283, 
22565-22572 
 
182. Barish, G. D., Yu, R. T., Karunasiri, M. S., Becerra, D., Kim, J., Tseng, T. W., 
Tai, L. J., Leblanc, M., Diehl, C., Cerchietti, L., Miller, Y. I., Witztum, J. L., 
Melnick, A. M., Dent, A. L., Tangirala, R. K., and Evans, R. M. (2012) The Bcl6-
SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell 
Metab 15, 554-562 
 
 41 
183. Andreassen, M., Frystyk, J., Faber, J., and Kristensen, L. O. (2012) GH activity 
and markers of inflammation: a crossover study in healthy  volunteers treated with 
GH and a GH receptor antagonist. Eur J Endocrinol 166, 811-819 
 
184. McGrath, S., Morris, M., and Bouloux, P. M. (1999) Growth hormone deficiency 
and atherosclerosis--is there a link? Growth Horm IGF Res 9, 9-13 
 
185. Sebastián, C., Serra, M., Yeramian, A., Serrat, N., Lloberas, J., and Celada, A. 
(2008) Deacetylase activity is required for STAT5-dependent GM-CSF functional 
activity in macrophages and differentiation to dendritic cells. J Immunol 180, 
5898-5906 
 
186. Grunstein, M. (1997) Histone acetylation in chromatin structure and transcription. 
Nature 389, 349-352 
 
187. Strahl, B. D., and Allis, C. D. (2000) The language of covalent histone 
modifications. Nature 403, 41-45 
 
188. Kornberg, R. D., and Lorch, Y. (1999) Twenty-five years of the nucleosome, 
fundamental particle of the eukaryote chromosome. Cell 98, 285-294 
 
189. Berger, S. L. (2002) Histone modifications in transcriptional regulation. Curr. Op. 
Gen. Dev. 12, 142-148 
 
190. Ruthenburg, A. J., Li, H., Patel, D. J., and Allis, C. D. (2007) Multivalent 
engagement of chromatin modifications by linked binding modules. Nat Rev Mol 
Cell Biol 8, 983-994 
 
191. Gardner, K. E., Allis, C. D., and Strahl, B. D. (2011) Operating on chromatin, a 
colorful language where context matters. J Mol Biol 409, 36-46 
 
192. Krogan, N. J., Dover, J., Wood, A., Schneider, J., Heidt, J., Boateng, M. A., Dean, 
K., Ryan, O. W., Golshani, A., Johnston, M., Greenblatt, J. F., and Shilatifard, A. 
(2003) The Paf1 complex is required for histone H3 methylation by COMPASS 
and Dot1p: linking transcriptional elongation to histone methylation. Mol Cell 11, 
721-729 
 
193. Ng, H. H., Robert, F., Young, R. A., and Struhl, K. (2003) Targeted recruitment 
of Set1 histone methylase by elongating Pol II provides a localized mark and 
memory of recent transcriptional activity. Mol Cell 11, 709-719 
 
194. Bernstein, B. E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D. K., 
Huebert, D. J., McMahon, S., Karlsson, E. K., Kulbokas, E. J. r., Gingeras, T. R., 
Schreiber, S. L., and Lander, E. S. (2005) Genomic maps and comparative 
analysis of histone modifications in human and mouse. Cell 120, 169-181 
 
 42 
195. Keogh, M. C., Kurdistani, S. K., Morris, S. A., Ahn, S. H., Podolny, V., Collins, 
S. R., Schuldiner, M., Chin, K., Punna, T., Thompson, N. J., Boone, C., Emili, A., 
Weissman, J. S., Hughes, T. R., Strahl, B. D., Grunstein, M., Greenblatt, J. F., 
Buratowski, S., and Krogan, N. J. (2005) Cotranscriptional set2 methylation of 
histone H3 lysine 36 recruits a repressive Rpd3 complex. Cell 123, 593-605 
 
196. Carrozza, M. J., Li, B., Florens, L., Suganuma, T., Swanson, S. K., Lee, K. K., 
Shia, W. J., Anderson, S., Yates, J., Washburn, M. P., and Workman, J. L. (2005) 
Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S 
to suppress spurious intragenic transcription. Cell 123, 581-592 
 
197. Li, J., Moazed, D., and Gygi, S. P. (2002) Association of the histone 
methyltransferase Set2 with RNA polymerase II plays a role in transcription 
elongation. J Biol Chem 277, 49383-49388 
 
198. Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., and Reinberg, 
D. (2002) Histone methyltransferase activity associated with a human 
multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 16, 
2893-2905 
 
199. Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, 
R. S., and Zhang, Y. (2002) Role of histone H3 lysine 27 methylation in 
Polycomb-group silencing. Science 298, 1039-1043 
 
200. Aagaard, L., Laible, G., Selenko, P., Schmid, M., Dorn, R., Schotta, G., Kuhfittig, 
S., Wolf, A., Lebersorger, A., Singh, P. B., Reuter, G., and Jenuwein, T. (1999) 
Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-9 
encode centromere-associated proteins which complex with the heterochromatin 
component M31. EMBO J 18, 1923-1938 
 
201. Mungamuri, S. K., Benson, E. K., Wang, S., Gu, W., Lee, S. W., and Aaronson, 
S. A. (2012) p53-mediated heterochromatin reorganization regulates its cell fate 







Identification of Bcl6 as a novel GH-regulated transcriptional repressor: Bcl6 and 





Sequencing of the human genome has provided new tools for addressing long-standing 
questions regarding transcription regulatory events. Whereas GH has long been 
recognized as a key regulator of growth and metabolism, new questions continually arise 
as to how it modulates cellular function. We have made considerable progress in 
understanding how GH signals through the GH receptor and its associated tyrosine kinase 
Janus kinase-2 (1, 2) and have achieved some knowledge of how GH regulates gene 
transcription, through analysis of well-studied GH target genes such as those encoding 
Igf1, C-fos, Spi2.1, Cyp2, and Cyp3 family members (3, 4, 5, 6, 7, 8, 9, 10). However, to 
understand the diverse and complex events that are modulated by GH, it is informative to 
gain a global perspective of how GH regulates target genes and how GH target genes 
relate to physiological responses to GH.  
!
GH is a major promoter of postnatal longitudinal growth. In addition, GH antagonizes 
insulin action as part of the coordinated mechanisms by which multiple hormones 
maintain metabolic homeostasis. In conditions of chronic GH excess, development of 
insulin resistance and diabetes have long been recognized (11, 12, 13). The signaling  
 
______________________________________________________  
*Portions of this chapter are published in the following publication:!!
Chen Y*, Lin G*, Huo JS, Barney D, Wang Z, Livshiz T, States DJ, Qin ZS, Schwartz J. 
(2009) Computational and functional analysis of growth hormone (GH)-regulated genes 
identifies the transcriptional repressor B-cell lymphoma 6 (Bcl6) as a participant in GH-
regulated transcription. Endocrinology150:3645-3654. *Co-first authors.!
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molecule phosphoinositide 3! kinase (PI3K) has been implicated in GH-induced insulin 
resistance (14, 15), and the gene encoding its regulatory subunit p85 " (PI3K p85") is 
induced by GH in adipocytes (15, 16). Adipose tissue is one of the most sensitive target 
tissues for GH and plays a central role in its metabolic actions. In the present study, a 
profile of GH-regulated genes obtained using GH-treated adipocytes (16) was subjected 
to deep data mining to gain insight into genes involved in the physiological responses to 
GH. Through an integrative series of computational analyses, B cell lymphoma 6 (Bcl6), 
a transcriptional repressor, was identified as a new participant in GH-regulated gene 
transcription. Functional studies support the role of Bcl6 in transcriptional repression of 
GH-regulated genes.  
!
The gene profile used for analysis was obtained from microarray data sets from 3T3-
F442A adipocytes treated with GH for 48 h, a time when GH induces insulin resistance, 
or for 4 h or 30 min for insight into triggering events. Genes were induced or inhibited by 
GH in time-dependent waves associated with biological processes regulated by GH. 
Expression of genes involved in transcription regulation was induced at 30 min, and 
expression of genes associated with lipid and cholesterol biosynthesis was inhibited at 
later times tested (48 h) (16). The present analysis used the gene data sets to assess 
physiological pathways in which the GH-regulated genes are enriched and to identify key 
regulatory genes, with results pinpointing the genes for suppressor of cytokine signaling 
2 (Socs2) and PI3K p85a. Clustering using the model-based Chinese Restaurant 
Clustering (CRC) algorithm identified the same genes in a cluster of genes highly 
responsive to GH at 48 h; the cluster also included the gene for Bcl6, a transcriptional 
repressor, which was potently inhibited by GH. Transcriptional network analysis 
predicted relationships among the GH-regulated genes and showed expression of several 
of them, including Bcl6, to be linked to signal transducer and activator of transcription 
(Stat) 5, an established GH-regulated transcription factor. The computational predictions 
led to measurements suggesting inverse roles of Bcl6 and Stat5 in regulating the Socs2 
gene. Together these analyses identify the transcriptional repressor Bcl6 as a new 
transcriptional mediator in GH action and suggest that Bcl6 may play general roles in 




Gene Set Enrichment Analysis (GSEA) predicts GH-regulated pathways 
!
For insight into mechanisms by which gene transcription mediates diverse responses to 
GH, a profile of genes regulated by GH was subjected to deep data mining. The profile 
identified 225 genes that were stimulated in time-dependent patterns after GH treatment 
in 3T3-F442A adipocytes as well as 287 genes that were repressed at the same times, as 
reported previously (16).  
!
GSEA was used to identify pathways that showed overall gene expression changes with 
GH treatment. GSEA discerns changes between two biological states in the expression 
levels of sets of genes selected a priori in transcriptional profiling experiments. This 
method has the advantage of evaluating the overall effect of a gene set rather than any 
single gene, a feature important to studies of complex physiological responses such as 
growth or metabolic regulation, in which small changes in a set of genes in a pathway 
might have a larger impact than a greater change in a single gene (17). GSEA was 
performed on the entire microarray data set of GH-regulated genes in 3T3-F442A 
adipocytes. Because earlier analysis of the gene profile (16) revealed GH-regulated 
waves of gene transcription over time, the gene expression data for each time point were 
analyzed separately. The outcome yielded ranked gene sets at each time, evaluated 
through their normalized enrichment scores (NES), which indicate the extent that genes 
within the set are enriched in the study samples. Combining NES score rankings for each 
pathway at all time points indicated that the top five highly enriched gene sets regulated 
by GH include (in order) cell growth and death, insulin signaling, apoptosis, Janus 
kinase-Stat signaling and phosphoinositide signaling. These gene sets are consistent with 
reported biological processes and physiological functions regulated by GH (2, 12, 13, 
35). Another gene set that was relatively highly ranked was Toll-like receptor signaling; 
gene sets that were inhibited include pathways for tyrosine metabolism and glutathione 
metabolism. Because the original samples for microarray were obtained under conditions 
associated with GH-induced insulin resistance, the pathway for insulin signaling was 
! 46 
examined further. Interestingly, within this pathway, the genes encoding Socs2 and PI3K 
p85! were the most highly induced after GH treatment for 48 h.  
!
Cluster analysis singles out Bcl6 as a novel gene inhibited by GH 
!
The goal of clustering gene expression profiles is to group genes that display related 
expression patterns. Hierarchical clustering (36) of the data set of GH-regulated genes 
studied here had revealed clusters of genes sharing similar temporal patterns of response 
to GH (16). In the present analysis, a recently developed, model-based clustering 
approach based on the CRC algorithm (22) was applied to cluster the genes regulated by 
GH (16). CRC is able to recognize complex correlation patterns such as time-shifted 
and/or inverted patterns and group them into the same cluster and thus reveals 
functionally related genes not detected by most other clustering approaches. Inverted 
patterns are as important as positively correlated patterns because they show activities 
and regulatory functions of repressive transcription regulators.  
!
Of the 12 clusters that were defined by CRC analysis (Fig. 2.1, left panel), Cluster D was 
selected for initial analysis because it contains genes showing the greatest fold changes 4-
-48 h after GH (Fig. 2.1, right panel), consistent with delayed timing of GH responses 
such as longitudinal growth and insulin resistance (12, 13, 35). The genes include well-
studied GH target genes encoding Igf1 (3, 4, 37) and signaling molecules in the SOCS 
family, Socs2 and Cish (29, 38), as well as PI3K p85! (15). The genes for Socs2 and 
PI3K p85! were also highlighted in the GSEA pathway analysis. Additional genes 
stimulated by GH in this paradigm encode the transcription factors activating 
transcription factor (ATF) 3 and Kruppel-like factor (KLF) 5; signaling molecules 
repressor of G-protein signaling 16 and interferon-inducible p47 GTPase; the cytokine 
IL6; and growth arrest and DNA damage inducible-45". These genes were induced by 
GH in adipocytes, and all except IL6 showed highest levels of induction at 4 and 48 h. 
Importantly, one other gene in the cluster stood out as being the most highly repressed by 









Figure 2.1  
 
CRC analysis of GH-regulated genes clusters coregulated genes. A, Heat map shows 
results of CRC cluster analysis of a data set of GH-regulated genes. Among the 12 
defined clusters, Cluster D contains genes showing greatest differential regulation by GH 
at 4 and 48 h. Red indicates increase; green indicates decrease. B, Expanded heat map of 






The expression patterns in response to GH of most of the genes in this cluster, including 
the dramatic decrease in Bcl6 expression, were confirmed by quantitative real-time PCR 
of RNA from GH-treated 3T3-F442A adipocytes (Fig. 2.2). The overall changes in 
mRNA for each gene correspond with microarray findings at 4 or 48 h: Expression of 
Socs2 and Cish mRNA was the most highly stimulated by GH (50- to 60-fold). Bcl6 
expression was inhibited almost 80%. These findings identify the gene encoding the 
transcriptional repressor Bcl6 as a novel target of GH and suggest that regulation of 
transcriptional repression plays a role in GH-regulated gene expression. 
!
Transcriptional network analysis highlights Stat 5-regulated genes, including the 
repressor Bcl6 
!
For an unbiased view of transcriptional relationships among the GH-regulated genes in 
Cluster D, a transcriptional regulation network (Fig. 2.3) was built for genes in this 
cluster and their known interacting transcription factors, using the GeneGo database (St. 
Joseph, MO) with MetaCore software from GeneGo. The network relates the genes 
submitted with transcription factors that regulate them, as reported in the literature; for 
genes submitted that encode transcription factors, the target genes that they regulate are 
also linked. The analysis revealed links for regulation of seven of the genes in the cluster. 
Prominently, Stat5 emerged as a hub linking four of the genes: Stat5 has been shown to 
activate expression of the genes for Socs2, Cish, and Igf1 (4, 29, 38). Bcl6, the only gene 
in the cluster that was repressed by GH, was also linked to Stat5. Several reports have 
shown Stat5 to be a regulator of Bcl6 expression, either as an inducer or a repressor, 
depending on cell type (39, 40, 41). The coordination via Stat5 of these four genes, as 
revealed in the network, suggests that the genes may be coregulated by mechanisms 
involving Stat5 in response to GH. Genes for KLF5, ATF3, and IL6 appear from the 
network analysis to be transcriptionally regulated by mechanisms not directly involving 
Stat5.  
!
Because the genes in Cluster D had similar expression patterns in response to GH over 
time, it was speculated that they might be regulated by similar transcriptional 






Figure 2.2  
 
Expression of mRNA for representative genes in Cluster D. 3T3-F442A adipocytes 
were treated with GH for the indicated times; RNA was prepared and analyzed by 
quantitative real-time PCR. Responses to GH are expressed as (GH-C)/C. Gray bars 
indicate activation of gene expression in response to GH, black bars indicate repression. 
Data are representative of two to eight independent experiments. The GH-responsive 

















Network analysis using GeneGo MetaCore identifies coregulated GH target genes 
coordinated by Stat 5. Boxes indicate genes submitted; oval designates transcription 






promoter regions of genes in Cluster D (Table 2.1). Conserved sites for Stats and for 
Bcl6, as well as for CCAAT/enhancer binding protein (C/EBP), KLF/SP1, and ATF 
family factors, were predicted in almost every gene in the cluster. Stats and C/EBP family 
proteins are reported mediators of GH-regulated gene transcription (42, 43); ATFs, 
members of the cAMP response element-binding protein family of transcription factors, 
are also regulated by GH (44, 45). Bcl6 and KLF/SP1 factors appear to be novel 
transcriptional regulators of the GH target genes containing these binding sites. 
 
The transcriptional repressor Bcl6 mediates expression of GH target genes 
 
The relationships between Bcl6 and Stat5 suggested by network and promoter analyses 
raise the possibility that these two transcription factors may be coordinated in regulating 
the expression of some of the other genes in this cluster. Socs2 expression is not only 
highly stimulated by GH, but Socs2 protein participates in GH signaling (46, 47). When 
the most highly stimulated (Socs2) and most highly repressed (Bcl6) genes in the present 
analysis were compared, the lowest GH concentrations (5 ng/ml) inhibited Bcl6 mRNA 
and induced Socs2 expression, suggesting an inverse relationship that is highly 
responsive to GH (Fig. 2.4). Consistent with this, in multiple experiments, inhibition of 
Bcl6 and induction of Socs2 expression by GH followed a similar time course, with little 
or no responses at 30 min and substantial responses at 4 or 48 h, in both 3T3-F442A 
adipocytes and preadipocytes (Fig. 2.5). Furthermore, the endogenous Bcl6 protein was 
detectable in 3T3-F442A preadipocytes; Bcl6 was also detected in H4IIE rat hepatoma 
cells (Fig. 2.4, inset).  
 
The inverse regulation of Bcl6 and Socs2 by GH was evaluated further because Socs2 is 
an established Stat5 target gene. The human Socs2 gene contains a GH-inducible region 
in the promoter, which contains two GH-responsive Stat5 binding sites (29) (Fig. 2.6). 
This sequence, fused upstream of thymidine kinase-luc (termed Socs2-luc), was 
transfected into 293T cells along with a construct encoding GH receptor. Treatment with 
GH for 24 h stimulated Socs2-luc as expected (Fig. 2.7). However, when Bcl6 was 








Table 2.1  
 
Predicted transcription factor binding sites in GH-regulated genes. Promoters of 
murine genes in cluster D were analyzed using Genomatix tools to predict binding sites 
for the indicated transcription factors.  KLF sites were searched as SP1 sites; ATF sites 
were searched as CREB family sites.  Letters indicate that conserved sites are found in 
orthologs of corresponding species as follows:  H: Homo sapiens; P: Pan troglodytes; M: 
Macaca mulatta; C: Canis familiaris; B: Bos Taurus; R: Rattus norvegicus.  Outcomes 
are expressed as Y = sites were found; Y(-) = sites were found in mouse genes, but the 











Inverse regulation of Bcl6 and Socs2 mRNA in response to GH. Dose response: 
Comparison of Bcl6 (top) and Socs2 (bottom) mRNA in 3T3-F442A preadipocytes after 
48 h incubation with varying concentrations of GH. Data are expressed as fold change 
due to GH over control (set to 1). Each point shows mean ± SE for three independent 
experiments. (Data by T Livshiz.) Inset, Bcl6 protein is detected in 3T3-F442A 
preadipocytes and hepatoma cells. Immunoblotting with anti-Bcl6 demonstrates the 
presence of Bcl6 protein (arrowhead) in lysates of 3T3-F442A preadipocytes (lane P) and 
H4IIE hepatoma cells (lane H). Lane R shows Ramos B cells for reference. Lysates used 











Inverse regulation of Bcl6 and Socs2 mRNA in response to GH. 3T3-F442A 
adipocytes or preadipocytes were incubated without (open bars) or with (filled bars) GH 
for the times indicated.  RNA was prepared and analyzed by quantitative real-time PCR 
using primers for Bcl6 (top) or Socs2 (bottom), as for Fig. 4.  Data are expressed as fold 
change relative to control (set to 1).  Each bar shows mean ± SE (n=5 independent 
experiments) for adipocytes, mean ± range (n=2) for preadipocytes. Responses to GH in 
adipocytes were statistically significant (p < 0.01) for Bcl6 at 0.5, 4 and 48 hr, and for 

















Figure 2.6  
 
Schematic of the human SOCS2 gene. The GH responsive region of SOCS2 is located 
in the promoter region of the gene. This sequence contains two GH-responsive Stat5 sites 
(labeled black boxes) and an enhancer box (E-box) site (gray box). Shown below are the 
DNA binding consensus sequences for Bcl6 and Stat5, as well as the Stat5 consensus 













Figure 2.7  
 
Bcl6 mediates expression of GH target genes: Bcl6 inhibits expression of Socs2-luc. 
A plasmid containing the GH-responsive sequence of the Socs2 gene upstream of 
luciferase (Socs2-luc), and plasmids for the GH receptor and !-galactosidase were 
transfected into 293T cells in the absence or presence of an expression plasmid for Bcl6. 
Cells were treated without (white bars) or with GH (black bars) for 24 h, and luciferase 
activity was measured, expressed as RLU (relative luciferase units). Bars, mean ± se for 
observations in six independent experiments. The expression of Socs2-luc in the presence 
of Bcl6 was significantly (P < 0.01) less than in the absence of Bcl6 (compare white 
bars). The response to GH (compare white and black bars) was significant (P < 0.01) in 
the absence of Bcl6 but was not significant in the presence of Bcl6. Socs2-luc in the 
presence of GH (compare black bars) in the absence of Bcl6 was significantly (P < 0.01) 






consistent with the role of Bcl6 as a transcriptional repressor. In the presence of Bcl6, GH 
failed to elicit a significant stimulation of Socs2-luc over the repressed basal activity. 
Consistent with inverse regulation by GH, Socs2-luc is inhibited by Bcl6, whereas GH, 
via Stat5, activates it, as expected (29). 
 
Endogenous Bcl6 and Stat5 also show an inverse relationship in occupying endogenous 
Socs2 DNA, as demonstrated by chromatin immunoprecipitation (ChIP). Because Socs2 
is regulated by Bcl6 as well as Stat5, the occupancy of these two factors on the Socs2 
GH-responsive sequence was examined in vivo by ChIP (Fig. 2.8). Occupancy of 
endogenous Bcl6 on Socs2 was evident in the absence of GH and decreased 
progressively after GH treatment; Bcl6 occupancy was almost undetectable 48 h after 
GH. For Stat5, occupancy on Socs2 was negligible or absent without GH treatment (time 
0), but Stat5 occupancy increased after GH. Thus, the occupancy of Bcl6 decreased as 
that of Stat5 increased. Occupancy of acetylated histone H4 is a positive control 
consistent with transcriptional activation of Socs2; no occupancy was detected with IgG 
or beads alone. Together these findings indicate that endogenous Bcl6 occupies the Socs2 
gene in vivo. The occupancy of Bcl6 on DNA encompassing the GH-responsive sequence 
of Socs2 decreases with GH treatment, whereas occupancy of Stat5 increases with GH. 
The inverse relationship between occupancy of Bcl6 and Stat5 on Socs2 DNA is 




An integrative computational strategy reveals novel aspects of GH-regulated 
transcription 
 
High throughput technologies such as DNA microarrays provide a global view of the 
expression patterns of all genes in the genome. This is important for analyzing complex 
biological processes such as those regulated by GH, including longitudinal growth or 
insulin resistance, in which it is crucial to understand how genes cooperate to carry out 











Bcl6 and Stat5 occupy Socs2 inversely in response to GH. 3T3-F442A adipocytes or 
preadipocytes were treated with GH for the indicated times and nuclei were analyzed by 
ChIP, using antibodies against Bcl6, Stat5, or acetylated histone 4 (AcH4), with primers 
for the GH-responsive sequence in the Socs2 gene. Samples treated with IgG or no 
antibody served as controls; 1% or 0.5% input is shown as indicated. Data are 
representative of over seven independent experiments. Comparable Bcl6 occupancy was 
seen when immunoprecipitations for Bcl6 were carried out using a different antibody 




throughput technologies, a key challenge is how to extract biological insights effectively 
from massive and noisy data. Powerful computational and statistical data mining tools 
have been developed and are able to translate the raw and noisy data into new scientific 
knowledge when applied appropriately. The computational tools used, when applied 
independently, provide pieces of evidence from different perspectives. Here an 
integrative computational data mining strategy was used; the combined approaches allow 
interpretation in the face of limitations inherent in each computational tool. This study 
demonstrates the effectiveness of a strategy using an array of computational tools to bring 
fresh insights and provide new clues for understanding complex biological processes 
regulated by hormones.  
 
Through deep data mining, this study used several distinct computational approaches 
which reinforced each other to identify Bcl6 as a new player in GH-regulated 
transcription, and suggest its interplay with Stat5. GSEA focused on functionally 
important GH target genes, which facilitated identifying a cluster of interest. CRC 
clustering singled out Bcl6 because it identified Bcl6 among the genes most highly 
regulated by GH at 4-48 h, despite the fact that Bcl6 was the one gene that was highly 
repressed, whereas other genes in the cluster were stimulated. Construction of a 
transcriptional network highlighted the role of Stat5 by linking Bcl6 with Stat5 as well as 
Socs2 with Stat5, suggesting Socs2 as a possible target gene of Bcl6. Promoter analysis 
predicted that some GH target genes contain both Stat5 and Bcl6 sites. Thus, the 
combination of high throughput technologies, integrative use of data mining tools, and 
statistical analysis, applied to questions in understanding GH transcription and its 
physiological actions have provided an efficient strategy to improve our understanding of 
mechanisms of transcriptional repression and their interface with transcriptional 
activation in the context of GH action.  
 
The transcriptional repressor Bcl6 participates in GH-regulated transcription 
 
This work implicates Bcl6 in GH-regulated transcription and demonstrates that Bcl6 
serves as a potent repressor. The transcriptional repression properties of Bcl6 are well 
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documented (48), based on its established roles in immune function. Bcl6 is a member of 
the poxvirus and zinc finger/broad-complex, tramtrack and bric-a-brac zinc finger family 
of proteins. Translocations involving Bcl6 occur frequently in B cell lymphomas. Bcl6 is 
known for its essential role in B cell differentiation in germinal centers (48, 49). 
Transcriptional repression by Bcl6 involves a variety of mechanisms: it recruits 
corepressors such as silencing mediator of retinoid and thyroid receptors (SMRT), 
nuclear receptor corepressor (NCoR), and Bcl6 interacting corepressor (BCoR) as well as 
histone deacetylases (50, 51, 52, 53), and it associates with chromatin remodeling 
complexes and other repressors (54, 55, 56). A potent transcriptional repressor such as 
Bcl6 has not previously been implicated in GH-regulated transcription. Previous 
investigation of gene repression by GH showed that Stat5 was modulated by other 
transcription regulatory molecules such as Forkhead box O1 (FoxO1), and hepatocyte 
nuclear factor (HNF)-3!, -4", and -6 (9, 57, 58, 59). It remains to be determined whether 
Bcl6, and associated transcription regulatory factors, interact in complexes to regulate 
GH target genes.  
 
Because Bcl6 expression is dramatically inhibited by GH, the consequence of such 
reversal of repression likely contributes to activation of genes in response to GH. Socs2 is 
an excellent candidate because Bcl6 occupies Socs2 DNA within a GH-responsive 
sequence (29), and its occupancy decreases on GH treatment. Furthermore, expression of 
Bcl6 inhibited Socs2-luc under basal conditions; a small residual increase with GH was 
not statistically significant. Together these findings are consistent with Socs2 being a new 
gene target of Bcl6. It can be speculated that in response to GH, Bcl6 functions in 
coordination with Stat5, which increases occupancy on Socs2 DNA in a pattern 
reciprocal to the decrease in occupancy of Bcl6 after GH treatment. The consequence of 
both the increase in Stat5 and the decrease in Bcl6 is to increase expression of Socs2 in 
response to GH. Thus, Bcl6 and Stat5 may participate in an inverse transcriptional 
repressor/activator relationship to facilitate expression of Socs2 and perhaps other GH-
regulated genes. It is relevant in this regard that the consensus DNA sequences that bind 
Bcl6 and Stat5 are remarkably similar (60, 61). It is also recognized that reduced 
availability of Bcl6 protein through its degradation or inactivation may contribute to its 
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reduced occupancy after GH; Erk-mediated phosphorylation and acetylation of Bcl6 have 
been reported to result in its degradation or inactivation (62, 63). GH is known to induce 
phosphorylation via Erk 1/2 and acetylation to activate transcription factors such as 
C/EBP! (28, 32) and may similarly modulate other transcription regulatory proteins in 
the nucleus. Overall, Bcl6 appears to be a highly responsive new player in GH-regulated 
transcription.  
 
Several studies have implicated Stats, particularly Stat5, in the regulation of Bcl6 gene 
expression. This regulation may be cell type specific because in a subset of germinal 
center cells, Stat5 increased expression of Bcl6 (41), whereas in B-lymphoma and other 
hematopoietic cell lines, Stat5 inhibited expression of Bcl6 (40). Interestingly, Stat3 
activation is coordinated with Bcl6 inhibition in regulating Blimp1 in plasma cell 
differentiation during B cell maturation (64). Furthermore, prolactin, which activates 
Stat5, induces Bcl6 in pancreatic !-cells (39); Bcl6 in turn represses Menin expression, 
which allows the !-cell proliferation of adaptive islet growth, as in pregnancy or obesity 
(39). Another report indicates that prolactin inhibits Bcl6 expression in breast cancer cell 
lines (65), suggesting that regulation of Bcl6 may vary with cell type. Further analysis of 
the role(s) of Bcl6 in repressing GH-regulated gene expression will provide new 
mechanistic insights into GH action.  
 
Contributions of Bcl6 to physiological responses to GH 
 
A novel observation in this study is that the transcriptional repressor Bcl6 is expressed 
and tightly regulated in adipocytes. Bcl6 is also detected in hepatoma cells, consistent 
with preliminary findings of Bcl6 mRNA in mouse liver (LaPensee, C., and J. Schwartz, 
unpublished data). These observations raise possibilities for identifying previously 
unrecognized functions of Bcl6 in metabolic regulation. Bcl6"/" mice are reported to 
show growth retardation (66, 67, 68), but their metabolic status has not been described. In 
a gene profile of human muscle biopsy samples before and after euglycemic insulin 
clamp studies, the gene for Bcl6 was reported to be repressed by insulin (69). A 
metabolic role of Bcl6 is further supported in this study by the observed coordination of 
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the functions of Bcl6 with those of Stat5 in regulating Socs2 because Stat5 has been 
amply demonstrated to participate in regulation of genes implicated in metabolic 
regulation and adipogenesis (70, 71, 72, 73). In this regard, it is of note that the original 
microarray experiments that generated the gene profile analyzed in this study were 
performed using adipocytes under conditions in which GH can induce insulin resistance 
(16, 74). The functions of many of the GH-regulated genes, identified by gene ontology 
categories, correspond with established physiological responses to GH (16). GSEA 
identified the insulin signaling pathway as one of the major pathways regulated by GH, 
implicating Socs2 and PI3K p85!. Suggestions that Socs2 contributes to insulin 
resistance are also reported (34). The present findings that Bcl6 is expressed in 
adipocytes and highly regulated by GH, which can induce insulin resistance, open new 
directions for analyzing mechanisms involving Bcl6 and transcriptional repression in 
regulation of metabolism in conditions such as obesity and diabetes.  
 
Together, these studies demonstrate how systems biology approaches involving 
integrative computational strategies can lead to identification of Bcl6 as a new participant 
in GH-regulated gene transcription, incorporating a potent and tightly regulated repressor 
as part of its regulatory mechanisms. Bcl6 is of additional interest because of its potential 
interplay with Stat5 in regulating target genes; such interactions may have broad 
relevance in metabolic and growth regulation and in the spectrum of cytokine actions that 
contribute to immune regulation and overall growth in normal and pathological 
conditions.  
 




This study analyzes a microarray data set with 561 probe sets showing significant 
differential expression signals in 3T3-F442A adipocytes treated with GH (500 ng/ml) for 
30 min, 4 h, or 48 h (16). Microarray data, based on U74A chip (Affymetrix, Santa Clara, 
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CA), have been deposited in Gene Expression Omnibus (GSE2120). The data were 
submitted to the following computational analyses.  
 
Gene set enrichment analysis (GSEA) 
 
To identify pathways in which GH-regulated genes are enriched, GSEA (17) version 1.0 
Java desktop application (http://www.broad.mit. edu/gsea/) was downloaded from Broad 
Institute of Massachusetts Institute of Technology and Harvard (Boston, MA). The 
analyses were performed separately on the microarray data at each of the three time 
points. The 175 gene sets used in the analysis were built from Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways (18, 19, 20). Each gene set is comprised of all of 
the genes either in one murine KEGG pathway or in multiple murine KEGG pathways 
belonging to the same category documented by KEGG 
(http://www.genome.jp/kegg/pathway. html). For example, the cell growth and death 
category includes the pathways for cell cycle, apoptosis, and p53 signaling. The 
microarray data were normalized using robust multichip average (21) and then analyzed 
using GSEA, with the maximum gene set size of 500 and the minimum gene set size of 
25; the other parameters were set as default. Outcomes were evaluated as normalized 
enrichment scores (NES).  
 
Gene expression profile clustering 
 
To examine patterns among highly regulated genes, the CRC algorithm 1.0 (22), a model-
based algorithm capable of clustering genes displaying complex correlations (e.g. time 
shifted and/or inverted), was downloaded (http://www.sph.umich.edu/csg/qin/CRC). The 
CRC algorithm automatically infers the number of clusters and assigns cluster 
membership. CRC also ranks predicted clusters and their members. The settings for CRC 
clustering were selected to allow clustering of inverted, but not time-shifted correlations, 




Transcriptional network analysis 
 
To evaluate transcriptional relationships among genes highly responsive to GH, a 
transcriptional network was built using the GeneGo MetaCore database and tools for the 
cluster of genes (murine), which were strongly regulated by GH at 4 and 48 h (cluster D), 





Conserved transcription factor binding sites of interest were predicted by scanning the 
promoters of the genes in the cluster showing a similar pattern of responses to GH at 4 
and 48 h (cluster D), using Genomatix tools. The orthologs for six species (Homo 
sapiens, Pan troglodytes, Macaca mulatta, Canis familiaris, Bos Taurus, Rattus 
norvegicus) of the analyzed mouse genes were retrieved from the Genomatix (Munich, 
Germany) genome annotation system ElDorado. The Genomatix optimized promoter 
length was used when available; otherwise a default region of !500 bp upstream of first 
transcription start site and +100 bp downstream of last transcription start site was used. 
The promoter sequences of orthologs were aligned with Genomatix DiAlign and the 
binding sites were predicted with Genomatix MatInspector. The associated motif 






Murine 3T3-F442A adipocytes or preadipocytes were incubated with GH for various 
times. RNA was isolated and analyzed by quantitative real-time PCR as described 
previously (16). Published primer sequences were used for Atf3, Gadd45", Gapdh (16); 
Socs2 (23); Cish, Bcl6 (24); KLF5 (25), and Igf1 (26). The primers for Pik3r1 were 
designed using Primer Express software (Applied Biosystems, Foster City, CA): 5’-
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CGTGGCACAGACTTGGTGTTT-3’ (sense) and 5’-GGCAGTGCTGGTGGATCC-3’ 
(antisense). Data were normalized to glyceraldehyde-3-phosphate dehydrogenase, which 
was constant between experimental groups, and responses to GH are expressed either as 




Lysates of 3T3-F442A preadipocytes (from H. Green; Harvard University, Boston, MA) 
and H4IIE rat hepatoma cells (from J. Messina; University of Alabama, Birmingham, 
AL) were analyzed by immunoblotting with anti-Bcl6 (C-19) (1:500; Santa Cruz 
Biotechnology, Santa Cruz, CA) as described (27). Lysates from Ramos B cells [from R. 
Kwok (University of Michigan, Ann Arbor, MI) and W. Dunnick (University of 
Michigan, Ann Arbor, MI) served as positive controls because they typically express 
Bcl6. The proteins were visualized using IRDye 800-coupled antirabbit IgG (1:12000; 
Rockland Immunochemicals, Gilbertsville, PA) on an Odyssey infrared scanning system 
(LI-COR Biosciences, Lincoln, NE). Molecular weight was estimated using protein 




293T cells (28) were transfected by calcium phosphate coprecipitation with a Socs2-
luciferase (luc) plasmid in which the GH-responsive sequence of the human Socs2 
promoter drives thymidine kinase-luc (29), in the presence of the plasmids CMV-human 
Bcl6 (30) or pcDNA3. Cells were additionally transfected with plasmids for rat GH 
receptor (31) and RSV-!-galactosidase for normalization. Eighteen hours later, cells were 
deprived of serum by replacing it with 1% BSA, incubated with human GH (500 ng/ml = 
22 nm; Eli Lilly, Indianapolis, IN)) for 24--26 h and used to measure luciferase activity 
as described previously (32). Data were analyzed by ANOVA with Bonferroni correction 




Chromatin Immunoprecipitation (ChIP) 
 
3T3-F442A adipocytes or preadipocytes were treated with GH (500 ng/ml) for the 
indicated times. Lysates of cross-linked cells (input) were used for ChIP as described (33) 
using anti-Bcl6 (N-3), anti-Stat5 (C-17) (Santa Cruz), antiacetylated histone H4 (AcH4, 
Millipore, Billerica, MA), or normal rabbit IgG (Santa Cruz). The anti-Stat5 antibody 
used recognizes both Stat5a and 5b. The term Stat5 is used herein to refer to both Stat5a 
and Stat5b, unless a distinction between them is pertinent. Primers targeting the binding 
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Identification of novel Bcl6 target genes and potential roles for Bcl6 in GH signaling 




Bcl6 is a potent transcriptional repressor best known for its role in the immune system, 
where it functions as a key regulator of Bcl6 differentiation (1-4). Bcl6 expression is high 
in germinal centers as developing B cells undergo somatic hypermutation and class 
switch recombination, and Bcl6 expression must be turned off for B cells to exit the 
germinal center stage and undergo terminal differentiation. Mechanisms by which 
dysregulation of Bcl6 results in pathologies of the immune system, such as B or T cell 
lymphoma, have long been a target of study.  
!
A microarray analysis carried out in cultured 3T3-F442A adipocytes revealed Bcl6 to be 
the gene most strongly inhibited in response to GH at later time points (4 h and 48 h), 
when adipocytes show phenotypes consistent with insulin resistance (5, 6). This 
suggested a novel role for Bcl6 in GH function, and possibly in the pathogenesis of 
diseases such as insulin resistance and diabetes. Bcl6 expression had not previously been 
described in adipocytes, and it was unknown what physiological relevance Bcl6 might 
have in GH and adipocyte specific functions such as regulation of metabolism or 
adipocyte differentiation. As demonstrated in Chapter 2, further experiments showed that 
not only is Bcl6 a novel GH-regulated target gene, the Bcl6 protein itself also functions 
as a transcriptional repressor of the GH target gene Socs2, further suggesting that Bcl6 is 
a mediator in GH-regulated transcription and GH signaling (6).  
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To gain insight into the roles that Bcl6 may play in GH action, a high throughput 
sequencing approach was utilized to identify potential Bcl6 target genes across the 
genome. ChIP-Sequencing, also known as ChIP-Seq, is a high throughput sequencing 
technique where chromatin immunoprecipitation (ChIP) is combined with massively 
parallel DNA sequencing to identify DNA-protein interactions across the genome (7, 8). 
To map global binding sites for Bcl6 and Stat5 in the presence or absence of GH, ChIP 
was carried out in highly GH-responsive 3T3-F442A adipocytes treated with GH for 0 or 
48 hours. Antibody against Bcl6 or Stat5 was used to immunoprecipitate chromatin 
fragments associated with these transcription factors, and the ChIP DNA was used to 
generate a sequencing library comprised of Bcl6 or Stat5 target sites in vivo. The ChIP-
Sequencing libraries were then sequenced, and analysis of the sequence output with 
mouse whole-genome sequence databases yielded regions where Bcl6 or Stat5 signal is 
enriched on a genomic sequence in either the presence or absence of GH. These genomic 
regions of enriched ChIP-Sequencing signal for Bcl6 and Stat5 represent potential Bcl6 
or Stat5 binding sites in vivo, and the genes closest to the putative binding sites are genes 
with a high likelihood of being regulated by either Bcl6 or Stat5. While the development 
of the ChIP-Sequencing technique is fairly recent, this versatile approach has already 
been used to characterize genome-wide binding sites for several key transcription factors 
and the corresponding chromatin landscape for important biological processes such as 
growth factor response (9, 10), differentiation of adipocytes and other cells (11), and 
embryonic development (12, 13). Results from such studies have also provided much 
insight on transcriptome evolution (14-16), epigenetics (13, 17, 18), and differences in 
transcription regulatory networks between cell types (19).  
!
Analysis of the Bcl6 and Stat5 ChIP-Sequencing results provided us with maps of 
potential Bcl6 and Stat5 binding sites in adipocytes in either the presence or absence of 
GH. From these data, we plan to identify novel Bcl6 target genes. Of particular interest 
would be the identification and verification of novel GH-regulated Bcl6 target genes, as 
this would greatly expand our knowledge of how GH represses transcription through 
Bcl6, and increase our understanding of novel functions for Bcl6 outside of the immune 
system. As Bcl6 has more recently been described to participate in protecting testicular 
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germ cells from apoptosis (20), repressing proliferation of pancreatic ! cells (21), and 
mediating sexual dimorphism of gene expression in the liver (22, 23), the ChIP-
Sequencing results will be invaluable for comparison with other available or future ChIP-
Sequencing datasets, and allow us to computationally assess similarities and differences 
in Bcl6 or GH action in different tissues, under different treatment conditions, or in 
different species. Similarly, the Stat5 ChIP-Sequencing profiles could provide us with 
novel Stat5 target genes, and comparison of Stat5 ChIP-Sequencing profiles from 
different cell types would provide insight into cell type specific functions of Stat5. 
 
Concurrently, comparison of the Bcl6 and Stat5 occupancy profiles in the presence or 
absence of GH would also help identify GH target genes reciprocally regulated by Bcl6 
and Stat5 in response to GH, similar to what is seen for Socs2 (Chapter 2). This analysis 
would shed light on whether or not the mechanism of reciprocal regulation of 
transcription by an activator-repressor pair using the same DNA regulatory region is 
operant for other GH target genes. Analysis of the downstream biological effects or 
transcriptional regulatory analysis of genes found to be reciprocally regulated by Bcl6 
and Stat5 could provide insight on the types of genes likely to be regulated by this 
mechanism, and may provide clues as to how such a regulatory mechanism evolved. 
Interestingly, Ken and Barbie, the Drosophila homolog of Bcl6, also appears to repress 
expression of a subset of Jak/Stat target genes in the fly (24), suggesting that cooperation 
between Bcl6 and Stat5 in regulating target genes is an ancient mechanism that has been 
maintained over the course of evolutionary history. Similarly, identification of genes 
regulated by both Bcl6 and Stat5, but not necessarily in the same reciprocal manner as 
Socs2, would help us better understand the opposing roles of Bcl6 and Stat5 in GH 
response, and the variety of mechanisms used by different genes to modulate 










Bcl6 expression is inhibited by insulin and EGF as well as GH in 3T3-F442A 
preadipocytes, suggesting a broad role for Bcl6 in adipocyte biology 
!
Previous data showed that Bcl6 is a novel GH target gene in 3T3-F442A adipocytes and 
preadipocytes, and treatment of cells with GH strongly inhibited Bcl6 mRNA expression 
at concentrations as low as 5 ng/ml (6). To learn more about mechanisms by which Bcl6 
gene expression is regulated in preadipocytes, and identify potential roles for Bcl6 in 
adipocyte biology, 3T3-F442A preadipocytes were treated with varying concentrations of 
epidermal growth factor (EGF) or insulin (Figure 3.1) to test for potential regulation of 
Bcl6 expression under different treatment conditions. Cells were treated with the various 
factors for 24 h, a time point at which Bcl6 expression is strongly inhibited by GH (6). 
EGF has been found to play a dual role in proliferation and differentiation of 3T3-L1 
preadipocytes to adipocytes, with low concentrations (<1 nM) promoting adipogenesis, 
while higher concentrations appear to inhibit adipogenesis (25). Insulin and GH are 
required factors for 3T3-F442A adipocyte differentiation (26-29), and chronic GH 
treatment of 3T3-F442A adipocytes results in an insulin resistant phenotype in the cells 
(30, 31). Results showed that mRNA expression of Bcl6 is inhibited by EGF and insulin 
in 3T3-F442A preadipocytes even at the lowest treatment concentrations, and expression 
remains repressed to a similar extent with increasing treatment concentrations, suggesting 
that expression of Bcl6 is strongly regulated by other growth factors and hormones 
important in adipocyte biology. 
!
Bcl6 is a novel transcriptional repressor of Socs2 gene expression in an animal 
model 
!
Previous results showed that in addition to being a novel GH-regulated gene, translated 
Bcl6 protein also functioned as a transcriptional repressor on the GH target gene Socs2 
(6). Luciferase reporter gene assays showed that the presence of Bcl6 inhibited 











Multiple growth factors and hormones regulate Bcl6 mRNA expression in 
preadipocytes. 3T3-F442A preadipocytes were treated with the indicated concentrations 
of GH, insulin, or epidermal growth factor (EGF) for 24 h. RNA was harvested and Bcl6 
mRNA expression was measured by quantitative real-time PCR. mRNA expression was 
normalized to Bcl6 expression in untreated cells for each experiment, set as 1.0. Results 







luciferase by GH (Figure 2.7). ChIP data showed occupancy of endogenous Bcl6 and 
Stat5 on Socs2 DNA in both preadipocytes and adipocytes, with occupancy of Bcl6 high 
in the absence of GH and decreasing after GH treatment. The occupancy pattern of Stat5 
on the Socs2 gene was reciprocal to that of Bcl6, with little to no occupancy of Stat5 in 
the absence of GH and strong and rapid recruitment of Stat5 to the Socs2 promoter upon 
GH treatment (Figure 2.8). 
!
To verify whether inhibition of Socs2 expression by Bcl6 also occurs in an in vivo 
physiological context, Socs2 mRNA expression was measured in the livers of wild type 
mice or mice with Bcl6 deficiency (Bcl6 knock out mice) (32) (Figure 3.2). As Bcl6 
knock out mice have little to no adipose tissue, another GH-responsive target organ, liver, 
was used to examine consequences of Bcl6 deficiency in mice. Results showed that basal 
Socs2 mRNA expression was greatly elevated in Bcl6 knock out mouse liver compared 
to wild type, consistent with endogenous Bcl6 repressing Socs2 expression in an animal 
model as well as in cultured 3T3-F442A cells. As the mice had not been subjected to any 
treatment, these results also suggest that the loss of Bcl6 repression is sufficient to induce 
some level of Socs2 gene expression above the average basal levels found in wild type 
mouse liver. 
!
ChIP assays carried out using livers from male wild type (Figure 3.3A, lanes 1 and 2) and 
Bcl6 knock out mice (Figure 3.3A, lanes 3 and 4) showed that there was occupancy of 
Bcl6 on Socs2 DNA in wild type mice but no occupancy of Bcl6 on Socs2 DNA in Bcl6 
knock out mice, as expected. In the absence of Bcl6, Stat5 and phosphorylated Stat5 
occupy Socs2 DNA (Figure 3.3A, lanes 3 and 4), suggesting that the recruitment of 
activated Stat5 to the Socs2 promoter is not dependent on the prior occupancy of Bcl6. 
Furthermore, in ChIP carried out on livers from male Bcl6 heterozygous mice treated 
with GH (Figure 3.3B, lanes 2 and 3) or vehicle (Figure 3.3B, lane 1), occupancy of Bcl6 
on Socs2 DNA was lower in the samples from the GH-treated mice compared to the 
untreated mouse. In contrast, occupancy of Stat5 and phosphorylated Stat5 was higher in 
samples from GH-treated mice compared to the untreated sample (Figure 3.3B), a pattern 
















Figure 3.2  
 
Bcl6 represses Socs2 transcription in vivo. Endogenous Socs2 mRNA expression was 
measured by quantitative real-time PCR in livers of male wild type (Wt, gray bar) or Bcl6 
knock out mice (Bcl6 KO, black bar). mRNA expression, calculated as fold-change for 
Bcl6 KO compared to WT, is shown as the mean + SE for 4 mice of each genotype. Socs2 
mRNA was significantly increased (p<0.05) in Bcl6 knock out compared to wild type. 
















Figure 3.3  
 
Bcl6 and Stat5 occupy Socs2 DNA in vivo. A. ChIP was carried out on livers of male wild 
type (Wt, n=2) or Bcl6 knock out (KO, n=2) mice. Immunoprecipitation was carried out 
using antibody against Bcl6, Stat5, or phosphorylated Stat5 (P-Stat5), and samples were 
analyzed with primers for the Bcl6/Stat5 binding site in the Socs2 gene.  Samples 
immunoprecipitated with IgG served as negative controls; 1% input is shown as indicated. 
B. ChIP was carried out on livers of male Bcl6 +/- mice (Het) treated with (n=2) or without 
(n=1) GH as indicated. Immunoprecipitation was carried out using antibody against Bcl6, 
Stat5, or phosphorylated Stat5 (P-Stat5), and samples were analyzed with primers for the 
Bcl6/Stat5 binding site in the Socs2 gene.  Samples immunoprecipitated with IgG served as 








suggest that reciprocal occupancy of Bcl6 and Stat5 on Socs2 DNA occurs in a 
physiological animal model as well as in cell culture systems, and supports the hypothesis 
that Bcl6 plays important and as yet unknown roles in GH biology. 
!
High throughput ChIP-Sequencing identifies Bcl6 and Stat5 occupancy across the 
genome  
!
As cell culture and animal models both support biological roles for Bcl6 in GH action 
and in non-canonical Bcl6 target tissues outside of the immune system, we decided to use 
a high throughput sequencing approach to identify novel Bcl6 target genes to learn more 
about the functions of Bcl6 in GH signaling and actions. ChIP-Sequencing is a technique 
that combines the specificity of ChIP for identifying DNA-bound transcription factors 
with massively parallel sequencing to provide highly sensitive, genome-wide 
identification of DNA associated with transcription regulatory proteins (7, 8).  
!
3T3-F442A adipocytes were treated with or without GH for 48 hours and ChIP was 
carried out using antibody against Bcl6 or Stat5. ChIP-Sequencing libraries were 
prepared from the resulting ChIP DNA using the Illumina ChIP-Seq sample prep kit, and 
samples were sequenced by the UM Sequencing Core using a Solexa/Illumina Genome 
Analyzer (Figure 3.4). Input genomic DNA from untreated adipocytes was sequenced as 
a normalization control to identify enriched regions of sequencing signal across the 
genome. As there was difficulty in obtaining sufficient starting material, ChIP-
Sequencing libraries for immunoprecipitation background controls from samples 
immunoprecipitated with IgG were not generated. A total of two separate ChIP-
Sequencing runs were carried out, and the sequence read data from both runs were 
combined to form a single dataset that was used in subsequent analyses. The ChIP-
Sequencing dataset was analyzed with the H-Peak algorithm (33) to identify locations of 
Bcl6 or Stat5 occupancy across the mouse genome. H-Peak identified over 3000 potential 
binding sites for Bcl6 and at least 900 for Stat5 across the genome (Table 3.1). In 







Figure 3.4  
 
Schematic of ChIP-Sequencing experiment design. 3T3-F442A adipocytes were treated 
with GH for 0 or 48 h. Immunoprecipitation was carried out using antibodies against Bcl6 
or Stat5. ChIP samples were made into ChIP-Sequencing libraries using the Illumina ChIP-
Seq sample prep kit, and Solexa sequencing was carried out by the University of Michigan 
Sequencing Core. A library sample of input genomic DNA was used as a background 
control. ChIP-Sequencing results were analyzed by the H-Peak algorithm to identify 

















Table 3.1  
 
Summary and analysis of ChIP-Sequencing results. ChIP-Sequencing was performed 
using 3T3-F442A adipocytes treated with GH (48 h) or without GH (0 h). 
Immunoprecipitation was carried out using antibodies against Bcl6 or Stat5 as indicated. 
Samples were analyzed as shown in Figure 3.4. ChIP-Sequencing results were analyzed 
using the H-Peak algorithm and results from 2 independent ChIP-Sequencing experiments 
were combined for bioinformatic analysis. Shown are the number of regions enriched for 
Bcl6 or Stat5 occupancy across the genome as identified by H-Peak under different GH 
treatment conditions. The Bcl6 and Stat binding consensus motifs were found to be 
enriched and highly ranked in the output sequences generated by ChIP-Sequencing. The 
Stat binding consensus motif was less highly ranked in the 0 h GH treatment Stat5 
immunoprecipitation sequencing results compared to the other conditions, and is indicated 









decreased in response to GH treatment, consistent with the repression of Bcl6 expression 
upon GH treatment. 
!
In both ChIP-Sequencing runs, a peak of Bcl6 signal was mapped near the promoter of 
the Socs2 gene, consistent with previous ChIP results (Figure 3.5). Motif analysis carried 
out on the sequencing data showed Bcl6 and Stat5 motifs were highly ranked among the 
sequences for the 0 hr GH Bcl6 immunoprecipitation data and the 48 hr GH Bcl6 
immunoprecipitation data (Table 3.1). Stat motifs were found to be highly ranked in 48 hr 
GH Stat5 immunoprecipitation data, and were listed among common transcription factor 
binding motifs identified in the 0 hr GH Stat5 immunoprecipitation data, consistent with 
experiment design and expected results (Table 3.1). 
!
Bioinformatic analysis of ChIP-Sequencing results identifies potential novel Bcl6 
target genes 
!
A goal of the ChIP-Sequencing approach was to obtain information on novel Bcl6 target 
genes and novel GH-regulated Bcl6 target genes. Comparisons of the genomic occupancy 
profiles between the Bcl6 immunoprecipitation data and the Stat5 immunoprecipitation 
data would also identify genes that are potentially regulated by both Bcl6 and Stat5, 
similar to what had previously been seen for Socs2 (Figure 2.7, Figure 2.8). Gene profiles 
of the known Bcl6 occupancy site on the Socs2 gene and motif analysis of the sequencing 
data supported that the ChIP-Sequencing results were biologically reliable (Table 3.1, 
Figure 3.5). Therefore, the ChIP-Sequencing datasets were subjected to bioinformatics 
analyses to mine for potential functions of Bcl6 in GH action, and mechanisms by which 
regulation of Bcl6 target genes in response to GH occurs. Novel Bcl6 target genes of 
particular interest would be genes involved in GH signaling pathways, GH-regulated 
metabolic pathways, and adipocyte differentiation, as these would be examples of 
previously unknown non-immune functions of Bcl6 in GH action.  
!
To identify genes that were likely to be regulated by Bcl6, the 0 h GH Bcl6 












Figure 3.5  
 
Distribution of Bcl6 signal on Socs2. Two separate ChIP-Sequencing runs were carried 
out. A peak of Bcl6 occupancy was identified at the transcription start site of the Socs2 
gene in both runs in the presence and absence of GH, corresponding with previous ChIP 









predicted to be higher in the absence of GH based on previous observations (6). Genes 
that contained a peak of Bcl6 binding identified by ChIP-Sequencing and H-Peak 
analysis located within 10 kilobases of the transcription start site were considered top 
candidate Bcl6 target genes. These genes were subjected to Gene Ontology analysis to 
evaluate biological functions of potential novel Bcl6 target genes. Results showed that 
high percentages of candidate Bcl6 target genes are involved in cellular processes such as 
growth, differentiation, metabolism, and signaling (Figure 3.6). Further experimental 
evaluation of whether or not these genes are bona fide Bcl6 target genes and the 
transcriptional mechanisms by which expression of these genes is regulated by GH and 
Bcl6 will greatly increase our knowledge of transcriptional mechanisms in general and 
further our understanding of the novel roles of Bcl6 in cellular physiology. It would also 
be interesting to compare this list of potential Bcl6 target genes with known Bcl6 target 
genes in immune cells (34-36), as this would provide insight into similarities and 
differences in the types of genes regulated by Bcl6 in different tissues. 
!
To identify genes that are likely to regulated by Bcl6 in response to GH, the list of genes 
that contained a peak of Bcl6 binding identified by ChIP-Sequencing within 10 kilobases 
of the transcription start site in the absence of GH was analyzed in conjunction with a list 
of genes found to be strongly regulated by GH (p<0.001) at 48 h in our adipocyte 
microarray (6, 37). A list of genes that were identified by both ChIP-Sequencing and the 
microarray was obtained, and these genes are expected to be the top candidates regulated 
by Bcl6 in response to GH (Table 3.2). Many of these genes are known to be 
physiologically relevant in GH responses, but most of them are not currently known to be 
regulated by Bcl6. Further experimental verification of GH and Bcl6-mediated regulation 
of these genes will provide novel information on the roles of Bcl6 in GH action and the 




The role of Bcl6 as a transcriptional repressor that functions as a master regulator of the 
















 Gene Ontology analysis of Bcl6 occupied genes at 0 h GH treatment shows a high 
percentage of genes associated with GH function. Genes containing a peak of Bcl6 
binding identified by ChIP-Sequencing located within 10 kilobases of the transcription start 
site in the absence of GH were subjected to Gene Ontology analysis to evaluate biological 
functions of potential novel Bcl6 target genes. Results showed that a high percentage of 
candidate Bcl6 target genes are involved in cellular processes such as growth, 












Table 3.2  
 
Combined analysis of ChIP-Sequencing and microarray data yields list of potential 
Bcl6- and GH-regulated genes in 3T3-F442A adipocytes. To identify genes that are 
likely to regulated by Bcl6 in response to GH, a list of genes that contained a peak of Bcl6 
binding identified by ChIP-Sequencing located within 10 kilobases of the transcription start 
site in the absence of GH was analyzed in conjunction with a list of genes found to be 
strongly regulated by GH (p<0.001) at 48 h in the adipocyte microarray. Shown are lists of 
genes obtained from the combined analysis grouped by direction of gene expression change 
in response to GH, and ranked by significance of response to GH in the adipocyte 
microarray. TSS, transcription start site; 5’UTR, 5’ untranslated region. (Analysis by 
Rajasree Menon.)  
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Bcl6 function and the identity of its target genes outside this context. We recently 
demonstrated a role for Bcl6 in GH action in adipocytes (6). Expression of Bcl6 is 
strongly regulated by GH, suggesting a role for Bcl6 in GH response (6, 22, 38). The 
Bcl6 protein in turn was found to function as a transcriptional repressor of the GH target 
gene Socs2 (6). Further experiments found that Bcl6 expression was inhibited by EGF 
and insulin, a growth factor and a hormone respectively, that also have important 
functions in cellular proliferation and adipocyte differentiation (25, 29), supporting a 
biological role for Bcl6 outside of the immune system. ChIP and qPCR experiments 
carried out using mouse liver tissue further suggest that Bcl6 regulates, and most likely 
represses, expression of GH target genes in a physiological model as well as in cell 
culture systems. 
!
High throughput ChIP-Sequencing provides insight on genome-wide Bcl6 and Stat5 
occupancy 
!
High throughput ChIP-Sequencing using ChIP samples from 3T3-F442A adipocytes 
treated with or without GH for 48 h and immunoprecipitated with antibody against either 
Bcl6 or Stat5 was used to identify Bcl6 and Stat5 occupancy across the genome in the 
presence or absence of chronic GH treatment. Results yielded over 3700 potential Bcl6 
occupancy sites in the absence of GH, and the number of sites where Bcl6 was potentially 
occupying the genome decreased to about 1500 upon GH treatment. This is consistent 
with our previous observations that GH inhibits Bcl6 mRNA expression, which would 
likely decrease Bcl6 protein levels, leading to less Bcl6 occupancy. Another possibility 
for the decrease in Bcl6 occupancy upon GH treatment is that activation of GH signaling 
may also result in post-translational modification of the Bcl6 protein, such as 
phosphorylation through extracellular-signal-related kinases (ERKs) (39) or acetylation 
by acetylases such as p300 (40). GH is known to cause post-translational modifications of 
many transcription factors, and thus regulate their actions (41). A relevant example is the 
tyrosyl phosphorylation and activation of Stat5 in response to GH treatment (42, 43). 
Similarly, GH treatment can induce post-translational modification of the transcription 
factor C/EBP! (44-47). Phosphorylation of murine C/EBP! by Erk 1/2 at Thr-188 and 
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acetylation at Lys-39 by p300 both appear to facilitate the GH-dependent transcriptional 
activation activity of C/EBP! at early response genes, such as c-Fos. Phosphorylation and 
acetylation of Bcl6 have been shown previously (39, 40); both of these post-translational 
modifications target Bcl6 for proteasomal degradation and would contribute to a loss of 
Bcl6 occupancy across the genome.  
!
However, we observed around 1300 potential occupancy sites for Stat5 in the absence of 
GH, and only around 900 potential occupancy sites after GH treatment. As GH induces 
Stat5 phosphorylation, dimerization, and recruitment to the nucleus where activated Stat5 
can then bind to the regulatory regions of its target genes (42, 43), we did not expect to 
see a decrease in the number of Stat5-occupied regions after GH treatment. Surprisingly, 
Stat5 occupancy peaks were not detected at several known Stat5 occupancy sites even in 
the GH-treated genomic profiles, including the GH-responsive Stat5 site in the Socs2 
promoter (6, 48, 49). Examination of the sequences obtained from the Stat5 sequencing 
runs showed that many of the sequences in the Stat5 data consisted of overamplified 
sequences that may be artifacts that occurred during PCR amplification of the ChIP-
Sequencing library. As there appeared to be variability in the quality of the ChIP-
Sequencing libraries prepared from the different treatment and immunoprecipitation 
conditions, in addition to possible differences in the sequencing efficiency for each 
library, the approach used for further analysis of the ChIP-Sequencing results was to 
concentrate efforts on analyzing a particular dataset of interest, and to use comparisons 
with data from other treatment conditions as supporting, but not decisive, information for 
identifying follow-up gene candidates. 
!
We focused on the 0 h GH Bcl6 immunoprecipitation samples to identify potential novel 
Bcl6 target genes and potential novel GH-regulated Bcl6 target genes. Gene ontology 
analysis was performed for about 1500 genes that contained a peak of Bcl6 binding 
identified by ChIP-Sequencing, located within 10 kilobases of the transcription start site 
in the absence of GH, to identify biological processes that candidate Bcl6 target genes 
could be involved in. Results showed that a large number of candidate Bcl6 target genes 
were involved in processes such as metabolism (21%), signaling (10%), and growth and 
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differentiation (31%), while a relatively small number of candidate Bcl6 target genes 
were associated with biological processes more canonically associated with Bcl6 function 
in the immune system, such as immune function (4%) and cell stress and cell death 
(10%).  
 
Bcl6 occupancy is detected at widespread locations across the genome  
!
As the ChIP-Sequencing experiment was carried out in cultured adipocytes, where genes 
related to metabolic or differentiation processes are likely to be actively expressed, it is 
possible that Bcl6 occupancy was detected at some of these sites due to the open 
chromatin structure near these genes facilitating Bcl6 occupancy of consensus binding 
sequences or low affinity sequences available in these genomic regions, and that not all 
of the Bcl6 occupancy sites detected are actively involved in transcriptional regulation of 
nearby genes. Many of the Bcl6-occupied regions identified by ChIP-Sequencing did not 
show significant peak height as determined by H-Peak or a distinct peak profile when 
visualized using the UCSC Genome Browser, further suggesting that Bcl6 may not be 
regulating transcription at all of the occupancy sites detected. It should also be noted that 
a large percentage of the potential binding sites detected for Bcl6 fall in intronic (48%) or 
intergenic (31%) regions of genes, with transcription start site (TSS, 3%), 5’UTR (12%), 
3’UTR (2%), and exon (5%) sequences making up the remainder, similar to the 
widespread binding patterns observed for Stat1 (9), GATA1 (50), or MyoD (51).  
!
A current hypothesis on the function of widespread binding for certain transcription 
factors is that the weaker binding sites serve as a reservoir for the transcription factors 
and this acts as a buffering system for maintaining optimal transcription factor 
availability levels to fine-tune occupancy of factors at bona fide regulatory regions (52). 
Expression and function of Bcl6 is regulated at multiple levels, from transcription to 
translation (53-55), and both overexpression and depletion of Bcl6 can be deleterious to 
cell survival (20, 56-60). This suggests that Bcl6 plays important roles in cell physiology, 
and the proper function of this system relies on the careful control, specific balance, and 
rapid response of Bcl6 levels in the cell to external stimuli. It would not be surprising if 
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Bcl6 availability at regulatory DNA bindings sites, and thus Bcl6 action and response to 
stimuli, could be further modulated by sequestration of the protein at non-regulatory 
regions of the genome.  
!
Another hypothesis is that transcription factors with widespread genome occupancy, as 
observed for Bcl6, carry out other functions when they occupy regions of the chromatin 
not directly associated with regional gene transcription. For example, the transcription 
factor CTCF is now recognized to have a broad role in nuclear and chromatin 
organization (61, 62). Similarly, MyoD binding induces changes in chromatin structure, 
and genomic regions occupied by MyoD are enriched with histone marks associated with 
active or accessible chromatin (51). Bcl6 is known to interact with many coregulatory 
proteins associated with chromatin remodeling (35, 63, 64). Therefore, it is possible that 
Bcl6 is associating either directly or indirectly with the chromatin at some of these 
potential binding sites and functioning as part of a chromatin remodeling complex, and 
not as a transcription factor. In either case, it is likely that Bcl6 is not directly regulating 
expression of target genes at all of the potential binding sites identified through ChIP-
Sequencing. 
!
Bioinformatic analyses of ChIP-Sequencing and gene expression data suggest novel 
roles for Bcl6 in regulation of GH physiology 
!
However, occupancy peaks with strong peak height and distinct peak profiles were 
detected on multiple genes, including Socs2, suggesting that at least some of these Bcl6 
occupancy sites are involved in direct regulation of nearby genes. Further experiments to 
examine if transcription of any of the Bcl6 candidate genes are regulated by Bcl6 will 
identify novel Bcl6 target genes and potentially provide information that can be used to 
better correlate ChIP-Sequencing data with biological regulation of a nearby gene by a 
candidate transcription factor in our future studies. At the moment, the ChIP-Sequencing 
data suggest that what is known about the role of Bcl6 in cellular and physiological 




The list of genes that contained a peak of Bcl6 binding identified by ChIP-Sequencing 
located within 10 kilobases of the transcription start site at 0 h GH treatment was also 
analyzed in conjunction with a list of genes found to be strongly regulated by GH 
(p<0.001) at 48 h in the adipocyte microarray. A list of 12 genes that were repressed by 
GH and 15 genes that were activated by GH were detected in both the ChIP-Sequencing 
results and the GH-regulated gene profile and are considered the gene candidates most 
likely to be regulated by Bcl6 in response to GH. Among the 27 genes that appeared in 
this list, several are very interesting candidates to follow up: Fasn (fatty acid synthase), 
Scd1 (stearoyl-Coenzyme A desaturase 1), Scd2 (stearoyl-Coenzyme A desaturase 2), 
Igfals (insulin-like growth factor binding protein acid labile subunit), Igf2 (insulin-like 
growth factor 2), Rgs2 (regulator of G protein signaling 2), Rgs16 (regulator of G protein 
signaling 16), Socs2, and Cish (cytokine inducible SH2-containing protein). All have 
known roles in GH signaling, adipocyte differentiation, and/or lipid synthesis and 
metabolism (65-70), while angiotensinogen (encoded by the Agt gene) is a hormone 
precursor known to be synthesized by adipose tissue (71). Several of the genes in the list 
also have predicted Bcl6 occupancy sites in classical regulatory regions such as the 
5’UTR or proximal promoter region (identified by H-Peak as TSS, transcription start site) 
of the gene. It would be expected that Bcl6 is likely to participate in regulation of those 
genes. Current plans are to verify GH regulation of these genes by qPCR and Bcl6 
regulation of these genes using reporter gene constructs or by examining the mRNA 
expression of these genes in Bcl6 knock out mouse tissues compared to wild type. 
Occupancy of Bcl6 on the predicted genomic locations will also be experimentally 
verified using ChIP, and changes in Bcl6 occupancy at sites in response to GH examined.  
!
Of note is that several of the genes were predicted by ChIP-Sequencing to have multiple 
Bcl6 binding sites in different locations of the gene; for example, ChIP-Sequencing 
detected Bcl6 occupancy signal in multiple introns, exons, and intergenically for Agt. Of 
these regions, locations showing a peak height above 10 as determined by H-Peak, along 
with distinct peak profiles, would be top candidate peaks for follow-up verification using 
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ChIP. Of great interest would be identifying which regions provide the most regulatory 
input towards transcription of Agt and the underlying mechanisms involved. 
!
Conclusions and future directions 
!
In conclusion, the ChIP-Sequencing results have provided us with a wealth of exciting 
directions to pursue in regards to learning more about GH biology, Bcl6 function, and 
mechanisms of transcription. However, as a last point of interest, it is also worth 
mentioning that little is known about the mechanisms by which GH regulates 
transcription of the Bcl6 gene itself, or the effects of GH treatment on function of the 
Bcl6 protein. It is known that Bcl6 autoregulates its own transcription by occupying Bcl6 
binding sites in the upstream region of the Bcl6 gene and inhibiting gene expression (54). 
It is also known that Stat5 regulates Bcl6 gene expression, although the direction of 
regulation and the mechanisms involved seem to differ depending on cell type and 
sequence context (72-75). As Stat5 is a well known GH-regulated transcription factor, 
and Bcl6 expression is strongly inhibited by GH, it would be interesting to see if Bcl6 
and Stat5 regulate expression of Bcl6 in response to GH similarly or differently from 
their known mechanisms of action in other cell types.  
 
As the downstream effects of Bcl6 expression also seem to differ between cell types, with 
Bcl6 overexpression promoting cell survival in B cells but possibly promoting cell death 
in preadipocytes (C LaPensee unpublished data), investigating the results of this 
differential transcriptional regulation of Bcl6 in adipocytes compared to other cell types 
would also be interesting. A preliminary experiment where 3T3-F442A preadipocytes 
were treated with various signaling disruptors (U0126, MEK inhibitor; wortmannin, 
phosphoinositide-3-kinase inhibitor; forskolin, adenylyl cyclase activator) showed that 
treatment of cells with these disruptors did not inhibit the GH-induced repression of Bcl6 
mRNA expression, suggesting that these GH-regulated signaling pathways are not 
involved in modulating expression of the Bcl6 gene. As the Jak/Stat inhibitor AG490 was 
unable to sufficiently reduce Jak/Stat activation in response to GH in 3T3-F442A 
preadipocytes, we were unable to test the effect of this signaling pathway on regulation of 
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Bcl6 using this inhibitor. Further experiments using different GH-responsive cell lines or 
reporter gene assays could shed light on the mechanisms by which Bcl6 expression is 
regulated in response to GH and how these mechanisms may be similar or different to 
how Bcl6 is regulated in other cell lines or in response to other growth factors.  
!




The generation of mice with targeted deficiency of Bcl6 has been described previously 
(32). Animals were euthanized between 1000 and 1200 h by CO2 inhalation and cervical 
dislocation. In some of the present studies, tissues were obtained courtesy of Dr. A. L. 
Dent, from a colony of Bcl6 knock out (KO) mice housed at the Indiana University 
School of Medicine. Bcl6 heterozygous (+/-) male and female mice from the Indiana 
colony were used to establish a breeding colony at the University of Michigan to generate 
Bcl6 knock out mice. Pups were genotyped by PCR analysis of tail DNA as previously 
described (76). Mice were housed on a 12-h light, 12-h dark cycle (lights on at 0600 h), 
with food and water available ad libitum unless otherwise specified. Liver tissue was 
rapidly removed, weighed, frozen on dry ice and stored at -80°C. For the analysis of GH 
responses in vivo, Bcl6 +/- male mice were injected IP with human GH (1.5mg/kg BW) 
or with vehicle twice daily for 2.5 days, and were fasted for the final 16-18 hr. Animal 
protocols were approved by the Indiana University School of Medicine Animal Use and 
Care Committee or the University Committee on Use and Care of Animals at the 
University of Michigan. All parameters were comparable when mice from Indiana and 




Stocks of murine 3T3-F442A preadipocytes were provided by H. Green (Harvard Univ) 
and M. Sonenberg (Sloan-Kettering, NY). Recombinant human GH (Lot# N70315) for 
animal experiments was from Genentech (So. San Fancisco CA), and for cell culture 
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studies was a gift from Lilly (Indianapolis, IN). Insulin, dexamethasone, and 
isobutylmethylxanthine were from Sigma (St. Louis, MO). Epidermal growth factor was 
from Cell Signaling Technology (Danvers, MA). Culture media, L-glutamine, and 
antibiotic-antimycotic were purchased from Invitrogen (Grand Island, NY). Fetal bovine 
serum (FBS) and calf serum (CS) were from Atlanta Biologicals (Lawrenceville, GA). 
Bovine serum albumin (BSA, Fatty acid-free, cat. # 62150101) was purchased from 
Proliant (Ankeny, IA). TRIzol® Reagent was purchased from Invitrogen, and Taqman 
Reverse Transcription Kit from Applied Biosystems (Carlsbad, CA). Protease inhibitors 
leupeptin and aprotinin were purchased from Roche (Indianapolis, IN), and 
phenylmethylsulfonylfluoride (PMSF) from Mallinckrodt (St Louis, MO). Sodium 




3T3-F442A preadipocytes were differentiated into adipocytes as follows: Preadipocytes 
were grown to confluence in Dulbecco’s Modified Eagle Medium, 1% L-glutamine, 1% 
antibiotic-antimycotic (DMEM) containing 8% calf serum. 48 h later, cells were induced 
to differentiate by exposure to adipogenic medium (DMEM, 8% FBS, 0.5 mM 
isobutylmethylxanthine, 0.25 µM dexamethasone, 2 µg/ml insulin). After 48 h, medium 
was replaced with DMEM containing 8% FBS and 1 µg/ml insulin. 48 h later, medium 
was changed to DMEM with 8% FBS, in which cells were maintained until use in 
experiments. Prior to all experiments with GH, insulin, or EGF treatment, 3T3-F442A 
cells were deprived of serum for 16-18 h in DMEM containing 1% BSA instead of 
serum. Cells were then treated without or with human GH (500 ng/ml = 22 nM) for 48 h 
on day 7 following initiation of adipogenesis. 
!
Quantitative Real-time PCR (qPCR) 
 
Murine 3T3-F442A preadipocytes were incubated with GH, insulin, or epidermal growth 
factor for 24 h. RNA was isolated and analyzed by quantitative real-time PCR (qPCR) as 
described previously (37). Primers for Bcl6 have been described previously (77), and data 
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were normalized to glyceraldehyde-3-phosphate dehydrogenase expression levels (37). 
For mouse liver experiments, qPCR was performed on total RNA isolated from mouse 
liver tissues. The Socs2 qPCR primer sequences were based on published studies (78). 
Gene expression was normalized to RPLP0 (Ribosomal protein, large P0) expression 
levels, and is expressed as fold-change compared to control group, where the control is 
set to1.0. All qPCR data were analyzed using the 2!!cT method (79). Values from 
analysis of wild type and Bcl6 knock out mice were compared statistically using 
Student’s t-test. 
!
Chromatin Immunoprecipitation (ChIP) 
 
ChIP was carried out as described for cells (6, 80). The following modifications were 
made for analysis of liver: Frozen mouse liver (~200 mg) was thawed, minced in PBS 
and incubated in 1% formaldehyde in PBS for 15 min at room temperature before 
centrifugation for 2 min at 1500 rpm. The pellet was suspended in ChIP SDS lysis buffer 
(80) and sonicated using a Misonix S-3000 sonicator eighteen times for 15 seconds, with 
a 1 minute pause between cycles to achieve approximately 200 base pair fragments. For 
each immunoprecipitation, 100 µg of liver protein was incubated overnight at 4 °C with 4 
µg of anti-Bcl6 antibody (N-3, Santa Cruz), anti-Stat5 antibody (C-17, Santa Cruz), or 
phosphorylated Stat5 antibody (cat. #71-6900, Zymed). Samples incubated with an 
equivalent amount of normal rabbit IgG (Santa Cruz) served as a negative control. 1% 
input was used to indicate the relative amount of each sample used for individual ChIP 
analysis. ChIP samples were analyzed by PCR using primers targeting the reported 
Bcl6/Stat5 binding site in the murine Socs2 gene (6, 48). PCR products were separated on 
2% agarose gels and stained with ethidium bromide. 
!
Generation of ChIP DNA libraries for high throughput ChIP-Sequencing  
 
3T3-F442A adipocytes cultured in 15 cm culture plates were treated with GH (500 
ng/ml) for 0 or 48 h (40 plates for each treatment condition). Lysates of cross-linked cells 
(input) were used for ChIP as described (80) using anti-Bcl6 (N-3) and anti-Stat5 (C-17) 
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(Santa Cruz). ChIP DNA samples were pre-tested for quality by PCR using primers 
specific for the Bcl6/Stat5 binding site in murine Socs2 (48), and multiple ChIP DNA 
samples immunoprecipitated with the same antibody under the same GH treatment 
conditions were pooled to obtain a sufficient amount of DNA (>10 ng) for generating 
ChIP-Sequencing libraries as recommended by the Illumina ChIP-Sequencing Library 
Preparation Protocol. ChIP-Sequencing libraries were generated by ligation of adapter 
sequences and PCR amplification of chromatin fragments using the Illumina ChIP-Seq 
Sample Prep Kit following the manufacturer’s protocol. The quality of the ChIP- 
Sequencing libraries was then validated by the University of Michigan Sequencing Core 
using an Agilent Bioanalyzer and submitted to the University of Michigan Sequencing 
Core for high throughput sequencing on the Illumina GAIIx sequencing platform. A 
DNA library was also prepared using input DNA from untreated adipocytes and 
sequenced for use as a background control. A background control for 
immunoprecipitation artifacts carried out using ChIP-Sequencing libraries generated from 
ChIP samples immunoprecipitated with normal rabbit IgG was not carried out due to 
difficulties in obtaining sufficient starting material. 
!
!
Analysis of ChIP-Sequencing output 
 
Identification of genome-wide occupancy of Bcl6 and Stat5 by H-Peak  
 
Sequencing data obtained from the ChIP-Sequencing libraries was analyzed using the H-
Peak algorithm (http://www.sph.umich.edu/csg/qin/HPeak/), a hidden Markov model-
based peak finding algorithm which allows for rigorous statistical inference (33). Distinct 
from other currently available algorithms, H-Peak explicitly assumes probability 
distributions to model coverage profiles of DNA fragments. H-Peak also provides the 
location of nearby genes and the genomic location of a peak. Occupancy profiles for Bcl6 
or Stat5 on the mouse genome were visualized using the UCSC Genome Browser 
(http://genome.ucsc.edu/). Peaks of occupancy with a peak height of 4 or greater, as 
determined by H-Peak, were used in subsequent bioinformatic analyses.  
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!
Gene Ontology analysis of ChIP-Sequencing dataset from Bcl6 
immunoprecipitation sample in the absence of GH  
 
A list of genes that contained a peak of Bcl6 signal within 10 kilobases of the 
transcriptional start site without GH treatment was generated from the 0 h GH treatment 
Bcl6 immunoprecipitation ChIP-Sequencing data. This list of genes was then subjected to 
Gene Ontology (http://www.geneontology.org/) analysis using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID, 
http://david.abcc.ncifcrf.gov/) using the standard stringency settings. 
!
Computational analysis of combined ChIP-Sequencing dataset from Bcl6 
immunoprecipitation samples in the absence of GH and microarray results  
 
A microarray data set with 561 probe sets showing significant differential expression 
signals in 3T3-F442A adipocytes treated with GH (500 ng/ml) for 48 h has been 
described previously (37) and updated as of Nov./Dec. 2011. A list of genes that showed 
significant differential expression in response to GH at 48 h under stringent selection 
criteria (p<0.001) in the microarray was compared with the list of genes that contained a 
peak of Bcl6 signal within 10 kilobases of the transcriptional start site without GH 
treatment as identified from the 0 h GH treatment Bcl6 immunoprecipitation ChIP-
Sequencing data. Genes that appeared in both lists were considered top candidates for 
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To identify novel Bcl6 target genes and better understand the role of Bcl6 in GH 
physiology, high throughput ChIP-Sequencing was carried out to identify potential Bcl6 
occupancy sites across the genome. ChIP-Sequencing results yielded several thousand 
potential Bcl6 occupancy sites in 3T3-F442A adipocytes in the absence of GH, when Bcl6 
occupancy is expected to be highest and occupancy of target genes regulated by Bcl6 is 
more likely to be detected (1). Combined analysis of ChIP-Sequencing and microarray 
results from GH-treated adipocytes also provided a list of genes likely to be regulated by 
Bcl6 in response to GH. Included in this list of genes are many well known GH target 
genes or genes that would logically participate in GH action. Identifying the role that Bcl6 
plays in regulation of these genes would greatly expand our understanding of both GH-
mediated transcriptional repression and mechanisms by which GH carries out its 
physiological actions. 
 
In addition to identifying novel Bcl6 target genes, another goal of the ChIP-Sequencing 
was to identify genes that might be regulated by both Bcl6 and Stat5, with a focus on 
genes that are regulated by both Bcl6 and Stat5 in response to GH using the same 
regulatory DNA sequence. As shown previously, the GH target gene Socs2 is reciprocally 
regulated by Bcl6 and Stat5 in response to GH, with Bcl6 playing a repressive role and 
Stat5 playing an activating role (1). Bcl6 and Stat5 show similar DNA binding consensus 
sequences (2-5), and appear to occupy the same DNA regulatory region in the Socs2 
promoter under different treatment conditions to regulate the changes in Socs2 
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transcription (1). This mechanism of regulation by Bcl6 and Stat5 for Socs2 is one of the 
first examples of a reciprocal transcriptional activator-repressor relationship in GH-
mediated gene transcription. Therefore, the goal was to identify other genes regulated by 
both Bcl6 and Stat5 to examine if the mechanism of reciprocal regulation by these two 
transcription factors is common to other GH target genes, or if this mechanism is unique 
to regulation of Socs2. Furthermore, analysis of other reciprocally regulated gene 
candidates could yield insight into mechanisms by which GH regulates the actions of the 
Bcl6/Stat5 activator-repressor switch. 
 
Experimental validation of 35 ChIP-Sequencing peaks identified Cish (cytokine-inducible 
SH2-containing protein) and Bcl6 as two other gene candidates that may be reciprocally 
regulated by Bcl6 and Stat5 in response to GH, in addition to the known example of 
Socs2. Occupancy patterns of Bcl6 and Stat5 on all three genes was similar, with Bcl6 
occupancy high in the absence of GH and decreasing progressively after GH treatment, 
while occupancy of Stat5 was low in the absence of GH and increased with treatment. 
However, as Socs2 and Cish expression is induced by GH while Bcl6 expression is 
repressed (1), the effects that Bcl6 and Stat5 have on the transcriptional state of these 
genes is likely different, despite the similar occupancy patterns. 
 
At the molecular level, transcription is regulated by both the recruitment of specific 
transcription factors to their respective target genes and the recruitment of coregulatory 
proteins, which modulate transcription but may not directly bind the target DNA (6-8). 
Coregulators often associate with target DNA through their interaction with transcription 
factors. The nuclear proteins present in a transcription regulatory complex work in concert 
to direct the transcriptional output of a gene. Coregulatory molecules that have an 
activating effect on transcription of a target gene are generally known as coactivators, 
while coregulators that inhibit gene transcription are called corepressors. However, recent 
studies have shown that proteins canonically known as coactivators, such as p300, can 
also have repressive roles on transcription (9), and corepressors such as histone 
deacetylases (HDACs) are involved in activating the expression of some genes (10, 11). 
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Bcl6 is well known to associate with corepressors when repressing transcription of target 
genes in immune cells. Examples include histone deacetylases, NCoR (nuclear receptor 
corepressor), and SMRT (silencing mediator of retinoic acid and thyroid hormone 
receptor) (12-16). Similarly, when functioning as a transcriptional activator, Stat5 is 
known to interact with many coactivating molecules, such as p300, CBP (cyclic AMP 
response element binding protein binding protein) and NCoA-1 (nuclear receptor 
coactivator 1), which aid in driving Stat5 target gene transcription in response to cytokine 
stimulation (17-20). So far, little is known about the role of corepressors in GH-mediated 
transcription or mechanisms by which Bcl6 regulates GH target genes.  
 
As shown below, ChIP was carried out to identify candidate coregulatory molecules 
involved in Bcl6- or Stat5-mediated transcription of Socs2, Cish, or Bcl6 and evaluate 
how these coregulators relate to transcriptional regulation. The coregulatory molecules 
p300 and Hdac3 were found to consistently occupy the promoters of Socs2, Cish, and 
Bcl6 in both the presence and absence of GH. Reporter gene assays carried out using 
regulatory sequences of Socs2, Cish, and Bcl6 fused to the firefly luciferase gene, in 
conjunction with overexpression constructs for Bcl6, Stat5, p300, and Hdac3, showed that 
p300 and Hdac3 participate in the regulation of Socs2, Cish, and Bcl6 expression by Bcl6 
and/or Stat5. Results suggest that the effects of any transcription factor-coregulator 
combination on transcription of the reporter gene were different for each gene regulatory 
sequence tested, with regulation of the Socs2 and Cish promoters, which are both 
activated by GH, being more similar to each other compared to regulation of the Bcl6 
promoter, which is inhibited by GH. In the case of Socs2-luciferase and Cish-luciferase, 
the coregulatory molecules tested appeared to exert their effects mainly through their 
interactions with Stat5, with p300 in particular providing a coactivating effect on Stat5-
mediated transcription. In the case of Bcl6-luciferase, p300 and Hdac3 appeared to interact 
with both Bcl6 and Stat5, with the results of these interactions mostly favoring 
transcriptional repression. This is a relatively unique situation, especially for p300. These 
results highlight the various different and intricate input signals involved in regulation of 
each GH target gene even by the same transcription factors, resulting in distinct 
downstream transcriptional outputs.  
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The Bcl6/Stat5 target genes identified through ChIP-Sequencing have provided a novel 
system to study the roles of coactivators and corepressors in GH-mediated transcription, 
and results from these experiments have already identified several coregulators associated 
with Bcl6 in response to GH stimulus. Further study will provide novel insight into 
similarities and differences between mechanisms of Bcl6 action in GH-responsive 
metabolic tissues and in immune tissues, as well as further our understanding of how the 
many protein components in a transcriptional regulatory complex function together to 




ChIP-Sequencing identifies Cish and Bcl6 as candidate genes reciprocally regulated 
by Bcl6 and Stat5 
 
ChIP-Sequencing results were expected to provide information on novel Bcl6 target 
genes, novel GH-regulated Bcl6 target genes, and genes potentially regulated by both Bcl6 
and Stat5. To identify gene candidates reciprocally regulated by Bcl6 and Stat5 similar to 
what is seen for regulation of Socs2 expression (1), follow-up candidate peaks identified 
through ChIP-Sequencing were chosen based on literature searches for genes associated 
with Bcl6 or Stat5, peak height values, peak p values, or peak profiles generated from 
ChIP-Sequencing analysis, with the gene or genes located closest to a peak predicted to be 
the most likely targets for transcriptional regulation (Figure 4.1). 35 candidate Bcl6 and/or 
Stat5 occupancy peaks identified through ChIP-Sequencing were analyzed using ChIP and 
primers specific for the genomic regions of ChIP-Sequencing signal (Table 4.1).  
 
Of the 35 candidate occupancy regions tested by ChIP, two regions (Figure 4.2) showed 
clear reciprocal occupancy of Bcl6 and Stat5 in response to 48 hours of GH treatment in 
adipocytes (Figure 4.3). The first region was a ChIP-Sequencing peak of Bcl6 signal 





Figure 4.1  
 
Schematic for selection of follow up peaks of Bcl6 and/or Stat5 occupancy from 
ChIP-Sequencing output data. To find genes reciprocally regulated by Bcl6 and Stat5 
in response to GH, sequences on the genome that have the potential to be bound by both 
Bcl6 and Stat5, and sequences where occupancy of Bcl6 and Stat5 changed in response to 
GH would be of particular interest. ChIP-Sequencing data for each of the four 
immunoprecipitation conditions were sorted by peak height and peak p value, and the 
highest or most statistically significant peaks were given priority as candidates. The 
names of genes closest to these candidate peaks were also subjected to a Pubmed 
literature search, and genes that have previously been published to have biological 
relationships with either Bcl6 or Stat5 were also given priority. UCSC Genome Browser 
(http://genome.ucsc.edu/) profiles were also generated for peaks of interest, and peaks 
that showed defined peak enrichment profiles were also prioritized for experimental 
verification. ChIP primers were designed to flank the peaks identified by ChIP-














Table 4.1  
 
35 ChIP-Sequencing peaks were tested for reciprocal occupancy of Bcl6 and Stat5 in 
response to GH using ChIP. Shown is a list of genes closest to the ChIP-Sequencing 
peaks tested for reciprocal occupancy of Bcl6 and Stat5 in response to GH using ChIP 
samples generated from 3T3-F442A adipocytes treated with GH for 0 or 48 hours and 
immunoprecipitated with antibody against Bcl6 or Stat5. Genes are grouped in general 












Figure 4.2  
 
Distribution of Bcl6 signal on Socs2, Cish, and Bcl6. Peaks of Bcl6 occupancy were 
identified at the transcription start sites of Cish and Bcl6, in addition to the previously 
identified site of Bcl6 occupancy at the Socs2 transcriptional start site. Shown are the 
UCSC Genome Browser profiles for Bcl6 occupancy in the absence of GH for A. Socs2, 
B. Cish, and C. Bcl6. Arrows to the left of gene names indicate direction of transcription, 
from 5’ to 3’. D. H-Peak output results for the Bcl6 occupancy sites for Socs2, Cish, and 
Bcl6 from the combined ChIP-Sequencing run data. Shown are the peak chromosomal 
locations, peak coverage, peak height, and peak location in the respective genes. TSS: 












The Socs2, Cish, and Bcl6 regulatory regions identified by ChIP-Sequencing show 
reciprocal occupancy of Bcl6 and Stat5 in response to GH in adipocytes. 3T3-F442A 
adipocytes were treated with GH for 0 or 48 h and ChIP was carried out using antibodies 
against Bcl6 and Stat5. ChIP DNA was probed with primers specific to the Bcl6 
occupancy sites predicted by ChIP-Sequencing (peaks) on the Cish (lanes 3 and 4) and 
Bcl6 (lanes 1 and 2) genes. PCR using primers specific to the known reciprocal 
Bcl6/Stat5 site in the Socs2 promoter was carried out as a positive control (lanes 1 and 2).  
1% input was used as an internal control and samples treated with IgG were used as 
negative controls. Of the 35 ChIP-Sequencing peaks tested (Table 4.1), predicted 
occupancy sites for Bcl6 which were identified at the Cish and Bcl6 transcriptional start 
sites showed reciprocal occupancy of Bcl6 and Stat5 in response to GH, in addition to the 








protein) gene (Figure 4.2, B), and the second region was a peak of Bcl6 signal identified in 
the transcription start site of the Bcl6 gene (Figure 4.2, C). The verification by ChIP of 
reciprocal Bcl6 and Stat5 occupancy suggested that expression of Cish and Bcl6 mRNA in 
response to GH is reciprocally regulated by Bcl6 and Stat5. Cish is a member of the SOCS 
(suppressor of cytokine signaling) family proteins (21, 22), of which Socs2 is also a 
member, and is a known Stat5 target gene (23). Occupancy of Bcl6 has been reported 
previously at the Cish promoter in liver (17). Bcl6 is known to inhibit the expression of its 
own mRNA (24-26), and Stat5 has been reported to have either an activating or repressive 
effect on Bcl6 transcription depending on cell type (27-31). However, this is the first 
evidence suggesting that Bcl6 and Stat5 may work together to regulate the expression of 
either Cish or Bcl6 in response to GH in adipocytes using dual Bcl6/Stat5 regulatory 
regions in the proximal promoters of these genes. 
 
 In the case of both the Cish ChIP-Sequencing peak and the Bcl6 ChIP-Sequencing peak, 
occupancy of Bcl6 was high without GH treatment, and occupancy of Bcl6 decreased with 
GH. Stat5 occupancy was low in the absence of GH and increased with GH treatment, 
similar to what had previously been seen for Socs2 (Figure 4.3). In the case of the three 
reciprocally regulated gene candidates identified so far, the location of the Bcl6 and Stat5 
reciprocal occupancy ChIP-Sequencing peaks were all located in the transcription start site 
(TSS)/proximal promoter of the gene (Figure 4.2), while peaks tested on other genes 
(Table 4.1) were located at other genomic locations such as introns or intergenic regions, 
suggesting that the location of the regulatory region may be a possible common feature of 
Bcl6/Stat5 reciprocal regulation sites.  
 
Mechanisms by which Bcl6 and Stat5 regulate Socs2, Cish, and Bcl6 expression are 
likely to be different  
 
As shown previously, Cish mRNA expression increases with GH treatment in a pattern 
similar to that seen for Socs2, with Socs2 and Cish being the genes most highly induced 
by GH treatment at later time points, such as 24 and 48 h (Figure 2.2). However, Bcl6 
expression is strongly inhibited by GH treatment (Figure 2.2). This suggests that while the 
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Bcl6 and Stat5 occupancy patterns of the regulatory regions of the three genes are similar, 
the mechanisms of action of Bcl6 and Stat5, and the effects that Bcl6 and Stat5 have on 
transcription of these genes, is likely different. Furthermore, the occupancy patterns of 
Bcl6 and Stat5 in response to GH on Socs2 and Cish in both preadipocytes and adipocytes 
were very similar (Figure 4.4). Bcl6 occupancy on Socs2 and Cish was 3-6 times higher in 
the absence of GH compared to the presence of GH, and Stat5 occupancy increased by 2-5 
fold upon GH treatment. These results correlated with the reciprocal occupancy of Bcl6 
and Stat5 on the Socs2 gene in response to GH in both preadipocytes and adipocytes 
observed previously (Figure 2.8). 
 
In contrast, the occupancy pattern of Bcl6 and Stat5 on the regulatory region of the Bcl6 
gene was different between preadipocytes and adipocytes. Bcl6 occupancy signal on the 
Bcl6 promoter was higher in adipocytes in the absence of GH than in the presence of GH, 
but in preadipocytes Bcl6 occupancy was low in the absence of GH and did not decrease 
with GH treatment. In adipocytes, Stat5 occupancy was low in the absence of GH and 
increased 4 fold with GH. Stat5 occupancy in preadipocytes in the absence of GH 
appeared to be higher than Stat5 occupancy in the absence of GH in adipocytes. However, 
Stat5 occupancy in preadipocytes only showed a slight increase (less than 1.5 fold) upon 
GH treatment. Occupancy patterns for phosphorylated Stat5 showed the same trends as 
occupancy of Stat5 for all conditions, consistent with activated Stat5 mediating 
transcriptional regulation. Quantification of occupancy evaluated by qPCR corresponded 
with previous observations evaluated by resolving PCR products on agarose gels (1), 
supporting the results.  
 
Overall, ChIP results for the Bcl6 gene in adipocytes show a much more distinct 
reciprocal pattern of occupancy between Bcl6 and Stat5 in response to GH compared to 
preadipocytes (Figure 4.4). The different occupancy patterns in adipocytes and 
preadipocytes for Bcl6 and Stat5 in response to GH on the Bcl6 gene, compared to the 
similar pattern of reciprocal occupancy on the Socs2 and Cish genes for Bcl6 and Stat5 in 
both adipocytes and preadipocytes, would also suggest that there are differences in the 









Figure 4.4  
 
Occupancy patterns for Bcl6 and Stat5 in response to GH differ in adipocytes and 
preadipocytes on the Bcl6 promoter, but not on the Socs2 or Cish promoters. 3T3-
F442A adipocytes (A) or preadipocytes (B) were treated without (white bars) or with GH 
(gray bars) for 24 h. ChIP was carried out using antibodies against Bcl6, Stat5, or 
phosphorylated Stat5 (P-Stat5). ChIP samples were probed with primers specific to the 
Bcl6/Stat5 occupancy sites identified by ChIP-Sequencing and quantified using 
quantitative real-time PCR. Immunoprecipitation samples were normalized to 
amplification signal from the input samples for each respective treatment condition. 
Socs2 and Cish show similar occupancy patterns in both adipocytes and preadipocytes for 
Bcl6 and Stat5 in response to GH. However, for the Bcl6 promoter, reciprocal occupancy 
of Bcl6 and Stat5 in response to GH is more marked in adipocytes than preadipocytes. 





to Bcl6, and that these mechanisms may even be different for the same gene under various 
conditions.  
 
Changes in histone modification profiles on the reciprocally occupied regions of 
Socs2, Cish, and Bcl6 correlate with changes in gene expression in response to GH  
 
To identify differences in transcriptional regulation by Bcl6 and Stat5 on the candidate 
reciprocally regulated genes Socs2, Cish, and Bcl6, ChIP was carried out for several 
well-studied histone modifications to examine the chromatin state of the respective 
Bcl6/Stat5 reciprocally occupied regions in the presence and absence of GH. Adipocytes 
were treated with GH acutely for 30 min to identify changes in chromatin state during 
early responses after treatment, when the transcriptional state of the gene is being 
established in response to hormone stimulus (Figure 4.5, A). ChIP was carried out using 
antibodies against acetylated histone H3 (AcH3), acetylated histone H4 (AcH4), and 
trimethylated histone H3 lysine 4 (H3K4me3), all general markers of open and accessible 
chromatin, and suggestive of active gene transcription (32-35). ChIP results (Figure 4.5, 
A) show that levels of AcH3 and AcH4 increase two to five fold on the Socs2 and Cish 
regulatory regions in response to GH, while AcH3 and AcH4 levels increase by less than 
two fold on the Bcl6 regulatory region. The presence of AcH3 and AcH4 at the Socs2, 
Cish, and Bcl6 promoters is consistent with active transcription of these target genes in 
response to GH. Further, the marked enrichment of AcH3 and AcH4 on Socs2 and Cish 
compared to their lesser changes in enrichment observed for Bcl6 is consistent with the 
contrast between strong induction of Socs2 and Cish in response to GH and inhibition of 
Bcl6 expression by GH. The slight increase in levels of AcH3 and AcH4 on Bcl6 in 
response to GH suggests that Bcl6 is a highly regulated and responsive gene and that the 
chromatin remains accessible to the various transcriptional regulatory factors that are 
recruited to it by different stimuli, enabling the cell to respond to the extracellular 
environment. Similarly, strong signal for H3K4me3 is detected at all three regulatory 
regions in both the presence and absence of GH, once again consistent with active 









Figure 4.5  
 
Enrichment of AcH3 and AcH4, histone marks associated with transcription 
activation, increases rapidly and levels remain elevated in response to GH on the 
Socs2 and Cish, but not the Bcl6 promoter. 3T3-F442A adipocytes were treated with 
(A) GH for 0 (white bars) or 30 min (gray bars) or (B) GH for 0 (white bars) or 24 h 
(gray bars). ChIP was carried out using antibodies against AcH3, AcH4, or H3K4me3. 
Enrichment of these activating histone marks at the Bcl6/Stat5 sites identified by ChIP-
Sequencing in the Socs2, Cish, and Bcl6 promoters was analyzed using quantitative real-
time PCR. Signal from ChIP DNA was normalized to signal from input samples of 
respective treatment conditions. Samples treated with IgG were used as negative controls. 
Results shown are the mean and standard error from 4 separate experiments for (A) and 
(B). Responses to GH were statistically significant (p < 0.05) for AcH3 at 0.5 hr and 
AcH4 at 0.5 and 24 h on Socs2, and for AcH4 at 0.5 and 24 h on Cish.  
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Levels of AcH3, AcH4, and H3K4me3 on the regulatory regions of Socs2, Cish, and 
Bcl6 were also examined at the later time of 24 hours after GH treatment when Socs2 and 
Cish are known to be strongly induced and Bcl6 expression is strongly inhibited (Figure 
4.5, B). ChIP results (Figure 4.5, B) in adipocytes show that at 24 h AcH4 levels tend to 
still be elevated by GH for the Bcl6/Stat5 occupied region in all three genes; however, the 
relative level of enrichment in response to GH was greater for Socs2 and Cish (about 2 to 
3 fold) than the negligible changes on Bcl6, consistent with Socs2 and Cish expression 
being induced and Bcl6 expression being repressed at 24 h of GH treatment. In contrast 
to AcH4, AcH3 levels on the Bcl6/Stat5 regulatory region for all three genes were 
modestly elevated if at all compared to AcH3 levels in the absence of GH. H3K4me3 
levels tended to be repressed by GH for the genomic regions examined, perhaps 
indicative of a mechanism for modulating the transcriptional state of these genes to trend 
towards repression as the GH stimulus subsides. 
 
ChIP was also carried out for several histone marks associated with repressed or inactive 
chromatin, such as trimethylated histone H3 lysine 9 (H3K9me3) (36-38) and 
trimethylated histone H3 lysine 27 (H3K27me3) (39, 40). Signals for these repressive 
chromatin marks at the Bcl6/Stat5 regulatory regions of Socs2, Cish, and Bcl6 were 
nearly undetectable (data not shown), consistent with the active transcription and 
regulation of these genes in response to cellular stimuli such as GH.  
 
The coregulatory proteins p300 and Hdac3 occupy the Bcl6/Stat5 regulatory region 
of Socs2, Cish, and Bcl6 in the presence and absence of GH 
 
An important mechanism for transcriptional regulation is the recruitment of coregulatory 
proteins to transcription factor-DNA complexes. To evaluate if histone deacetylases 
(HDACs), ubiquitous coregulators best known for functioning as corepressor molecules 
(41), participated in regulation of Socs2 or Bcl6 expression, preadipocytes were treated 
with trichostatin A (TSA), a general class I and II HDAC inhibitor, and changes in Socs2 
and Bcl6 transcript levels measured by qPCR (Figure 4.6). In a preliminary experiment, 











Figure 4.6  
 
Histone deacetylases participate in regulation of Socs2 and Bcl6 mRNA expression. 
3T3-F442A preadipocytes were pretreated with DMSO vehicle (white bars) or 1 µM 
trichostatin A (TSA, gray bars) for 18 h before treatment with GH for the indicated times. 
Socs2 and Bcl6 mRNA expression was analyzed using quantitative real-time PCR. 
mRNA expression was normalized to Socs2 (left) or Bcl6 (right) expression in vehicle 







with TSA, suggesting that HDAC activity potentiates Socs2 activation in response to GH. 
Conversely, basal Bcl6 levels were elevated in TSA-treated cells, although the repression 
of Bcl6 expression in response to GH appeared to be generally similar in treated and 
untreated cells, suggesting that HDACs play a role in regulating Bcl6 transcript levels, 
but not necessarily GH-mediated repression of Bcl6 expression. Together, these results 
suggest that one or several HDAC molecules play a role in Socs2 and Bcl6 transcription, 
and that the identity of the HDAC family member or members involved or the 
mechanism of HDAC action on transcription of the two genes appears to be different. 
 
To identify if specific coregulatory proteins are associated with Bcl6 and Stat5 at the 
Socs2, Cish, and Bcl6 regulatory regions, ChIP was carried out using antibodies against 
p300 and Hdac3. P300 is a lysine acetyltransferase known to interact with several classes 
of transcription factors (42), including Bcl6 and Stat5 (12, 43). P300 is widely expressed 
and participates in multiple cellular events, including metabolism and adipocyte 
differentiation, and has been shown to participate in regulation of GH target genes (17, 
44-47). Hdac3 is an ubiquitously expressed class I HDAC that has been implicated in 
lipid and energy metabolism and adipogenesis (48-50), and has also been identified as an 
important cofactor in regulating a subset of Bcl6 target genes involved in the innate 
immune response (51).  
 
To examine occupancy of p300 and Hdac3 on the Bcl6/Stat5 regulatory regions of the 
Socs2, Cish, and Bcl6 genes, adipocytes were treated with GH for 30 min, an early time 
point when the transcriptional state of the gene in response to GH is likely being 
established (Figure 4.7, A). For all three genes, Bcl6 occupancy was higher in the 
absence of GH, and Bcl6 occupancy decreased with GH treatment. Occupancy of Stat5 
was lower in the absence of GH, and increased upon GH treatment. These results 
matched the highly responsive reciprocal changes in occupancy of Bcl6 and Stat5 in 
response to GH previously observed on the Socs2, Cish, and Bcl6 genes (Figure 4.3 and 
4.4). ChIP results show that p300 occupancy is detected on Socs2, Cish, and Bcl6 in the 
absence of GH. Occupancy of p300 on Socs2 increased in response to GH. Occupancy of 






Figure 4.7  
 
ChIP for candidate coregulator molecules identifies p300 and Hdac3 as potential 
factors playing a role in Bcl6/Stat5-mediated transcription of Socs2, Cish, and Bcl6 
in response to GH. 3T3-F442A adipocytes were treated with (A) GH for 0 (white bars) 
or 30 min (gray bars) or (B) GH for 0 (white bars) or 24 h (gray bars). ChIP was carried 
out using antibodies against Bcl6, Stat5, p300, and Hdac3. ChIP DNA was analyzed 
using quantitative real-time PCR and primers specific to the Bcl6/Stat5 sites predicted by 
ChIP-Sequencing in the Socs2, Cish, and Bcl6 gene promoters. Signals from ChIP 
samples were normalized to signal from input DNA samples from respective treatment 
conditions. Results shown are the mean and standard error for 3 to 7 independent 
experiments for (A) and (B). Results were combined and graphed together as Bcl6 and 
Stat5 occupancy and changes in occupancy in response to GH for each gene in all 
experiments were comparable. Responses to GH were statistically significant (p < 0.05) 
for Stat5 at 0.5 and 24 hr on Cish, and for Stat5 at 24 h on Bcl6.  
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Occupancy of Hdac3 was also detected on Socs2, Cish, and Bcl6 in the absence of GH. 
In response to GH, the occupancy of Hdac3 trended toward a slight increase upon 
treatment. In general, the occupancy signal of Hdac3, as well as that of other HDACs 
tested (Hdac1, Hdac2, Hdac5, data not shown), appeared to be relatively low under the 
conditions of these experiments, and changes in occupancy to be of small magnitude, 
suggesting that active recruitment of HDACs to Socs2, Cish, and Bcl6 by Bcl6 or Stat5 is 
not a major mechanism in regulating transcription of these genes. Alternatively, the 
presence or absence of Bcl6 or Stat5 may be a major determinant for the transcriptional 
output of these genes, and HDACs may be present at constant low levels on all three 
genes. Thus, specific interactions of HDACs with the recruited transcription factors can 
be considered to fine-tune and modulate transcript levels. Similarly, the signal for p300 
occupancy was relatively low on all three genes under the conditions of these 
experiments, suggesting that the transcription factor itself at these regulatory regions is a 
main determinant for transcriptional output, and p300 is a secondary determinant to better 
regulate and control the outcome of gene activation or repression. These relationships are 
discussed further in Chapter 5. 
 
ChIP for p300 and Hdac3 was also carried out on adipocytes treated with GH for 24 
hours, a later time point of treatment when Socs2 and Cish expression are greatly 
elevated and Bcl6 expression strongly repressed by GH (Figure 4.7, B). For all three 
genes, Bcl6 occupancy was higher in the absence of GH, and decreased with GH 
treatment while occupancy of Stat5 was lower in the absence of GH, and increased upon 
GH treatment, correlating with the reciprocal changes in occupancy of Bcl6 and Stat5 in 
response to GH previously observed (Figure 4.3 and 4.4). P300 occupancy was detected 
on all three genes in the absence of GH, and occupancy increased slightly on all three 
genes even with prolonged GH treatment. Occupancy of Hdac3 was detected at all three 
genes in the presence and absence of GH, but the changes in occupancy pattern in 
response to GH were variable. A possible slight increase in Hdac3 occupancy in response 
to GH was seen for Socs2, while Hdac3 occupancy levels remained about the same in the 
presence and absence of GH for Cish. Occupancy of Hdac3 on Bcl6 decreased slightly 
with GH treatment on Bcl6. Overall, Hdac3 and p300 occupancy signals were detectable 
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but relatively low under the conditions of these experiments, consistent with the extent of 
occupancy and changes observed in p300 and Hdac3 occupancy levels seen at 30 min of 
GH treatment. 
 
Socs2, Cish, and Bcl6 are differentially regulated by p300 and Hdac3 
 
As p300 and Hdac3 occupancy were detected at the Bcl6/Stat5 regulatory regions of the 
Socs2, Cish, and Bcl6 genes in both the presence and absence of GH, but occupancy of 
these coregulatory molecules did not change markedly in response to GH treatment, it was 
of interest to evaluate the functional contributions of p300 and Hdac3 on Bcl6- or Stat5-
mediated regulation of Socs2, Cish, and Bcl6 transcription. To evaluate the regulatory 
effects of p300 and Hdac3 on Bcl6- or Stat5-mediated regulation of Socs2, Cish, or Bcl6 
expression, reporter gene assays were carried out. Reporter gene constructs in which the 
sequences for the Socs2, Cish, and Bcl6 promoters were fused upstream of the gene 
coding for firefly luciferase were generated for the three genes. For each promoter, a short 
and a long promoter construct were generated. The short promoter constructs (Figures 4.8-
4.10, A, top schematics) each contained a 200 bp fragment with the Bcl6/Stat5 site 
identified by ChIP-Sequencing for the respective gene near the center of the fragment. In 
each case this approximately corresponds to the transcription start site. The long promoter 
constructs (Figures 4.8-4.10, A, bottom schematics) contained more of the native genomic 
sequence context, including about 750 bp upstream and 250 bp downstream of the 
Bcl6/Stat5 site for each gene. All constructs were tested for their responses to the presence 
of Bcl6, constitutively active Stat5b, p300, or Hdac3 individually, and Bcl6 or 
constitutively active Stat5 in combination with either p300 or Hdac3. Constitutively active 
Stat5b (CA-Stat5b) was used as both a representation of GH treatment and to pinpoint the 
contributions of Stat5b on the regulation of the promoter of each of the three genes. 
 
In the case of Socs2-luc short (Figure 4.8, B), p300 had an activating effect on basal 
Socs2-luc short expression (Figure 4.8, B, lanes 1, 2), while Hdac3 had a slightly 
repressive effect on basal Socs2-luc short expression (Figure 4.8, B, lanes 1, 3). Bcl6 
inhibited Socs2 promoter activation (Figure 4.8, B, lanes 1, 4), correlating with previous  
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Figure 4.8  
 
P300 and Hdac3 can modulate Stat5-mediated transcription of Socs2-luc short and 
Socs2-luc long. A. Schematic of the Socs2-luc short and Socs2-luc long constructs. A 
200 bp fragment surrounding the Bcl6/Stat5 occupancy region (mouse chromosome 10: 
94879550-94879558) in the Socs2 promoter was cloned upstream of luciferase and the 
construct designated as Socs2-luc short (top). A DNA fragment consisting of the genomic 
sequences about 750 bp upstream and about 250 downstream of the Bcl6/Stat5 
occupancy region (mouse chromosome 10: 94879550-94879558) in the Socs2 promoter 
was cloned upstream of luciferase and the construct designated as Socs2-luc long 
(bottom). Transcription start site of the Socs2 gene: mouse chromosome 10: 94879491 
(from NCBI Reference Sequences). B. Socs2-luc short was transfected into 293T cells in 
the presence or absence of Bcl6, constitutively active Stat5b (CA-Stat5b), p300, and 
Hdac3 alone or in combination as indicated. Luciferase activity is expressed as RLU 
(relative luciferase units) and normalized to basal Socs2-luc short values (lane 1), set as 
1.0. Bars represent means and error bars show + standard errors from 7 to 10 independent 
observations.!Results of all experiments were combined and graphed together, as fold 
changes of response over basal luciferase levels between overlapping conditions were 
comparable between experiments. Comparisons between lane 1 and lane 4, lane 1 and 
lane 6, lane 1 and lane 9, and lane 7 and lane 9 reached statistical significance (p<0.05). 
C. Socs2-luc long was transfected into 293T cells in the presence or absence of Bcl6, 
constitutively active Stat5b (CA-Stat5b), p300, and Hdac3 alone or in combination as 
indicated. Luciferase activity is expressed as RLU (relative luciferase units) and 
normalized to basal Socs2-luc long values (lane 1), set as 1.0. Bars represent means and 
error bars show + standard errors from 3 independent experiments. Comparisons between 

















results (1). In the presence of Bcl6, neither p300 (Figure 4.8, B, lane 5) nor Hdac3 (Figure 
4.8, B, lane 6) appeared to markedly alter reporter gene expression compared to the effects 
of Bcl6 alone (Figure 4.8, B, lane 4) on Socs2-luc short, although p300 may have a 
derepressive effect on Bcl6-mediated inhibition of Socs2-luc short expression (Figure 4.8, 
B, lanes 4, 5). The addition of CA-Stat5b alone did not significantly activate reporter gene 
expression over basal Socs2-luc short expression levels (Figure 4.8, B, lanes 1, 7). 
However, in the presence of CA-Stat5b, the presence of p300 activated reporter gene 
expression (Figure 4.8, B, lanes 7, 8), even further than p300 alone activated basal Socs2-
luc levels (Figure 4.8, B, lanes 2, 8). In the presence of CA-Stat5b, the addition of Hdac3 
inhibited reporter gene expression when compared to CA-Stat5b alone (Figure 4.8, B, 
lanes 7, 9), or Hdac3 alone (Figure 4.8, B, lanes 3, 9).  
 
The relative regulatory effects of Bcl6, Stat5, p300, and Hdac3 on Cish-luc short reporter 
gene activation (Figure 4.9, B) appeared to be similar to those observed for Socs2-luc 
short (Figure 4.8, B). The presence of p300 appeared to slightly activate Cish-luc 
expression compared to basal levels (Figure 4.9, B, lanes 1, 2). The addition of Hdac3 
appeared to have a slight repressive effect on basal reporter gene expression (Figure 4.9, 
B, lanes 1, 3). Bcl6 inhibited Cish-luc short reporter gene expression (Figure 4.9, B, lanes 
1, 4). In the presence of Bcl6, neither p300 (Figure 4.9, B, lane 5) nor Hdac3 (Figure 4.9, 
B, lane 6) appeared to greatly alter reporter gene expression compared to the effects of 
Bcl6 alone (Figure 4.9, B, lane 4), suggesting that Bcl6 functions as a strong repressor of 
Cish transcription and this potent repression does not require the actions of p300 or 
Hdac3.  
 
The addition of CA-Stat5b alone did not appear to activate reporter gene expression above 
basal levels (Figure 4.9, B, lanes 1, 7). However, in the presence of CA-Stat5b, the 
addition of p300 further activated reporter gene expression compared to the effects of CA-
Stat5b alone (Figure 4.9, B, lanes 7, 8) or p300 alone (Figure 4.9, B, lanes 2, 8). In the 
presence of CA-Stat5b, the addition of Hdac3 had a repressive effect on reporter gene 





Figure 4.9  
 
P300 and Hdac3 can modulate Stat5-mediated transcription of Cish-luc short and 
Cish-luc long. A. Schematic of the Cish-luc short and Cish-luc long constructs. A 200 bp 
fragment surrounding the Bcl6/Stat5 occupancy region (mouse chromosome 9: 
107198991-107199010) in the Cish promoter was cloned upstream of luciferase and the 
construct designated as Cish-luc short (top). A DNA fragment consisting of the genomic 
sequences about 750 bp upstream and about 250 downstream of the Bcl6/Stat5 
occupancy region (mouse chromosome 9: 107198991-107199010) in the Cish promoter 
was cloned upstream of luciferase and the construct designated as Cish-luc long (bottom). 
Transcription start site of the Cish gene: mouse chromosome 9: 107199020 (from NCBI 
Reference Sequences). B. Cish-luc short was transfected into 293T cells in the presence 
or absence of Bcl6, constitutively active Stat5b (CA-Stat5b), p300, and Hdac3 alone or in 
combination as indicated. Luciferase activity is expressed as RLU (relative luciferase 
units) and normalized to basal Cish-luc short values (lane 1), set as 1.0. Bars represent 
means and error bars show + standard errors from 3 independent experiments. 
Comparisons between lane 1 and lane 4 reached statistical significance (p<0.05). C. Cish-
luc long was transfected into 293T cells in the presence or absence of Bcl6, constitutively 
active Stat5b (CA-Stat5b), p300, and Hdac3 alone or in combination as indicated. 
Luciferase activity is expressed as RLU (relative luciferase units) and normalized to basal 
Cish-luc long values (lane 1), set as 1.0. Bars represent means and error bars show + 
standard errors from 3 independent experiments. Comparisons between lane 1 and lane 9 



























Cish-luc short in the presence of CA- Stat5b alone (Figure 4.9, B, lanes 7, 9) or Hdac3 
alone (Figure 4.9, B, lanes 3, 9).  
 
Regulation of the Bcl6/Stat5 regulatory sequence of Bcl6-luc short (Figure 4.10, B) 
appeared to be very different from regulation of Socs2-luc short (Figure 4.8, B) or Cish-
luc short (Figure 4.9, B). Interestingly, both p300 (Figure 4.10, B, lane 2) and Hdac3 
(Figure 4.10, B, lane 3) appeared to slightly elevate Bcl6-luc short expression compared to 
basal levels (Figure 4.10, B, lane 1). Bcl6 inhibited Bcl6-luc short expression (Figure 4.10, 
B, lanes 1, 4) as predicted, since Bcl6 is known to repress its own transcription (24). In the 
presence of Bcl6, neither p300 nor Hdac3 appeared to greatly alter reporter gene 
expression compared to the effects of Bcl6 alone (Figure 4.10, B, lanes 4, 5, 6), similar to 
what was seen for Bcl6-mediated inhibition of Socs2-luc short and Cish-luc short 
expression. The potential lack of coregulator involvement in Bcl6-mediated repression of 
the Socs2, Cish, and Bcl6 short promoter constructs suggests that Bcl6 functions as a 
potent repressor on all three short promoter constructs, and the functional effects of p300 
and Hdac3 on the short luciferase constructs are primarily carried out through their 
interactions with Stat5 upon Stat5 recruitment to the promoter.  
 
Surprisingly, the presence of CA-Stat5b alone was sufficient to markedly induce 
expression of Bcl6-luc short over basal levels (Figure 4.10, B, lanes 1, 7). This 
corresponds with previous results shown for the corresponding region of the human Bcl6 
gene (27). Strikingly, the addition of p300 (Figure 4.10, B, lane 8) as well as Hdac3 
(Figure 4.10, B, lane 9) in the presence of CA-Stat5b resulted in repression of Bcl6-luc 
short expression compared to the presence of CA-Stat5b alone (Figure 4.10, B, lane 7). In 
the case of Hdac3, reporter gene expression was reduced to basal levels (Figure 4.10, B, 
lanes 1, 9). These intriguing observations suggest that Stat5 may function as a repressor of 






Figure 4.10  
 
P300 as well as Hdac3 appear to have repressive effects on Stat5-mediated 
regulation of Bcl6-luc short and Bcl6-luc long. A. Schematic of the Bcl6-luc short and 
Bcl6-luc long constructs. A 200 bp fragment surrounding the Bcl6/Stat5 occupancy 
region (mouse chromosome 16: 23988676-23988725) in the Bcl6 promoter was cloned 
upstream of luciferase and the construct designated as Bcl6-luc short (top). A DNA 
fragment consisting of the genomic sequences about 750 bp upstream and about 250 
downstream of the Bcl6/Stat5 occupancy region (mouse chromosome 16: 23988676-
23988725) in the Bcl6 promoter was cloned upstream of luciferase and the construct 
designated as Bcl6-luc long (bottom). Transcription start site of the Bcl6 gene: mouse 
chromosome 16: 23965138 (from NCBI Reference Sequences). B. Bcl6-luc short was 
transfected into 293T cells in the presence or absence of Bcl6, constitutively active Stat5b 
(CA-Stat5b), p300, and Hdac3 alone or in combination as indicated. Luciferase activity is 
expressed as RLU (relative luciferase units) and normalized to basal Bcl6-luc short 
values (lane 1), set as 1.0. Shown are combined preliminary results from 2 experiments. 
Results were combined and graphed together for ease of comparison, as fold changes of 
response over basal luciferase levels between overlapping conditions were comparable 
between experiments. Overlapping conditions are graphed as the mean fold change 
values over basal from 2 experiments. C. Bcl6-luc long was transfected into 293T cells in 
the presence or absence of Bcl6, constitutively active Stat5b (CA-Stat5b), p300, and 
Hdac3 alone or in combination as indicated. Luciferase activity is expressed as RLU 
(relative luciferase units) and normalized to basal Bcl6-luc long values (lane 1), set as 
1.0. Bars represent means and error bars show + standard errors from 3 independent 
experiments. Comparisons between lane 1 and lane 4, lane 1 and lane 5, lane 1 and lane 



























Regulation of Bcl6 expression is more dependent on promoter sequence context than 
Socs2 and Cish 
 
To investigate if the genomic sequence context surrounding the Bcl6/Stat5 regulatory 
regions in the Socs2, Cish, and Bcl6 promoters had an effect on Bcl6- or Stat5-mediated 
transcriptional regulation of target gene expression, the regulatory effects of p300 and 
Hdac3 on Bcl6- or Stat5-mediated regulation of the long luciferase constructs were tested. 
For the Socs2-luc long construct (Figure 4.8, C), relative changes were similar to those 
seen for the Socs2-luc short construct (Figure 4.8, B). Interestingly, p300 and Hdac3 did 
not appear to greatly alter Socs2-luc long expression levels compared to basal reporter 
gene levels when added alone (Figure 4.8, C, lanes 1, 2, 3). Bcl6 inhibited reporter gene 
expression (Figure 4.8, C, lanes1, 4).  In the presence of Bcl6, p300 (Figure 4.8, C, lane 5) 
may have a derepressive effect on Bcl6-mediated inhibition of Socs2-luc long expression 
when compared to Bcl6 alone (Figure 4.8, C, lane 4). However, Socs2-luc long expression 
levels in the presence of both Bcl6 and p300 (Figure 4.8, C, lane 5) are lower than in the 
presence of p300 alone (Figure 4.8, C, lane 2), once again demonstrating the strong 
inhibitory effects of Bcl6 on the Socs2 promoter. The addition of Bcl6 and Hdac3 together 
(Figure 4.8, C, lane 6) did not appear to greatly alter reporter gene expression compared to 
conditions with only Bcl6 added (Figure 4.8, C, lane 4).  
 
The addition of CA-Stat5b alone did not activate Socs2-luc long above basal levels 
(Figure 4.8, C, lanes 1, 7). However, in the presence of CA-Stat5b, the addition of p300 
further activated the promoter (Figure 4.8, C, lane 8) compared to CA-Stat5b alone 
(Figure 4.8, C, lane 7) or basal levels (Figure 4.8, C, lane 1). In the presence of CA-Stat5b, 
the addition of Hdac3 (Figure 4.8, C, lane 9) inhibited the promoter compared to Hdac3 
alone (Figure 4.8, C, lane 3) or CA-Stat5b alone (Figure 4.8, C, lane 7).  
 
Regulation of Cish-luc long by Bcl6, Stat5, p300, and Hdac3 (Figure 4.9, C) for the most 
part resembled observations for Cish-luc short (Figure 4.9, B). P300 appeared to have a 
slightly activating effect on basal Cish-luc long expression (Figure 4.9, C, lanes 1, 2) 
while Hdac3 had a slight repressive effect compared to basal (Figure 4.9, C, lanes 1, 3). 
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Bcl6 inhibited Cish-luc long expression (Figure 4.9, C, lanes 1, 4).  However, in contrast 
to regulation of the three short promoter constructs and Socs2-luc long, where p300 
appeared to either have potential derepressive effects or no marked effects at all on Bcl6-
mediated inhibition of reporter gene expression, results for regulation of Cish-luc long 
show slight inhibitory effects for Bcl6 and p300 together compared to Bcl6 alone (Figure 
4.9, C, lanes 4, 5) as well as relative to p300 alone (Figure 4.9, C, lane 2). Instead, Hdac3 
appeared to have a slight derepressive effect on Bcl6-mediated inhibition of Cish-luc long 
expression (Figure 4.9, C, lanes 4, 6). However, in general, the presence of p300 or Hdac3 
in addition to Bcl6 (Figure 4.9, C, lanes 5, 6) did not appear to greatly alter the effects of 
Bcl6-mediated repression of Cish-luc long expression compared to Bcl6 alone (Figure 4.9, 
C, lane 4). 
 
CA-Stat5b did not greatly activate the Cish-luc long promoter above basal values (Figure 
4.9, C, bars 1, 7). The presence of p300 in conjunction with CA-Stat5b (Figure 4.9, C, 
lane 8) further activated reporter gene expression compared to Cish-luc long in the 
presence of CA-Stat5b alone (Figure 4.9, C, lane 7), basal Cish-luc long expression levels 
(Figure 4.9, C, lane 1), or p300 alone (Figure 4.9, C, lane 2). In the presence of CA-
Stat5b, the addition of Hdac3 (Figure 4.9, C, lane 9) further inhibited reporter gene 
expression compared to CA-Stat5b alone (Figure 4.9, C, lane 7) or Hdac3 alone (Figure 
4.9, C, lane 3).  
 
In light of the inhibition of Bcl6 mRNA expression by GH, relative to activation of Socs2 
and Cish mRNA expression by GH, it is of great interest that regulation of Bcl6-luc long 
by Bcl6, Stat5, p300, and Hdac3 (Figure 4.10, C) appeared to be very different from the 
changes observed for regulation of Socs2-luc long and Cish-luc long (Figures 4.8, C and 
4.9, C). The presence of p300 (Figure 4.10, C, lane 2) and Hdac3 (Figure 4.10, C, lane 3) 
did not appear to greatly alter Bcl6-luc long expression compared to basal levels (Figure 
4.10, C, lane 1). The addition of Bcl6 strongly repressed Bcl6-luc long reporter gene 
expression compared to basal levels (Figure 4.10, C, lanes 1, 4).  Interestingly, the 
addition of either p300 (Figure 4.10, C, lanes 4, 5) or Hdac3 (Figure 4.10, C, lanes 4, 6) in 
combination with Bcl6 appeared to further repress reporter gene expression to a slight, but 
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noticeable extent, compared to the repression seen in the presence of Bcl6 alone (Figure 
4.10, C, lane 4).  
 
In contrast to what was observed for Bcl6-luc short, the addition of CA-Stat5b did not 
activate Bcl6-luc long expression (Figure 4.10, C, lanes 1, 7). The presence of CA-Stat5b 
together with Hdac3 (Figure 4.10, C, lane 9) still resulted in further inhibition of Bcl6-luc 
long expression compared to Bcl6-luc long expression levels with CA-Stat5b alone 
(Figure 4.10, C, lane 7) or Hdac3 alone (Figure 4.10, C, lane 3). Similar to observations 
for Bcl6-luc short, p300 appeared to have the same repressive effect on Stat5-mediated 
activation of reporter gene expression (Figure 4.10, C, lanes 7, 8), once again suggesting 
that Stat5 might function as a transcriptional repressor of Bcl6 expression in vivo with the 
aid of coregulatory proteins.  
 
Regulation of the Bcl6 promoter by Bcl6, Stat5, p300, and Hdac3 appears to be distinct 
from regulation of the Socs2 and Cish promoters. Interestingly, regulation of Bcl6-luc 
long (Figure 4.10, C) and Bcl6-luc short (Figure 4.10, B) also appeared to be different, 
demonstrating the complex layers of Bcl6 transcriptional regulation. These distinctive 
results for the Bcl6 promoter are consistent with a trend for Bcl6 transcription to be highly 
regulated by many intricate input signals, and correlate with the repression of Bcl6 




Bcl6 and Stat5 reciprocally occupy regulatory regions of the Socs2, Cish, and Bcl6 
genes 
 
Socs2 expression is reciprocally regulated by Bcl6 and Stat5 in response to GH, with Bcl6 
acting as a repressor in the absence of GH, and Stat5 functioning as an activator upon 
treatment, as shown in Chapter 2. High throughput ChIP-Sequencing allowed us to 
characterize the occupancy profiles of Bcl6 and Stat5 across the genome in the presence 
and absence of GH, as shown in Chapter 3. To identify other genes on which Bcl6 and 
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Stat5 share a DNA regulatory sequence, similar to Socs2, candidate ChIP-Sequencing 
peaks were selected and tested by ChIP for Bcl6 occupancy, Stat5 occupancy, and changes 
in Bcl6 and Stat5 occupancy in response to GH.  
 
It was predicted that gene candidates would be identified that were reciprocally regulated 
in a manner similar to Socs2, as Stat5 is best known as a transcriptional activator, and is a 
well characterized GH-regulated transcription factor (52-56). Bcl6 is also best known as a 
transcriptional repressor; currently, in most documented examples where Bcl6 directly 
regulates expression of a target gene, it has functioned as a repressor (2, 57, 58). However, 
both Bcl6 and Stat5 associate with other nuclear protein factors, and the activity of these 
associated proteins on transcriptional regulatory complexes containing Bcl6 or Stat5, 
could also lead to loss of Bcl6 repression on target gene expression, or conversely, Stat5-
mediated downregulation of transcription. Stat5 has been postulated to repress Bcl6 
expression in immune cells (27), and is known to repress germline transcription from the 
Igk (immunoglobulin kappa chain complex) locus (59). A recent study proposed a role for 
Bcl6 in activating expression of Oat (organic anion transporter) 1 and Oat3 expression in 
rat kidney proximal tubule cells, which may be a rare example of Bcl6 functioning as a 
transcription activator (60). If such examples appeared among our candidate genes, they 
would provide exciting model systems to characterize the less well-studied mechanisms of 
Stat5-mediated repression or Bcl6-mediated activation.  
 
Another potential possibility is that Bcl6 and Stat5 may work together to regulate 
expression of a target gene, but in a context where occupancy of these factors would not 
be reciprocal in response to GH. So far, no studies report that Bcl6 and Stat5 interact in a 
protein complex, and co-immunoprecipitation experiments using overexpressed Bcl6 and 
Stat5 together in 293T cells did not show interaction between the two factors (data not 
shown). However, it is possible that Bcl6 and Stat5 could both be occupying the same 
regulatory sequence on a gene using tandem or closely spaced consensus sequences, since 
Stat5 sites often occur in pairs or clusters (61, 62). If examples of this type of regulatory 
mechanism were identified and verified using the ChIP-Sequencing data, computational 
characterization of the occupancy sequences and comparison with other Bcl6 and Stat5 
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occupancy sequences would provide insight into potential sequence requirements for 
either Bcl6 or Stat5 occupancy. Experimental analysis of the binding kinetics and factor 
requirements for Bcl6 and Stat5 association with these genomic sequences would also 
provide endogenous models with which to examine the specificity requirements for a 
DNA sequence to serve as a Bcl6 binding site, a Stat5 binding site, or a dual Bcl6/Stat5 
site.   
 
Currently, the three reciprocally regulated gene candidates identified all contain a 
Bcl6/Stat5 regulatory site in the proximal promoter of the gene (designated as 
transcription start site by H-Peak). The occupancy patterns of Bcl6 and Stat5 at regulatory 
regions identified by ChIP-Sequencing for all three genes are also similar to each other. 
Bcl6 occupancy is high without GH and decreases with treatment, while the occupancy of 
Stat5 is low in the absence of GH and increases with GH treatment. Genomatix analysis of 
the Bcl6/Stat5 occupancy region for predicted Bcl6 or Stat5 binding sites revealed two 
potential occupancy sequences for Bcl6 and/or Stat5 on the Cish and Bcl6 genes (Figure 
4.11). Currently it is unknown which sequences Bcl6 and Stat5 occupy, or if Bcl6 and 
Stat5 occupy the same binding motif on the Cish and Bcl6 promoters. Alternatively, Bcl6 
and Stat5 could be occupying the Socs2, Cish, and Bcl6 promoters at as yet unidentified 
motifs. 
 
The Bcl6/Stat5 occupancy regions for Socs2, Cish, and Bcl6 are located near the 
transcriptional start sites of the respective genes 
 
Prior to experimental verification of the selected ChIP-Sequencing peaks, it was predicted 
that in addition to identifying regulatory sites in genomic sequences commonly associated 
with regulation of gene transcription, such as promoters, examples might also be 
discovered where Bcl6 and Stat5 regulate expression of target genes using genomic 
regulatory regions not commonly associated with direct regional regulation of 
transcription. Stat5, in particular, has been shown to regulate gene expression using 
intronic binding sites (61-63). Peaks with strong peak height or significant p values were 




Figure 4.11  
 
Predicted Bcl6/Stat5 binding motifs in the Socs2, Cish, and Bcl6 promoters as 
identified by ChIP-Sequencing. Bcl6 and Stat5 share a highly similar DNA binding 
consensus sequence; shown above are the Stat5 and Bcl6 binding consensus motifs for 
reference. Listed below are the Genomatix predicted Bcl6 or Stat5 binding sequences 
(boxed) identified in the region of Bcl6 occupancy detected on the mouse Socs2, Cish, or 
Bcl6 genes by ChIP-Sequencing. Location for Socs2 motif: chromosome 10: 94879550-
94879558. Location for Cish motis: (Left) Chromosome 9: 107198991-107198999, 
(Right) Chromosome 9: 107199002-107199010. Location for Bcl6 motifs: (Left) 
Chromosome 16: 23988676-23988684, (Right) Chromosome 16: 23988717-23988725. 
At present it is unknown which motif Bcl6 and/or Stat5 occupies on the Cish and Bcl6 
promoters, if Bcl6 and/or Stat5 can occupy both sequences, or if Bcl6 and/or Stat5 
occupy the Cish and Bcl6 promoters at an as yet unidentified binding motif. Adapted 





Among the 35 candidate ChIP-Sequencing peaks tested, many were located in upstream 
intergenic regions, introns, or downstream regulatory regions. However, of the peaks 
tested, the only regions that showed significant occupancy of both Bcl6 and Stat5 enriched 
over an IgG negative control, and the only occupancy regions that also showed reciprocal 
occupancy of Bcl6 and Stat5 in response to GH, were located near the transcription start 
sites of the Socs2, Cish, and Bcl6 genes.  
 
Many transcription factors are thought to primarily regulate transcription from target gene 
promoters. For example, ChIP-Sequencing experiments have shown that Rap1 binding in 
yeast and PHA-4 binding in C. elegans show strong correlation of target gene expression 
when these transcription factors are bound at gene promoters, and binding of these factors 
at the promoter region of target genes was strongly enriched over binding at other 
genomic locations (64, 65). However, our ChIP-Sequencing results revealed widespread 
Bcl6 and Stat5 binding across the genome with a large number of sites showing only 
modest ChIP-Sequencing signal. Transcription factor occupancy of either Bcl6 or Stat5 
was also not preferentially enriched on promoter regions in our ChIP-Sequencing results 
(Table 4.2). As discussed in Chapter 3, this widespread binding may be a mechanism by 
which the level of a transcription factor is buffered in the cell, with lower affinity binding 
sites serving as a sequestration mechanism (66). Another possibility is that these 
transcription factors may be participating in different functions at these secondary or 
weaker sites, such as chromatin remodeling or maintenance of nuclear architecture, and 
not functioning as canonical transcription factors (66). Widespread binding of 
transcription factors in genomic locations outside of gene promoters has also been 
observed in other ChIP-Sequencing studies for Stat5 using mouse embryonic fibroblasts 
(MEFs) from wild type or Stat5a knock out mice treated without or with GH for 45 
minutes (67). Interestingly, of the genes identified in the MEFs to have Stat5 occupancy at 
promoter or upstream regions correlating with a strong Stat binding motif at the 
occupancy region, the only genes shown to be highly regulated by Stat5 and responsive to 
GH were Socs2, Cish, Bcl6, and the SOCS family member Socs3. Bcl6 occupancy was 
not detected on Socs3 in our ChIP-Sequencing results, and our profile of GH-regulated 













Analysis of Bcl6 and Stat5 occupancy peak locations in ChIP-Sequencing results. 








(30 min). As Socs2, Cish, and Bcl6 were some of the genes most strongly regulated by 
GH at later times in our gene profile (1), regulation of these genes by Bcl6 and Stat5 may 
be an indicator of highly GH responsive genes. As the Stat5 ChIP-Sequencing study in 
MEFs excluded Stat5 sites that were not in promoter or upstream regions, and selected for 
Stat5 occupancy sites with a strong Stat binding consensus sequence (67), it remains to be 
determined if other Stat5 occupancy sites detected by ChIP-Sequencing in MEFs regulate 
expression of target genes.  
 
In light of the widespread binding of Bcl6 and Stat5 detected across the genome in our 
ChIP-Sequencing results, it is striking that Bcl6 and Stat5 were found to occupy the 
transcription start sites of all three of the reciprocally regulated gene candidates. Socs2, 
Cish, and Bcl6 were also clustered together in the group of genes found to be most 
strongly regulated by GH at later time points according to CRC analysis of the microarray 
of GH-treated adipocytes (1). It is currently unknown if there are other examples of 
reciprocally occupied Bcl6 and Stat5 sites in the genome; however, the current data lead to 
the postulation that reciprocal regulation of a GH target gene by Bcl6 and Stat5 is a 
mechanism used for regulating transcription of highly responsive GH target genes, and 
that the Bcl6/Stat5 regulatory region for such genes trend toward being located in the 
proximal promoter. Proximity to transcription start sites correlating with gene activation 
has also been demonstrated for PPAR! and C/EBP", two key transcription factors 
involved in regulating genes mediating the adipogenic differentiation program (68). The 
location of the Bcl6/Stat5 regulatory region in Socs2, Cish, and Bcl6 also suggests that 
Bcl6 and Stat5 may tend to function as transcription factors when located relatively near a 
gene promoter and perhaps function differently as chromatin-associated proteins when 
occupying other genomic regions. Further bioinformatic mining of ChIP-Sequencing and 
gene expression data, and experimental verification of predicted Bcl6/Stat5 regulatory 
regions, may identify additional reciprocally regulated gene candidates and provide 
information on functional or structural relationships among these Bcl6- and Stat5-
regulated genes.  
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Conversely, novel candidate Bcl6 target genes identified by ChIP-Sequencing may be 
more likely to be direct Bcl6 targets when the predicted Bcl6 binding site is located closer 
to the gene promoter. Proximity has guided our approach towards analyzing and 
prioritizing candidate Bcl6 target genes identified through ChIP-Sequencing: Genes that 
contained a Bcl6 occupancy peak within 10 kb of the gene promoter in the absence of GH 
were selected for functional bioinformatics analyses. Similarly, of the genes identified as 
top candidates for being GH-regulated Bcl6 target genes by comparing the ChIP-
Sequencing and microarray data, genes with predicted Bcl6 binding sites in upstream 
promoter, 5’ UTR regions, or within the first intron are considered top priority candidates 
for experimental validation and further exploration. 
 
Transcription of Socs2, Cish, and Bcl6 is differentially regulated by Bcl6 and Stat5 
 
The occupancy patterns for Bcl6 and Stat5 on Socs2, Cish, and Bcl6 were similar for all 
three genes. Occupancy of Bcl6 was high in the absence of GH and decreased with GH 
treatment, while occupancy of Stat5 was low in the absence of GH and increased with GH. 
However, Bcl6 stands out, since Socs2 and Cish mRNA expression is induced by GH 
while Bcl6 expression is inhibited (1), suggesting that the transcriptional consequences 
mediated by Bcl6 and Stat5 on expression of the three genes is different. To better 
characterize the transcriptional state of these genes in response to GH, and in the presence 
or absence of Bcl6 and Stat5, ChIP was carried out to probe for changes in the association 
of histone modification marks at the Bcl6/Stat5 regulatory site. Histone marks associated 
with active transcription and open chromatin structure were examined at an early 
treatment time after GH treatment (30 min) when the reciprocal switch of Bcl6 and Stat5 
is already known to occur, based on previous observations (Figure 2.8).  
 
ChIP revealed a marked increase in AcH3 and AcH4 on the Socs2 and Cish promoters in 
response to GH, corresponding to induction of Socs2 and Cish mRNA expression by GH, 
in keeping with AcH3 and AcH4 being histone marks associated with active transcription 
and accessible chromatin structure (32, 34, 69, 70). These results were similar to previous 
results demonstrating an increase in AcH3 and AcH4 at the promoters of Socs2 and Cish 
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in response to GH treatment (60 min) in rat liver (17). In contrast, on the Bcl6 promoter, 
AcH3 and AcH4 were highly enriched over background signal; however, the extent of 
enrichment did not significantly increase in response to GH, correlating with Bcl6 
repression by GH. H3K4me3, another histone mark associated with active transcription 
(32, 71), was found to be strongly enriched at all three promoters. These results suggest 
that Socs2, Cish, and Bcl6 are located in open chromatin and these genes are poised to be 
actively transcribed and regulated.  
 
Histone marks commonly associated with heterochromatin and untranscribed chromatin 
were not found to be enriched at the Socs2, Cish, and Bcl6 promoters, suggesting that the 
regulatory regions of these genes need to remain accessible to allow rapid modulation of 
transcription in response to stimuli. It is likely that the repression of Bcl6 expression in 
response to GH is regulated by the binding of protein factors at inhibitory regulatory 
regions in the gene, and it is speculated that restructuring of the chromatin state of the 
gene plays a lesser role than repressor binding in controlling transcriptional output. Some 
of the most likely candidates for inhibitory factors repressing Bcl6 expression in response 
to GH are Bcl6 and Stat5 themselves, as Bcl6 is well known as a transcriptional repressor, 
and Stat5 has been found to repress Bcl6 expression in response to cytokine treatment in 
immune cells (27, 57).  
 
Beyond Socs2: Bcl6 and Stat5 regulate expression of Cish and Bcl6 in response to 
GH in adipocytes 
 
After the identification of Socs2 as a novel Bcl6 target gene, and characterization of 
reciprocal regulation of Socs2 expression by Bcl6 and Stat5 in response to GH, it was 
hypothesized that Bcl6 would likely regulate the expression of other GH target genes in 
adipocytes, and the mechanism of reciprocal regulation of transcription by Bcl6 and Stat5 
would apply to other Bcl6 or Stat5 target genes beyond Socs2. As reported in Chapter 3, 
high throughput ChIP-Sequencing techniques (72-74) and genome-wide bioinformatic 
analyses (75) were applied to identify both novel Bcl6 target genes in adipocytes and 
other GH target genes reciprocally regulated by Bcl6 and Stat5. Among the candidate 
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Bcl6 target genes identified using this approach, Cish and the Bcl6 gene itself were 
shown to be regulated by Bcl6 using promoter construct reporter gene assays (Figure 4.9, 
4.10, lanes 1 and 4), and ChIP has shown reciprocal occupancy of Bcl6 and Stat5 on the 
same DNA regulatory region of these genes (Figure 4.3).  
 
Cish is a known GH and Stat5 target gene, and Bcl6 occupancy at the Cish promoter has 
been demonstrated previously (17). However, this is the first example where Bcl6 
inhibition of the Cish promoter has been demonstrated.  
 
Bcl6 is known to repress its own transcription using upstream Bcl6 binding sites (24-26). 
It has also been shown that Bcl6 expression is regulated by Stat5, with Stat5 acting as 
either an activator or repressor depending on cell type and promoter sequence context 
(27-31). The functional promoter analyses in this chapter are the first examples showing 
Bcl6 and Stat5 functioning to regulate Bcl6 expression using the same regulatory region. 
However, it should be noted that there are two predicted Bcl6 and/or Stat5 binding sites 
in the Bcl6/Stat5 occupancy regions identified by ChIP-Sequencing for the Cish and Bcl6 
genes (Figure 4.11). It is currently unknown which occupancy site or sites Bcl6 and Stat5 
occupy in these regulatory regions. However, the occupancy pattern of Bcl6 and Stat5 on 
this region in response to GH is reciprocal in adipocytes, suggesting that Bcl6 plays the 
major regulatory role in the absence of GH, and Stat5 occupancy of the regulatory region 
upon GH treatment mediates Cish and Bcl6 expression in response to GH. 
 
The complex relationship of Stat5-mediated transcriptional regulation of Bcl6 
expression 
 
In preadipocytes and adipocytes, GH, insulin, and EGF strongly inhibit Bcl6 gene 
expression (Figure 2.1). Bcl6 promoter assays support that downregulation of Bcl6 
transcription may be mediated at least partially by Stat5 in conjunction with associated 
coregulatory molecules such as Hdac3, suggesting that Stat5 might function as a 
transcriptional repressor for Bcl6 and inhibit Bcl6 expression (Figure 4.10). GH also 
strongly inhibits Bcl6 expression in liver (76) and muscle (77) as well as adipose tissue 
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(C LaPensee, unpublished data). However, the relationship between Stat5 and the 
regulation of Bcl6 expression appears to be extremely complex and to depend heavily on 
cell-specific or possibly stimulation specific or chromatin specific context.  
 
Stat5 inhibits Bcl6 expression in T follicular helper cells (78), and was found to 
negatively regulate Bcl6 expression in interleukin 7-dependent B cell precursors (79). 
Stat5a was also shown to inhibit Bcl6 mRNA expression in several breast cancer cell 
lines in response to prolactin stimulation (28). Erythropoietin, an activator of Stat5, is 
likely to repress Bcl6 expression in erythroblasts in a Stat5-dependent manner (80), and 
activation of Stat5 downregulates Bcl6 expression in B-lymphoma cells and other 
hematopoietic cell lines (27). However, other reports have indicated that Stat5 induces 
Bcl6 expression in primary human B cells (30, 31). Stat5 also appears to activate Bcl6 
expression in pancreatic beta cells in response to prolactin (29). It has been proposed, and 
demonstrated using reporter gene assays, that the effect of activated Stat5 on Bcl6 gene 
expression depends highly on the specific promoter sequence context included (27). 
These assays (27) (Chapter 4) have also demonstrated that there are likely multiple 
transcription factor binding sites and regulatory regions dispersed throughout the Bcl6 
gene, such that the integrated input from transcriptional complexes occupying the various 
regulatory regions under any condition in a specific cell type determines the final 
transcriptional outcome. Therefore, although Stat5 appears to inhibit Bcl6 expression in 
most of the examples studied so far, it is also possible that Stat5 acts as an activator of 
Bcl6 expression in specific cells types under specific conditions and chromatin structures.  
 
One possible explanation for the different regulatory effects of Stat5 on Bcl6 gene 
expression in different cell types may be differences in expression level or tissue 
specificity of various coregulatory molecules. Many coregulatory molecules are known to 
be rate-limiting or have tissue-specific distribution (41, 81).  
 
Another possibility for varied responses of the Bcl6 promoter to Stat5 is that the 
chromatin structure of the Bcl6 gene may vary in different cell types, and Stat5 may have 
access to different sets of occupancy sites in different tissues. This hypothesis is 
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supported by the observations of the differences between Stat5-mediated transcriptional 
regulation of the Bcl6-luc short (Figure 4.10, B) and Bcl6-luc long (Figure 4.10, C) 
constructs. The presence of constitutively active Stat5b alone was sufficient to induce 
Bcl6-luc short expression over basal levels, similar to what had been shown previously 
for the homologous sequence from the human Bcl6 gene (27). This is in contrast to what 
was seen for Stat5-mediated regulation of Socs2-luc short and Cish-luc short, where CA-
Stat5b alone did not appear to be sufficient to activate reporter gene expression. 
However, in the case of Bcl6-luc long, the addition of CA-Stat5b did not induce reporter 
gene expression above basal levels, suggesting that there are inhibitory sequences present 
in the longer Bcl6 promoter construct that were absent in the shorter one. These 
inhibitory sequences may be differentially accessible in different cell types. This is 
supported by observations from promoter luciferase experiments carried out using the 
homologous long promoter sequence from the human Bcl6 gene (27). When a longer 
sequence of the human Bcl6 gene was included in the promoter construct, CA-Stat5 
repressed reporter gene expression (27), suggesting that Stat5 regulation of the Bcl6 
promoter is different between human and mouse, likely partially due to sequence or 
chromatin context. 
 
A third possibility is that the amount of Stat5 varies in different cells types, resulting in 
different occupancy patterns of Stat5 on the Bcl6 gene in different tissues, and potentially 
leading to the formation of different Stat5 transcriptional regulatory complexes at 
multiple locations in the Bcl6 gene. A recent study has shown that sporadic Stat5 
occupancy at DNA sequences with a Stat binding motif increased in cells overexpressing 
Stat5 compared to cells expressing endogenous levels of Stat5 (67). However, the 
increased Stat5 binding did not correlate with increased expression of nearby genes or 
confer GH-responsiveness to these genes. 
 
Future work to understand the similarities and differences in how Stat5 regulates Bcl6 
gene expression in response to different growth factors and in different cell types, and the 
potential cooperative or conflicting effects of Bcl6 and Stat5 on Bcl6 gene expression, 
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will help us understand more about how Bcl6 is regulated, its potential physiological 
functions, and regulation of gene transcription in general. 
 
Potential differential regulatory mechanisms for Socs2, Cish, and Bcl6 expression: 
The role of coregulators in Bcl6/Stat5-mediated transcriptional regulation 
 
One of the potential mechanisms by which Bcl6 and Stat5 may be carrying out 
differential regulatory effects on Socs2, Cish, and Bcl6 expression is the recruitment of 
coregulatory proteins to the transcriptional regulatory complex. Coregulatory proteins are 
protein factors that interact with transcription factors to activate or repress transcription 
(6, 7, 82). Coregulators do not directly bind to the DNA, and often carry out their actions 
by modifying the activity of transcription factors or the structure of the surrounding 
chromatin (6, 8, 69). Coregulators that enhance transcription are known as coactivators, 
while coregulators that function to repress transcription are known as corepressors. In the 
past, molecules such as p300 and CBP have been considered coactivators, due to their 
lysine acetyltransferase activity and ability to acetylate histone tails, resulting in a relaxed 
chromatin structure conducive to transcription. Molecules such as histone deacetylases 
(HDACs) have traditionally been considered corepressors due to their lysine deacetylase 
activity, and the ability to deacetylate histone tails, resulting in a compacted and 
inaccessible chromatin state (32-34, 69, 70). However, p300/CBP and HDACs can target 
other substrates besides histones (83, 84), and more recently, examples of p300 
repressing gene expression (9) and HDAC molecules participating in transcriptional 
activation have been described (10, 11).  
 
Both Bcl6 and Stat5 are reported to interact with many coregulatory proteins in various 
transcriptional complexes to mediate their effects on expression of a target gene (19, 24, 
58, 85). Therefore, it was considered likely that coregulatory molecules would participate 
in the reciprocal regulation of Socs2 expression by Bcl6 and Stat5 in response to GH. It 
was also considered likely that either the same, or a different subset of coregulators would 
be involved in regulation of Cish and Bcl6 expression by Bcl6 and Stat5.  
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Previous work characterizing the roles of corepressors in Bcl6-mediated transcriptional 
regulation focused on the role of Bcl6 in the immune system (16, 24, 58, 86). While the 
role of Bcl6 in adipocytes and mechanisms by which it regulates GH target genes is still 
unclear, several of the characterized Bcl6 coregulators, such as p300, CBP, Hdac1, and 
Hdac3 are known to be present in adipocytes and play roles in regulation of GH target 
genes by other transcription factors such as Stat5 and C/EBP! (19, 47, 48, 85, 87). P300, 
in particular, has been shown to acetylate Bcl6 at a KKYK motif in the middle region of 
the protein (Figure 1.1). Acetylation of Bcl6 leads to the disruption of Bcl6 interactions 
with certain corepressive molecules, resulting in loss of Bcl6 inhibition on some target 
genes (12). The role of p300 as a coactivator of Stat and Stat5 target genes has been well 
described (20, 43). 
 
In the quest to evaluate whether candidate coregulator molecules could be mediating the 
differential regulatory effects of Bcl6 and Stat5 on Socs2, Cish, and Bcl6 expression, the 
activities of two coregulators, p300 and Hdac3, were examined in more detail by 
promoter activation assays and occupancy on target genes by ChIP.  
 
P300 in regulation of Bcl6- or Stat5-mediated transcription of Socs2, Cish, or Bcl6 
 
Bcl6 and p300 in regulation of Socs2 and Cish 
 
ChIP detected p300 occupancy at the Socs2, Cish, and Bcl6 promoters in 3T3-F442A 
adipocytes. Occupancy appeared to increase in response to GH for all three genes, but the 
increase was most detectable on the Socs2 promoter. Results from promoter construct 
reporter gene assays carried out in 293T cells suggest that in the case of Socs2 and Cish, 
p300 does not appear to greatly alter Bcl6-mediated inhibition of reporter gene 
expression, although p300 may have a derepressive effect on Bcl6-mediated repression of 
the Socs2 promoter. Bcl6 appears to function as a potent transcription repressor of Socs2 
and Cish expression, and Bcl6 may be inhibiting Socs2 and Cish expression by 
associating with other as yet unidentified coregulatory molecules to repress gene 
transcription. Socs2 and Cish promoter activation assays would suggest that p300-
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mediated inhibition of Bcl6 repression is likely not a mechanism by which Socs2 and 
Cish expression is highly induced by GH. However, significantly elevated Socs2 mRNA 
levels were observed in livers of mice deficient in Bcl6 (Bcl6 knock out mice) compared 
to livers of wild type mice, suggesting that loss of Bcl6 occupancy may result in 
significant derepression of Socs2 expression and activation of transcription in vivo. Due 
to the similarity in regulation of Socs2 and Cish by Bcl6 and Stat5, a similar mechanism 
may be involved in regulation of Cish transcription in vivo. As informative as it is to 
analyze promoter function under controlled experimental conditions, differences have 
been observed between regulation of gene expression in reporter gene assays compared to 
regulation of endogenous genes by transcription factors and associated coregulators 
where the activity of synthetic promoter fragments in response to p300/CBP did not 
match the activity observed for endogenous genes in MEFs (88). These differences may 
be due to differences in chromatin structure between the promoter constructs and the 
endogenous gene promoter, or due to different levels of protein factors between cell 
types.  
 
Stat5 and p300 in regulation of Socs2 and Cish 
 
For the Socs2 and Cish promoters, p300 provided a coactivating effect on Stat5-mediated 
transcription of reporter gene expression on both the short and long promoter constructs, 
consistent with p300 functioning as a coactivator for Stat5, and activated Stat5 inducing 
Socs2 and Cish expression in response to GH (1). Interestingly, CA-Stat5b alone did not 
appear to be sufficient to activate Socs2 or Cish reporter gene expression above basal 
levels, and in some experiments, a slight inhibitory effect was seen. This would 
correspond with previous results seen for activation of Cish expression by Stat5 in 
response to Il3 stimulation; constitutively active Stat5 alone was not sufficient to activate 
Cish expression, and the presence or activity of other factors was necessary to achieve 
Stat5-mediated transcriptional activation of Cish expression (10). Previous promoter 
activation assays for Socs2-luc demonstrated that treatment with GH results in induction 
of Socs2-luc expression (Figure 2.7) (1, 89). As it appears that p300, in addition to 
activated Stat5, is necessary for Stat5-mediated activation of Socs2 and Cish expression, 
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GH treatment may result in the recruitment or activation of p300 activity, thereby 
stimulating Stat5-mediated activation of Socs2 and Cish. 
 
Strikingly, in the case of the Socs2-luc short promoter construct, the addition of p300 
alone greatly activated basal reporter gene expression, without addition of CA-Stat5b. 
This may be due to the high basal levels of Stat5 and phosphorylated Stat5 in 293T cells 
(A Taylor, G Lin, unpublished data). It is likely that the activating effects of 
overexpressed p300 on basal Socs2-luc short reporter gene expression is at least partially 
due to the activity of endogenous Stat5 present in 293T cells. The activation of Socs2-luc 
short in the presence of p300 and endogenous Stat5 would be consistent with the 
activation of the Socs2 promoter seen when both CA-Stat5b and p300 are transfected into 
the cells. The hypothesis that endogenous Stat5 can activate reporter gene expression 
above basal values when p300 is transfected into the cells is supported by preliminary 
experiments where the activation of basal Socs2-luc short expression by the addition of 
p300 was inhibited in cells treated with the Jak/Stat inhibitor AG490 (data not shown). 
Due to the high levels of endogenous Stat5 in the 293T cell line, future experiments 
characterizing the effects of Stat5 and its associated coregulatory molecules on Socs2, 
Cish, and Bcl6 expression should likely be carried out in a different cell line or focus on 
observing the effects of Stat5 depletion on gene expression. Examining the regulatory 
effects of p300 on Socs2 expression by depletion of Stat5 may also help clarify if the 
derepressive effect of p300 on Bcl6-mediated inhibition of the Socs2 promoter is due to 
potential competitive effects of endogenous Stat5 on the Socs2 promoter constructs. 
Future experiments where levels of Bcl6 and Stat5 are titrated and the binding kinetics of 
Bcl6 and Stat5 are determined will also help in understanding the interplay between Bcl6 
and Stat5 on determining gene expression. 
 
P300 in Bcl6- and Stat5- mediated regulation of Bcl6 gene expression: Bcl6-luc short 
 
In the case of Bcl6, when the short promoter fragment of the Bcl6 gene was used to drive 
reporter gene expression, preliminary results showed that p300 did not appear to greatly 
alter Bcl6-mediated repression of reporter gene expression, similar to what was seen for 
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Socs2 and Cish. In contrast to the Socs2 and Cish short promoter constructs, CA-Stat5b 
alone was sufficient to induce Bcl6-luc short expression, and p300 appeared to have an 
inhibitory effect on Stat5-mediated transcription of Bcl6 reporter gene expression.  
 
One possible explanation for the difference in ability of CA-Stat5b to activate reporter 
gene expression from the Socs2, Cish, and Bcl6 short promoter constructs is that a 
putative potentiating factor necessary for activation of Stat5 activity is present on the 
Bcl6 promoter and absent on the Socs2 and Cish promoters. Another possibility is that 
there are different subsets of genes that can be activated by different post-translationally 
modified forms of Stat5. For example, in addition to its tyrosyl phosphorylation, Stat5 
can be phosphorylated at different serine residues. Different phosphorylated forms of 
Stat5 may then result in the recruitment or dissociation of various protein factors to the 
transcriptional machinery.  
 
Transcription factor complex specific interactions between p300 and the hypothetical 
Stat5 potentiating factor or different post-translationally modified forms of Stat5 could 
also explain the repressive activities of p300 on Stat5-mediated activation of Bcl6-luc 
short expression compared to the coactivation effects of p300 on Stat5-mediated 
induction of Socs2 and Cish short promoter construct expression. At the moment it is 
unknown if these preliminary results are representative of Stat5 and p300 regulatory 
interaction on the short Bcl6 promoter construct. If these results are consistent, they could 
be a rare example of Stat5 functioning as a transcriptional repressor and p300 functioning 
as a corepressor, likely using novel, and as yet unknown, mechanisms. One possible 
mechanism may be that p300 is regulating or interacting with other Stat5-associated 
proteins to regulate the net activity of the transcriptional complex, rather than p300 







P300 in Bcl6- and Stat5- mediated regulation of Bcl6 gene expression: Bcl6-luc long 
 
Interestingly, when a longer segment of the Bcl6 promoter was used in the reporter gene 
construct to evaluate sequence context effects on transcriptional regulation, results 
indicated that p300 appeared to have a corepressive effect on Bcl6-mediated 
transcriptional repression of reporter gene expression. One possibility for this observation 
is again that p300 is acting as a scaffold protein to recruit other factors to Bcl6 to repress 
transcription, and is not functioning to acetylate Bcl6 and inhibit Bcl6 repressive activity, 
or acetylate histones to relax the surrounding chromatin structure and promote 
transcription. Similar to what was seen for Stat5-mediated transcription of the Bcl6 short 
promoter construct, p300 appeared to have a repressive effect on Stat5-mediated reporter 
gene expression of the Bcl6 long promoter construct. This suggests that p300 could 
potentially function as a Stat5-associated corepressor when regulating Bcl6 expression in 
vivo. The differences in transcriptional regulation by Bcl6, Stat5, and p300 between the 
Bcl6 short promoter construct and Bcl6 long promoter construct also suggest that there 
are multiple regulatory regions in close proximity on the Bcl6 promoter, and the sum 
effects of various input signals determine the final level of Bcl6 transcription. This is in 
contrast to regulation of Socs2 and Cish promoter construct expression, where the 
regulatory effects of Bcl6, Stat5, and p300 appear to be generally similar for both the 
long and short promoter constructs, suggesting that the major Bcl6, Stat5, and p300 
regulatory regions for the Socs2 and Cish long promoter constructs are located within the 
sequence used in the short promoter constructs. 
 
P300 is structurally and functionally similar to CBP, and the two proteins belong to the 
same family of transcriptional coregulators (90-92). It is predicted that regulation of CBP 
activity is similar to that for p300. As many of the signaling pathways regulating p300 
activity are activated in response to GH, it would be of interest for future work to involve 
pinpointing the molecular mechanisms by which p300 interacts with Bcl6 or Stat5 in 
response to GH to regulate target genes, and elucidating the effects of GH signaling on 
post-translational modification and function of these proteins and their interactions. 
Similarly, it would be of interest to see if CBP participates in regulation of Socs2, Cish, 
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and Bcl6 expression, or if p300 and CBP target different subsets of GH or Bcl6/Stat5 
reciprocally occupied target genes.  
 
Hdac3 in regulation of Bcl6- or Stat5-mediated transcription of Socs2, Cish, or Bcl6 
 
Bcl6 has been shown to interact with Hdac3, and more recently, a high throughput 
sequencing study has shown that Bcl6 and Hdac3 occupancy correspond on a subset of 
Bcl6 target genes in immune cells (16, 51, 58, 93). Many of these genes are related to 
inflammatory responses, and LPS treatment induced the recruitment of p300 to these 
regulatory regions resulting in increased histone acetylation. Another high throughput 
sequencing study has hinted at a role for Hdac3 in the regulation of lipid metabolism 
genes in liver in response to circadian rhythm (50). The role of Hdac3 in Stat5-mediated 
transcriptional regulation has not been well studied; however, two other class I HDACs, 
Hdac1 and Hdac2, have both been shown to be important in Stat5-regulated gene 
transcription and adipogenesis (85, 87, 94). Another report has shown evidence that 
activation of Stat5 at certain target genes may be dependent on the activity of one or more 
HDACs by an as yet unidentified mechanism (10), further supporting an important role for 
HDACs in Stat5-regulated gene transcription. In this chapter, ChIP probing for histone 
modifications also showed an increase in activating histone mark enrichment at the Socs2 
and Cish promoters with GH. In addition, qPCR experiments carried out on 3T3-F442A 
preadipocytes treated with the class I and class II HDAC inhibitor trichostatin A showed 
that induction of Socs2 mRNA by GH was inhibited in the presence of HDAC inhibitor, 
suggesting that HDACs may factor in GH stimulation of Socs2. On the other hand, Bcl6 
mRNA levels were elevated in cells treated with trichostatin A. These results support roles 
for HDACs and other coregulatory or chromatin remodeling factors in Socs2, Cish, and 
Bcl6 transcription in adipocytes.  
 
Bcl6 and Hdac3 in regulation of Socs2 and Cish 
 
ChIP detected occupancy of Hdac3 at the Socs2, Cish, and Bcl6 promoters in 3T3-F442A 
adipocytes. Occupancy of Hdac3 generally appeared constitutive and did not change 
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markedly with GH treatment for all three genes. Results using promoter reporter gene 
assays in 293T cells indicate that for the Socs2 and Cish promoter constructs, Hdac3 did 
not appear to greatly alter Bcl6-mediated inhibition of reporter gene expression. 
 
Stat5 and Hdac3 in regulation of Socs2 and Cish 
 
Hdac3 appears to have a repressive effect on Stat5-mediated transcription of Socs2 and 
Cish reporter gene expression. The repressive effects of Hdac3 on Stat5-mediated 
transcription from the Socs2 and Cish promoters may be indicative of an extra layer of 
regulatory control involved in modulating Socs2 and Cish expression in vivo, where 
transcription is induced to a certain extent upon GH treatment, but mechanisms must be 
in place to prevent overexpression or be prepared to downregulate transcription levels as 
necessary.  
 
Repression of Stat5-mediated activation of Socs2 and Cish promoter construct expression 
is consistent with the role of Hdac3 as a corepressor, and may be a mechanism by which 
the cell can fine tune Socs2 and Cish expression levels or downregulate transcription in 
response to further stimuli or loss of GH. However, GH induction of Socs2 mRNA levels 
was inhibited in cells that had been treated with trichostatin A, a class I and class II 
HDAC inhibitor, which would have indicated that HDAC activity was needed for 
activation of Socs2 expression in response to GH and Stat5, consistent with previous 
results seen for Cish where HDAC activity was needed for activation of Cish expression 
by Stat5 (10, 95). One possibility for the conflicting results between the inhibitor 
treatment experiment and promoter activation assays may be that these experiments are 
measuring different steps in the Stat5-mediated transcriptional activation process. 
Endogenous HDACs present in 293T cells may have already primed the overexpressed 
CA-Stat5b for transcriptional activation upon p300 recruitment, while the presence of 
additional Hdac3 resulted in downregulation of reporter gene expression. Another 
possibility is that the conditions of the reporter gene assay are not fully reflective of the 
events that occur for endogenous Socs2 expression in adipocytes. If so, the presence of 
other environmental factors and genomic or chromatin context cues would be expected to 
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give different results. As results for the Socs2 long promoter construct and the Cish 
promoter constructs suggest that a similar mechanism of regulation by Bcl6, Stat5, and 
Hdac3 is seen for both the short and long promoter fragments, this would suggest that 
either all significant regulatory regions for Bcl6, Stat5, and Hdac3 are already present in 
the short promoter fragments of Socs2 and Cish, and differences in HDAC regulation of 
Stat5-mediated Socs2 and Cish expression between promoter constructs and adipocytes 
are due to chromatin context or cell specific factor availability, or that an alternative 
regulatory region for Hdac3 activity on Socs2 and Cish expression in adipocytes lies 
outside the fragments tested in the long promoter constructs.  
 
Hdac3 in Bcl6- and Stat5- mediated regulation of Bcl6 gene expression 
 
For the Bcl6 promoter, the effects of Hdac3 on Bcl6- or Stat5-mediated transcription of 
Bcl6 reporter gene expression varied greatly from what was seen for Socs2 and Cish, and 
was dependent on the length of the Bcl6 promoter sequence included in the construct. 
Hdac3 did not appear to greatly alter Bcl6-mediated inhibition of Bcl6-luc short 
expression, but did appear to have a repressive effect on Stat5-mediated activation of 
Bcl6-luc short expression. When the long Bcl6 promoter construct was used, Hdac3 
appeared to have inhibitory effects on both Bcl6- and Stat5-mediated transcription of 
reporter gene expression, suggesting that multiple types of protein interactions are 
occurring at the Bcl6 promoter, likely in a DNA context-dependent manner. 
 
Nearly all combinations of transcription factors and coregulators that were tested had the 
potential to be inhibitory for either Bcl6-luc short or Bcl6-luc long expression under the 
conditions tested, differentiating regulation of Bcl6 expression from regulation of Socs2 or 
Cish transcription. The differences in regulation of Bcl6-luc short and Bcl6-luc long 
expression by Bcl6, Stat5, p300, and Hdac3 also suggest that the Bcl6 promoter contains 
multiple cis regulatory regions near the Bcl6/Stat5occupancy site identified by ChIP-
Sequencing. In vivo, several or all of these regulatory regions and the associated proteins 
may work in concert, with the net effects of the factors present on the Bcl6 gene under any 
condition determining the transcriptional output of the gene. It has already been shown 
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that Bcl6 is one of the most variably expressed genes in liver (96), and previous studies 
have shown that Bcl6 is highly regulated and transcription is under the complex control of 
many regulatory regions and nuclear proteins (24, 27, 57, 58). Our results also suggest that 
Bcl6 expression is highly regulated in adipocytes in response to GH and other growth 
factors and hormones. Further characterization of Bcl6 regulatory sequences and the 
associated protein factors will shed more light on the complex transcriptional regulatory 
titration involved in precisely regulating Bcl6 expression levels. Preliminary 
overexpression or siRNA-mediated knock down experiments carried out in preadipocytes 
suggest that altering the levels of Bcl6 expression in either direction is deleterious for the 
cell (C LaPensee, G Lin, data not shown). It will be interesting to see if varying levels of 
Bcl6 protein in adipocytes or other metabolic or GH target tissues using knock out animals 
or an inducible expression system may also result in differences in downstream gene 
activation or repression. 
 
Occupancy patterns of p300 and Hdac3 at the Socs2, Cish, and Bcl6 promoters 
suggest that Bcl6 and Stat5 occupancy are a major determinant of transcriptional 
output for Socs2, Cish, and Bcl6 expression 
 
Occupancy signal for p300 and Hdac3 by ChIP was weak for all three promoters 
compared to Bcl6 and Stat5 occupancy signal under the experimental conditions used. 
One possibility for the low ChIP signal is that the antibodies for coregulatory proteins are 
not very efficient. This problem could potentially be circumvented by overexpressing a 
protein tagged version of the coregulator at endogenous levels and could possibly be 
combined with depletion of endogenous coregulator by RNAi to limit off target effects. In 
this manner, immunoprecipitations could be carried out using antibody against the protein 
tag, which would be likely to give more efficient immunoprecipitation and provide 
stronger and cleaner signals. In a study carried out in rat liver, p300 occupancy signal at 
the Socs2 and Cish promoters was also low compared to occupancy of Stat5b, correlating 
with the results seen in adipocytes (17). However, p300 occupancy signal in the rat livers 
was highly enriched at the Igf1 promoter, suggesting that p300 occupancy at the Socs2 
and Cish promoters may indeed be lower than other p300-occupied regions in the genome. 
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Regardless, even with relatively low signal, the presence of both p300 and Hdac3 were 
reproducibly detected at the Socs2, Cish, and Bcl6 promoters, suggesting these signals are 
biologically relevant. A similar situation has been observed previously in the recruitment 
of p300 and C/EBP! to the c-fos promoter in response to GH (47). ChIP occupancy signal 
for p300 was low compared to signal for C/EBP!; however, sequential chromatin 
immunoprecipitation assays demonstrated reliable recruitment of p300 to the c-fos 
promoter in association with C/EBP!, and promoter activation assays confirmed a 
functional role for p300 in regulation of c-fos gene expression. 
 
The constitutive occupancy of p300 and Hdac3 detected at the Socs2, Cish, and Bcl6 
promoters, and the relatively small changes in coregulator occupancy in response to GH 
treatment compared to the occupancy changes seen for Bcl6 and Stat5 at the Bcl6/Stat5 
regulatory region suggest that corecruitment or secondary recruitment of coregulators to 
the target regulatory sequence upon Bcl6 or Stat5 binding in response to signaling 
stimulus is not a major regulatory mechanism for coregulator action at these genes. The 
occupancy patterns observed by ChIP suggest that the occupancy of Bcl6 or Stat5 at the 
promoters of these genes are the main determinants of the direction of gene expression, 
and p300 and Hdac3 may be constitutively present at low levels to modulate and fine tune 
changes in gene expression based on the identity of the transcription factor present, or in 
conjunction with the transcription factor present and other transcriptional regulatory 
proteins in proximity. This model is further discussed in Chapter 5. Such a model would 
be opposite of a scenario where activation of target gene transcription is dependent on the 
recruitment of a rate-limiting coregulatory protein to the transcription factor complex, or 
where the direction of target gene transcription is dependent on the identity of the 
recruited coregulator, such as in the case of nuclear receptors and their coregulators (7, 81, 
82, 97, 98).   
 
Conclusions and future directions 
 
Analysis and experimental verification of ChIP-Sequencing results led to the identification 
of Cish and Bcl6 as genes reciprocally occupied by Bcl6 and Stat5 in response to GH, in 
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addition to Socs2. The occupancy patterns for Bcl6 and Stat5 on the regulatory region 
identified in the gene promoters were similar, with Bcl6 occupancy high without GH and 
decreasing with treatment, while Stat5 occupancy was low without GH and increased with 
treatment. Socs2 and Cish expression are induced by GH and Bcl6 expression is repressed 
(1), and this was reflected in different patterns of changes in enrichment of histone marks 
associated with active transcription in response to GH at the regulatory regions of the 
three genes. ChIP also showed constitutive occupancy of p300 and Hdac3 at the 
regulatory regions of all three genes, suggesting that the changes in the presence or 
absence of Bcl6 or Stat5 is a major switch that regulates activation or repression of 
transcription for Socs2, Cish, and Bcl6, and p300 and Hdac3 may be fine tuning the 
transcriptional output based on their interactions with either Bcl6 or Stat5. Promoter 
activation assays showed that association of p300 or Hdac3 with Stat5 has marked effects 
on transcription from the Socs2 and Cish promoters, with p300 functioning as a 
coactivator for Stat5 and Hdac3 as a corepressor. On the other hand, regulation of the Bcl6 
promoter was different, with p300 and Hdac3 exerting corepressive effects in the presence 
of Stat5 for the short promoter construct, and p300 and Hdac3 having corepressive effects 
in the presence of both Bcl6 and Stat5 for the longer Bcl6 promoter construct. These 
results provide important mechanistic insight into the molecular interactions mediating 
regulation of target gene expression by reciprocal occupancy of Bcl6 and Stat5 in response 
to GH.  
 
Experiments using promoter reporter construct variants such as Bcl6/Stat5 regulatory site 
mutants or longer/shorter promoter constructs will help to better characterize the 
contributions of the DNA sequence to the Bcl6/Stat5 reciprocal regulatory mechanism of 
Socs2, Cish, and Bcl6 transcription. Manipulating the levels or activity of endogenous 
Bcl6, Stat5, p300, and Hdac3 in adipocytes, such as by depletion alone or in combination 
with RNAi or treatment with small molecule inhibitors, will help clarify issues 
surrounding the precise sequence of events and mechanisms of action by which these 
protein factors interact with the target gene DNA and each other to influence transcription. 
Examination of potential GH-mediated post-translational modifications on Bcl6, Stat5, 
p300, and Hdac3, and the effects these post-translational modifications have on 
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transcription factor or coregulator activity in mediating Socs2, Cish, and Bcl6 
transcription will better characterize the role of GH signaling in mediating transcription by 
Bcl6/Stat5 in a reciprocal manner. Identification of other nuclear proteins that interact 
with Bcl6, Stat5, p300 or Hdac3, and investigating if these proteins also play a role in 
regulating Socs2, Cish, and Bcl6 expression in response to GH by modulating 
transcription factor or coregulator activity, or by modifying the surrounding chromatin, 
will help to better characterize the transcriptional regulatory complexes that Bcl6 and 
Stat5 form in response to GH on the Socs2, Cish, and Bcl6 promoters, and further our 
understanding of mechanisms by which GH regulates gene expression. 
 
 
Materials and Methods 
 
Identification of candidate ChIP-Sequencing peaks 
 
To identify a subset of candidate peaks and related genes for experimental verification of 
Bcl6 or Stat5 occupancy, ChIP-Sequencing peaks identified by the H-Peak software (75) 
under each of the four conditions (immunoprecipitation with antibody against Bcl6 or 
Stat5, each without or with GH for 48 h) were sorted by either peak height or peak p 
value, and the top 200 proximal genes either upstream or downstream of the ChIP-
Sequencing peak were submitted to a Pubmed literature search to find previous studies on 
Bcl6 or Stat5 in conjunction with these proximal genes. Genes that appeared in Pubmed 
abstracts along with Bcl6 or Stat5 were given more priority. Genome browser profiles of 
top H-Peak identified peaks were generated using the ChIP-Sequencing data and the 
USCS Genome Browser (http://genome.ucsc.edu/). Peak locations that showed signal 
across the various immunoprecipitation and treatment conditions were highly prioritized 
for follow up verification, as were locations that showed a single, distinct peak profile. A 
total of 35 ChIP-Sequencing peaks were selected for experimental verification of Bcl6 
and/or Stat5 binding in the presence or absence of GH. ChIP primers were designed to 
flank the ChIP-Sequencing peaks identified by H-Peak, with the final PCR product 
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Murine 3T3-F442A preadipocytes were provided by H. Green (Harvard Univ) and M. 
Sonenberg (Sloan-Kettering, NY). The 293T human kidney cell line was provided by M. 
Lazar (Univ Pennsylvania) and O. MacDougald (Univ Michigan). Recombinant human 
GH for cell culture studies was purchased from the National Hormone and Pituitary 
Program (Torrance, CA). Insulin, dexamethasone, isobutylmethylxanthine, 
formaldehyde, and trichostatin A (TSA) were from Sigma (St. Louis, MO). Culture 
media, L-glutamine, and antibiotic-antimycotic were purchased from Invitrogen (Grand 
Island, NY). Fetal bovine serum (FBS) and calf serum (CS) were from Atlanta 
Biologicals (Lawrenceville, GA). Bovine serum albumin (BSA, Fatty acid-free, cat. # 
62150101) was purchased from Proliant (Ankeny, IA). TRIzol® Reagent was purchased 
from Invitrogen, and Taqman Reverse Transcription Kit from Applied Biosystems 
(Carlsbad, CA). Protease inhibitors leupeptin and aprotinin were purchased from Roche 
(Indianapolis, IN), and phenylmethylsulfonylfluoride (PMSF) from Mallinckrodt (St 
Louis, MO). Sodium orthovanadate and SYBR green were purchased from Sigma (St. 




The expression construct for mouse Bcl6 in pCMV-SPORT6.1 was purchased from Open 
Biosystems (Lafayette, CO). The constitutively active rat Stat5b construct containing a 
point mutation of histidine for asparagine at residue 642 was generously provided by P. 
Rotwein (Oregon Health and Science Univ) (99). The p300 and Hdac3 expression 
constructs were generously provided by R. Kwok (Univ Michigan). For the Socs2, Cish, 
and Bcl6 short promoter luciferase constructs, an approximately 200 bp fragment with 
the Bcl6/Stat5 site predicted by ChIP-Sequencing in the center was PCR amplified from 
mouse genomic DNA and cloned into the multiple cloning region of pGL3-Basic 
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(Promega, Madison, WI). For the Socs2, Cish, and Bcl6 long promoter luciferase 
constructs, a region from about 750 bp upstream to 250 bp downstream from the ChIP-
Sequencing predicted Bcl6/Stat5 site of each gene was PCR amplified from mouse 
genomic DNA and cloned into the multiple cloning region of pGL3-Basic. Cloning 
primer sequences and restriction enzyme sites are as follows: 
 
Short promoter constructs: 
Socs2-luc short forward: 5’-CC GAG CAC CTC GAG GTG CAG GGT C-3’ (XhoI) 
Socs2-luc short reverse: 5’-GAG GCG GCG AGA TCT TGG CAA GAG-3’ (BglII) 
 
Cish-luc short forward: 5’-CCC GCC CCA CTC GAG CAC GTC AG-3’ (XhoI) 
Cish-luc short reverse: 5’-CAT CTT CCT AGA TCT GCG GGC TTT G-3’ (BglII) 
 
 
Bcl6-luc short forward: 5’-GGG AGG GCG CTC GAG GAG CGC GCC-3’ (XhoI) 
Bcl6-luc short reverse: 5’-GGA GCG GCA AGA TCT GCG GCG GCG G-3’ (BglII) 
 
Long promoter constructs: 
 
Socs2-luc long forward: 5’-GA CAA ACG CTC GAG GCC TGT GAC-3’ (XhoI) 
Socs2-luc long reverse: 5’-CA AGC TTC AGA TCT CCG GGC ACA AG-3’ (BglII) 
 
Cish-luc long forward: 5’-CT GAG CTC CAA GGT ACC CTG AAT TC-3’ (KpnI) 
Cish-luc long reverse: 5’-CCC TGT ACG CAA AGG ACC ATG TCC C-3’ (XhoI) 
 
Bcl6-luc long forward: 5’-GCA TCC CAA GGT ACC ATC CCC AAA G-3’ (KpnI) 






3T3-F442A preadipocytes were differentiated into adipocytes as follows. Preadipocytes 
were grown to confluence in Dulbecco’s Modified Eagle Medium containing 1% L-
glutamine, and 1% antibiotic-antimycotic (DMEM) and 8% calf serum. 48 h later, cells 
were induced to differentiate by exposure to adipogenic medium (DMEM, 8% FBS, 0.5 
mM isobutylmethylxanthine, 0.25 µM dexamethasone, 2 µg/ml insulin). After 48 h, 
medium was replaced with DMEM containing 8% FBS and 1 µg/ml insulin. 48 h later, 
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medium was changed to DMEM with 8% FBS, in which cells were maintained until use 
in experiments. Prior to all experiments with GH treatment, 3T3-F442A cells were 
deprived of serum for 16-18 h in DMEM containing 1% BSA instead of serum. Cells 
were then treated without or with human GH (500 ng/ml = 22 nM) for 48 h on day 7 
following initiation of adipogenesis. 293T cells were cultured in DMEM and 8% calf 
serum. 
 
Quantitative Real-time PCR (qPCR) 
 
Murine 3T3-F442A preadipocytes in 10 cm plates were serum deprived and incubated 
with 1 µM trichostatin A overnight before treatment with GH. Equivalent volume of 
DMSO vehicle was used for controls. RNA was isolated and analyzed by quantitative 
real-time PCR (qPCR) as described previously (100). Primers for Socs2 and Bcl6 have 
been described previously (96, 101), and data were normalized to glyceraldehyde-3-
phosphate dehydrogenase (100) using the 2!!cT method (102) and expressed as fold-
change compared to control untreated cells, where the control is set to1. For quantitative 
ChIP PCR experiments, qPCR was carried out as described (100) using ChIP DNA as the 
PCR template. Signals for each immunoprecipitation condition were normalized to the 
signal for input ChIP DNA for each of the respective treatment conditions. Input DNA 
amplification signal was consistent between all experiments. Primer sequences for 
quantitative ChIP PCR were designed using NCBI Primer-BLAST and sequences are as 
follows:  
Socs2 forward: 5’- GGC CTA AAG GTT CCC TCC TA-3’ 
Socs2 reverse: 5’- AGC CAA TGC CTA TTA AGC CA-3’ 
Cish forward: 5’- TAG ACG CCT GCA CCC CCG TT-3’ 
Cish reverse: 5’- GGG GCC AGG CGC CTC CTA AT-3’ 
Bcl6 forward: 5’- CTT CGC TGT AGC AAA GCT CG-3’ 





Chromatin immunoprecipitation (ChIP) 
 
ChIP was performed as described previously (47). Briefly, 3T3-F442A adipocytes or 
preadipocytes in 15 cm culture dishes were treated with 500 ng/ml GH for various times. 
Cells were washed 2X in cold PBS and crosslinked in 1% formaldehye in PBS at room 
temperature for 15 minutes. Sonication was carried out using a Misonix S-3000 sonicator 
eighteen times for 15 seconds, with a 1 minute pause between cycles, to achieve 
chromatin fragments of approximately 200 bp. Immunoprecipitation was carried out 
using antibodies against Bcl6 (N-3) (Santa Cruz), Stat5 (C-17) (Santa Cruz), 
phosphorylated Stat5 antibody (Zymed, Grand Island, NY), p300 (N-15) (Santa Cruz), 
Hdac3 (H-99) (Santa Cruz), acetylated histone H3 (Millipore, Billerica, MA), acetylated 
histone H4 (Millipore), and H3K4me3 (Abcam, Cambridge, MA). Samples incubated 
with equivalent amount of normal rabbit IgG (Cell Signaling, Danvers, MA) served as a 
negative control. 1% input was used to indicate the relative amount of each sample used 
for individual ChIP analysis.  
 
ChIP samples were analyzed either by PCR followed by separation of products on 2% 
agarose gels and staining with ethidium bromide (47), or by quantitative real time PCR. 
Primers for agarose gel analysis of the Bcl6/Stat5 site in the Socs2 promoter have been 
described previously (1, 89). Primers for agarose gel analysis of the Bcl6/Stat5 
occupancy sites in the Cish and Bcl6 promoters identified by ChIP-Sequencing were 
designed using NCBI Primer-BLAST, and sequences are as follows: 
Cish forward: 5’- GCT GGG ACG CAG CGG ACA AA-3’ 
Cish reverse: 5’- GTC CCA GAG ACA ACG GCG GC-3’ 
Bcl6 forward: 5’-CGC TCG CCG CCC TAT AGT GC-3’ 
Bcl6 reverse: 5’- GAG CGG GCG GTT CCA TCG G-3’ 
 
Reporter gene assays 
 
293T cells were transfected by calcium phosphate coprecipitation (47) with 200 ng 
luciferase reporter construct and 100 ng of mouse Bcl6, constitutively active rat Stat5b, 
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p300, or Hdac3 expression construct per well of a 12 well culture plate alone or in 
combination as indicated. Each transfection condition was done in duplicate for each 
experiment. DNA transfection amounts were normalized across transfections using 
pcDNA3 (Invitrogen). After 24 h incubation at 37 °C, cells were washed twice in cold 
PBS and lysed in 250 µl of 1X passive lysis buffer (Promega Dual Luciferase Kit, 
Promega). Luciferase reagents were from the Promega Dual Luciferase Kit. 10 µl of cell 
lysate from each transfection was read in duplicate on a 96 well opaque white plate using 
a Biotek Synergy 2 microplate reader (Biotek, Winooski, VT). Luciferase readings were 




Values from analysis of transcription factor occupancy, coregulator occupancy, or histone 
modification signal in adipocytes treated without or with GH for various times were 
compared statistically using Student’s t-test. Basal luciferase values for each reporter 
gene construct were compared to various transfection conditions using Student’s t-test. 
Each transcription factor transfection condition was also compared to the transcription 
factor together with either p300 or Hdac3 using Student’s t-test for each reporter 
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Conclusions and Future Directions 
 
Growth hormone is a peptide hormone secreted by the pituitary gland that regulates 
diverse physiological processes including statural growth and lipid, protein, and 
carbohydrate metabolism (1-5). Many functions of GH are believed to occur through 
regulation of specific target genes. While much is known about how GH regulates 
transcription of its target genes, research on GH-regulated gene transcription has focused 
on mechanisms involved in transcriptional activation. However, transcriptional repression 
and silencing are equally important but more poorly understood aspects of gene 
expression. The goal of this thesis was to explore factors involved in GH-mediated 
transcriptional repression and thus better understand GH action and transcriptional 
repression in general. 
 
Bcl6 is a newly identified GH-regulated transcriptional repressor 
 
In Chapter 2, analysis of a microarray profile of 3T3-F442A adipocytes treated with GH 
for various times identified Bcl6 as the gene most strongly repressed by GH at later time 
points (4h and 48 h) that coincide with GH-induced insulin resistance (6). The Bcl6 gene 
encodes a transcriptional repressor best known for its function in the immune system as a 
master regulator of B cell differentiation (7). At the time, expression of Bcl6 had not 
previously been identified in adipocytes, and there was little known about mechanisms by 
which GH could repress transcription of its target genes. 
 
To learn more about roles Bcl6 might have in regulation of GH target genes, bioinformatic 
network analysis was carried out on a subset of genes from the microarray gene profile  
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found to be strongly regulated under GH conditions that repress Bcl6 expression (8). The 
network suggested an interaction between Bcl6 and Signal Transducer and Activator of 
Transcription (Stat) 5, a transcription factor well known to be regulated by GH and to 
mediate GH-regulated gene transcription (9-11). Quantitative real-time PCR experiments 
showed that the GH- and Stat5-mediated stimulation of Socs2 (Suppressor of Cytokine 
Signaling 2) mRNA and Bcl6 mRNA inhibition were reciprocal with each other in 
response to increasing duration or concentrations of GH, suggesting that Bcl6 and Stat5 
may reciprocally regulate the expression of some GH target genes (8). 
 
Bcl6 and Stat5 reciprocally regulate Socs2 gene expression in response to GH 
 
Expression of Bcl6 was also found to inhibit expression of a Socs2-luciferase reporter 
driven by the GH-responsive Stat5 sequence in the Socs2 promoter, and to blunt the GH-
induced increase in Socs2-luciferase expression in 293T cells co-expressing the GH 
receptor. Chromatin immunoprecipitation (ChIP) experiments further showed a reciprocal 
relationship between endogenous Bcl6 and Stat5 on the Socs2 promoter: occupancy by 
Bcl6 is high in untreated cells and decreases progressively after GH treatment, while 
occupancy by Stat5 increases with GH (8). Bcl6 has also been postulated to function 
reciprocally with Stat5 in the regulation of target gene expression in immune cells (12, 
13). These observations served as the first example that reciprocal regulation of target 
gene expression by Bcl6 and Stat5 may be GH dependent and function as part of a general 
repressor/activator regulatory mechanism of gene transcription. Based on our findings, it 
was hypothesized that Bcl6 is a GH-regulated transcriptional repressor with novel roles in 
GH-mediated transcriptional repression, and that Bcl6 and Stat5 function as reciprocal 
regulators of other GH-regulated genes.  
 
High throughput ChIP-Sequencing reveals Bcl6 and Stat5 occupancy patterns across 
the genome 
 
In Chapter 3, further investigation of the role Bcl6 plays in GH-mediated transcriptional 
responses was examined. Socs2 mRNA expression was found to be strongly upregulated 
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in livers of mice deficient in Bcl6 (14) compared to wild type, suggesting that endogenous 
Bcl6 functions as a repressor of Socs2 transcription in an animal model as well as cultured 
cells. The in vivo and in vitro findings support the hypothesis that Bcl6 plays a role in 
physiological GH functions such as metabolism and adipose differentiation. ChIP carried 
out using livers of non-Bcl6 deficient mice treated with or without GH showed reciprocal 
occupancy of Bcl6 and Stat5 on the Socs2 promoter in response to GH, similar to what 
had been seen in cultured adipocytes, once again suggesting that endogenous Bcl6 plays 
an important physiological role in GH action in vivo. Bcl6 mRNA expression was also 
found to be inhibited in preadipocytes by insulin and EGF treatment, suggesting wider 
roles for Bcl6 in adipose tissue functions outside of GH signaling. Therefore, to identify 
Bcl6 target genes and further understand roles Bcl6 might be playing in GH action, high 
throughput ChIP-Sequencing was carried out to identify potential Bcl6 and Stat5 target 
genes across the genome. 
 
ChIP-Sequencing was carried out using 3T3-F442A adipocytes treated with GH for 0 or 
48 hours to match the microarray time points where expression of Bcl6 was highest (0 h) 
and strongly inhibited (48 h) (8). As chronic GH treatment in adipocytes results in an 
insulin resistant phenotype (4, 15), it was also reasoned that by comparing results from the 
two treatment conditions, we would be able to identify Bcl6 and/or Stat5 target genes 
potentially involved in the pathogenesis of diabetes and metabolic syndrome. ChIP was 
carried out using antibodies against Bcl6 or Stat5, and ChIP-Sequencing libraries prepared 
from the ChIP DNA samples were sent to the University of Michigan Sequencing Core for 
high throughput sequencing. ChIP-Sequencing results were analyzed using the H-Peak 
algorithm, and results showed over 3000 regions of occupancy for Bcl6 and at least 900 
for Stat5 on each of the genomic profiles. The number of occupancy regions for Bcl6 
decreased in the GH-treated genomic profile, consistent with GH-mediated repression of 
Bcl6 expression. A Bcl6-enriched signal peak was observed near the GH-regulated 
sequence of the Socs2 promoter, consistent with previous ChIP results (8, 16).  Motif 
analysis of ChIP-Sequencing results also showed that sequences occupied by Bcl6 
matched strongly with predicted Bcl6 motifs, and sequences occupied by Stat5 matched 
strongly with predicted Stat motifs.  
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Combined analysis of the GH gene profile and ChIP-Sequencing datasets identify 
candidate GH-regulated Bcl6 target genes 
 
Gene ontology analysis of genes predicted to likely be regulated by Bcl6 showed that over 
half of these genes functioned in biological processes related to GH action such as growth 
and differentiation, metabolism, or signaling. Comparison of genes from the ChIP-
Sequencing analysis and previous microarray results to identify genes likely to be 
regulated by both GH and Bcl6 generated a list of candidate target genes. Several of these 
genes are known GH target genes or well known to participate in GH and adipocyte 
biology. Among these genes, Igfals (insulin-like growth factor binding protein acid labile 
subunit), Igf2 (insulin-like growth factor 2), Fasn (fatty acid synthase), Scd1 (stearoyl-
Coenzyme A desaturase 1), Scd2 (stearoyl-Coenzyme A desaturase 2), Agt 
(angiotensinogen), Rgs16 (regulator of G-protein signaling 16), and Il1rl1 (interleukin 1 
receptor-like 1) would be of particular interest as follow up candidates for further 
investigation due to their known biological functions in adipose tissue and liver (17-22), 
or in the case of Il1rl1, as previously described Bcl6 target genes in the immune system 
(23).  
!
Examination of the mechanisms by which Bcl6 and GH coordinate to regulate expression 
of these potential target genes will expand understanding of GH physiology and 
transcriptional regulation, and could potentially lead to development of new therapies and 
drug targets for diseases such as hypertension and diabetes. For example, characterization 
of mice deficient in Bcl6 found that the animals exhibited multiple features of 
dysregulated lipid metabolism. Bcl6 deficiency was accompanied by decreased hepatic 
expression of Stearoyl-CoA desaturase 1 (Scd1) and Fatty acid synthase (Fasn), which 
encode lipogenic enzymes (C LaPensee, manuscript submitted). Both of these genes were 
also identified as potential GH- and Bcl6-regulated target genes by ChIP-Sequencing and 
microarray analysis, lending credibility to the other candidate genes identified, and 
suggesting that analysis of these other candidate genes in Bcl6 deficient mice could 
provide insight into the effects that transcriptional dysregulation of this potential gene 
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network has on growth and metabolism. Similarly, expression of angiotensinogen (Agt), 
which was also identified as a potential GH and Bcl6 target gene, was found to be 
elevated in livers of mice deficient in Bcl6 compared to wild type mice. Agt expression 
was induced by GH treatment in adipocytes, and Bcl6 occupancy was detected on the Agt 
gene. The regulation of Agt by GH and Bcl6 could provide insight into the development 
of hypertension and cardiovascular disease in metabolic syndrome and insulin resistance 
(22). Development of compounds that target Bcl6 activity, or the Stat5 and the Stat5-
mediated regulation of Bcl6 expression in response to GH or other growth factors could 
lead to new pharmaceutical agents in the treatment of these diseases. 
!
The Socs2, Cish, and Bcl6 gene promoters are reciprocally occupied by Bcl6 and 
Stat5 in response to GH 
!
Another goal of the ChIP-Sequencing experiment was to identify genes that were 
regulated by both Bcl6 and Stat5 in order to better understand how this transcriptional 
activator-repressor pair could function together to regulate expression of GH target genes. 
Therefore, Chapter 4 of this thesis focused on identifying other gene candidates regulated 
by both Bcl6 and Stat5 in response to GH, and elucidating possible mechanisms by which 
Bcl6 and Stat5 participate in modulating expression of these target genes.  
!
Genomic regions identified by ChIP-Sequencing showing significant signal for Bcl6 or 
Stat5 were selected as candidate sequences to test for occupancy of these transcription 
factors in response to GH in adipocytes. After experimental verification, a region in the 
Cish promoter and a region in the Bcl6 promoter identified by ChIP-Sequencing were both 
found to be reciprocally occupied by Bcl6 and Stat5 in response to GH. In addition to 
Socs2 (8), analysis and verification of the ChIP-Sequencing results has currently yielded 
these three gene candidates for study of mechanisms for reciprocal regulation of 
transcription by Bcl6 and Stat5. As Socs2 and Cish expression are induced by GH while 
Bcl6 expression is strongly repressed (8), Socs2, Cish and Bcl6 were used as experimental 
systems to test for similarities and differences in the manner by which Bcl6 and Stat5 
transcriptionally regulate the expression of different target genes in response to GH. 
!
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Socs2, Cish, and Bcl6 are differentially regulated in response to GH 
 
To this end, histone modifications associated with the promoter regions of Socs2, Cish, 
and Bcl6 were probed for changes in response to GH treatment or Bcl6/Stat5 occupancy to 
provide general supporting information on the transcriptional states of the target genes and 
potential actions of coregulatory proteins. Histone marks associated with active gene 
transcription increased rapidly in response to GH on the Socs2 and Cish promoters, 
consistent with the strong induction of these genes with GH treatment (8). Histone marks 
associated with active transcription were present at the Bcl6 promoter; however, 
enrichment of these histone modifications was not strongly induced by GH, consistent 
with Bcl6 expression being repressed by GH treatment (8, 24, 25) and suggesting that 
Bcl6 is a highly responsive gene that needs to remain accessible to the transcriptional 
machinery in order to respond quickly to changes in the cellular environment.  
!
P300 and Hdac3 constitutively occupy the Socs2, Cish, and Bcl6 promoters 
 
As Bcl6 and Stat5 are both known to interact with many coregulatory proteins to regulate 
target gene transcription (7, 10, 26-29), the effects of the coregulatory proteins p300 and 
Hdac3 on transcription of Socs2, Cish, and Bcl6 were also examined by ChIP and 
promoter activation assays. ChIP results showed strong and reproducible reciprocal 
changes in Bcl6 and Stat5 occupancy on all three gene promoters in adipocytes. However, 
occupancy signal and changes in recruitment of p300 and Hdac3 were small for all three 
genes respective to signal observed for Bcl6 or Stat5 under the experimental conditions 
used, with only Socs2 showing a more marked increase in p300 recruitment in response to 
GH. The findings so far support a putative mechanism in which the presence or absence of 
Bcl6 or Stat5 at the gene promoters are main determinants for the transcriptional state of 
the gene (Figure 5.1). Coregulatory proteins appear to be present at relatively low but 
constant levels, and the effects they exert on transcriptional output, either through their 
effects on Bcl6 and Stat5, the surrounding chromatin, or other nuclear protein factors, are 









Proposed model of Bcl6- and Stat5-mediated transcriptional regulation of Socs2, 
Cish, and Bcl6 expression in response to GH.  The Socs2, Cish, and Bcl6 genes contain 
a transcriptional regulatory region in the promoter that is occupied by Bcl6 in the absence 
of GH and activated by Stat5 in the presence of GH. The presence of Bcl6 or Stat5 
determines the transcriptional output of each gene in response to GH. The coregulatory 
proteins p300 and Hdac3, and perhaps other nuclear proteins, are present in the vicinity 
of the Bcl6/Stat5 regulatory region in both the presence and absence of GH, and interact 
with either Bcl6 or Stat5 depending on which transcription factor is present. P300 and 
Hdac3 may be modulating transcription of Socs2, Cish, and Bcl6 through their enzymatic 
activities on Bcl6, Stat5, other nuclear proteins, or through remodeling of the chromatin 
structure in the promoter region. The coregulators may also be functioning as scaffold 
proteins for the recruitment of other nuclear transcriptional regulatory proteins, Bcl6, or 
Stat5 to form a multi-protein transcriptional regulatory complex. The complex and 
differential interactions between Bcl6, Stat5, coregulators, and the surrounding chromatin 
in response to GH coordinate to regulate differential Bcl6- and Stat5-mediated 
transcriptional outcomes for Socs2, Cish, and Bcl6 expression in response to GH. Solid 
arrows indicate either known relationships, or interactions or relationships that were 
tested or demonstrated in this thesis. Dotted arrows indicate potential interactions. 
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Proposed model for regulation of Socs2, Cish, and Bcl6 expression in response to GH 
by Bcl6 and Stat5 
 
Bcl6 functions as a potent repressor of Socs2 and Cish transcription 
 
In the proposed model, Bcl6 and Stat5 reciprocally occupy the Bcl6/Stat5 regulatory 
region of the Socs2, Cish and Bcl6 promoters in response to GH. Bcl6 occupancy is high 
in the absence of GH, and based on results from Socs2, Cish, and Bcl6 promoter 
activation assays, Bcl6 functions as a repressor when regulating expression of all three 
genes (Figure 5.2). The coregulators p300 and Hdac3 are present in the vicinity of the 
Bcl6/Stat5 regulatory region of the Socs2, Cish, and Bcl6 genes in the absence of GH 
(Figure 5.2). Results from promoter activation assays suggest that p300 may be interacting 
with Bcl6 on the Socs2 promoter to relieve Bcl6-mediated inhibition of Socs2 expression. 
Potential mechanisms by which p300 may be relieving Bcl6-mediated repression include 
p300-mediated acetylation of Bcl6, resulting in disruption of Bcl6 interaction with 
corepressors (30), or p300-mediated acetylation of histones near the Bcl6/Stat5 regulatory 
region, resulting in a more accessible chromatin state or the recruitment of activating 
protein factors (31). Another possibility is that p300 is functioning as a scaffold protein in 
a transcriptional regulatory complex, and recruits other nuclear proteins to the Bcl6 
transcriptional regulatory complex that mediate derepression of Bcl6-mediated inhibition 
of Socs2 expression.  
 
For regulation of the Cish promoter, results from promoter activation assays suggest that 
the presence of p300 does not greatly alter Bcl6-mediated inhibition of Cish expression. 
However, p300 may still be an essential structural component of the transcriptional 

















Model: Bcl6 represses Socs2, Cish, and Bcl6 transcription in the absence of GH. 
Bcl6 occupies the Bcl6/Stat5 regulatory regions of the Socs2, Cish, and Bcl6 promoters 
in the absence of GH. Bcl6 functions as a transcriptional repressor of Socs2, Cish, and 
Bcl6 expression. The coregulatory proteins p300 and Hdac3, and perhaps other nuclear 
proteins, are present in the vicinity of the Bcl6/Stat5 regulatory region. P300 and Hdac3 
do not appear to greatly modulate Bcl6-mediated repression of Socs2, Cish, and Bcl6 
expression. However, p300 and Hdac3 may be interacting with other nuclear proteins to 
regulate transcription, or have alternate regulatory functions such as remodeling the 




Bcl6 inhibits the Bcl6 promoter: p300 may function as a Bcl6 corepressor in regulation of 
Bcl6 expression 
 
Importantly, results from promoter activation assays for the Bcl6 promoter suggest that 
p300 may have a corepressive effect on Bcl6-mediated repression of Bcl6 transcription, 
either through interactions of p300 with other nuclear proteins, or due to an as yet 
unidentified activity of p300 on Bcl6 function. The corepressive effect of p300 on Bcl6-
mediated inhibition of Bcl6 expression also appears to depend on the accessibility of 
different regulatory regions to transcription factor or coregulator occupancy in the Bcl6 
promoter. The presence of Hdac3 did not appear to greatly alter Bcl6-mediated inhibition 
of Socs2 and Cish promoter construct expression. Hdac3 appeared to have a corepressive 
effect when associated with Bcl6 at the Bcl6 promoter. The corepressive effects of both 
p300 and Hdac3 on Bcl6-mediated inhibition of Bcl6 transcription suggest that Bcl6 
mRNA levels in adipocytes need to be tightly controlled and restricted to low levels, and 
overexpression of Bcl6 may be deleterious to the cell.  
 
Stat5, in conjunction with p300, activates Socs2 and Cish transcription in response to GH  
 
Upon GH treatment, Bcl6 occupancy at the Bcl6/Stat5 regulatory regions decreases for 
all three genes, either due to GH inhibiting Bcl6 expression, GH decreasing Bcl6 
occupancy, or both. At the same time, Stat5 occupancy increases, and Socs2 and Cish 
expression are induced, and Bcl6 expression is repressed, suggesting that Stat5 functions 
as an activator for Socs2 and Cish (Figure 5.3), and a repressor for Bcl6 expression in 
adipocytes (Figure 5.4). Promoter activation assays support this hypothesis; association 
of Stat5 with p300 at the Socs2 and Cish promoters appears to induce gene transcription 
(Figure 5.3).  
 
Stat5 may function as a repressor of Bcl6 gene expression 
 
Interestingly, based on our findings so far, the effects of Stat5 on Bcl6 promoter 













Model: Stat5 induces Socs2 and Cish expression upon GH treatment.  The Bcl6/Stat5 
regulatory regions of the Socs2 and Cish promoters are occupied by activated Stat5 in the 
presence of GH. The coregulatory proteins p300 and Hdac3, and perhaps other nuclear 
proteins, are present in the vicinity of the Bcl6/Stat5 regulatory region. P300 functions as 
a coactivator for Stat5-mediated induction of Socs2 and Cish transcription in response to 
GH. Hdac3 has an inhibitory effect on Stat5-mediated transcription of Socs2 and Cish. 
The corepressive effect of Hdac3 on Stat5-mediated Socs2 and Cish transcription could 
function as a mechanism to fine tune transcript levels or downregulate transcription. P300 
and Hdac3 may also be interacting with other nuclear proteins to regulate transcription, or 
have alternate regulatory functions such as remodeling the nearby chromatin structure. 


















Model: Stat5 may function as a repressor of Bcl6 transcription in the presence of 
GH.  The Bcl6/Stat5 regulatory region of the Bcl6 promoter is occupied by activated 
Stat5 in the presence of GH. The coregulatory proteins p300 and Hdac3, and perhaps 
other nuclear proteins, are present in the vicinity of the Bcl6/Stat5 regulatory region. 
Both p300 and Hdac3 appear to function as corepressors of Stat5-mediated transcription 
of Bcl6. Stat5, in conjunction with p300 and Hdac3, may be functioning as a repressor of 
Bcl6 expression in vivo. P300 and Hdac3 may also be interacting with other nuclear 
proteins to regulate transcription, or have alternate regulatory functions such as 
remodeling the nearby chromatin structure. Solid arrows indicate known interactions or 
relationships; dotted arrows indicate potential interactions. 
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gene expression when a short Bcl6 promoter fragment, consisting of about 200 base pairs 
with the Bcl6/Stat5 occupancy region identified by ChIP-Sequencing in the center, was 
used in the Bcl6 promoter construct. Stat5 did not have an activating effect on Bcl6 
reporter gene expression when a longer fragment of the Bcl6 promoter was used, and 
appeared to have a slight inhibitory effect. As endogenous Bcl6 expression is repressed 
by GH in adipocytes (8), it is likely that Stat5 is functioning as a repressor of Bcl6 
expression in adipocytes in the context of the native gene (Figure 5.4). Surprisingly, 
interaction of p300, which is typically a coactivator, with Stat5 on the Bcl6 promoter 
resulted in inhibition of Stat5-mediated Bcl6 reporter gene expression for both the short 
and long Bcl6 promoter constructs. This suggests that p300 corepression of Stat5-
mediated transcriptional repression may contribute to a mechanism by which Bcl6 
expression is inhibited by Stat5 in vivo.  
 
Hdac3 functions as a corepressor of Stat5-mediated transcription of Socs2, Cish, and 
Bcl6 
 
Hdac3 appeared to have a corepressive effect on Stat5-mediated transcription of Socs2 
and Cish, either due to interactions between Hdac3 and Stat5, Hdac3 and other nuclear 
proteins, or Hdac3 and the surrounding nucleosomes (Figure 5.3). The constitutive 
presence of Hdac3 at the Socs2 and Cish promoters, and the corepressive effects of 
Hdac3 on Stat5-mediated transcriptional activation of Socs2 and Cish expression may be 
indicative of a repressive regulatory mechanism that functions to prevent Socs2 and Cish 
overexpression, or as a mechanism to downregulate Socs2 and Cish expression after 
activation. As the Socs2 and Cish proteins are potent signaling inhibitors, it is logical that 
Socs2 and Cish mRNA levels would be tightly regulated. Another possibility is that p300 
and Hdac3 constitutively occupy the Socs2, Cish, and Bcl6 promoters in order to 
constantly remodel the surrounding chromatin and prime the gene for multiple cycles of 
transcription. Various studies have shown that lysine acetyltransferases and lysine 
deacetylases are both targeted to transcribed regions of active genes marked by 
phosphorylated RNA pol II, suggesting that the dynamic cycle of histone acetylation and 
deacetylation are both needed to prime genes for further activation (31-33). Hdac3 
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appears to have corepressive effects on Stat5-mediated transcriptional regulation of Bcl6 
gene expression (Figure 5.4), with the combined results of Stat5 and Hdac3 resulting in 
inhibition of Bcl6 reporter gene expression compared to basal levels or lower, once again 
suggesting that Bcl6 expression needs to be tightly regulated, and low levels of Bcl6 
expression are sufficient to carry out Bcl6 cellular functions in adipocytes. 
 
Future experiments will better characterize reciprocal regulation of Socs2, Cish, and 
Bcl6 expression by Bcl6 and Stat5 in response to GH 
 
Future experiments that manipulate the levels or activity of Bcl6, Stat5, p300 and Hdac3 
in cells followed by evaluation of Socs2, Cish, or Bcl6 transcript levels will help to better 
characterize the mechanisms and protein interactions involved in regulation of Socs2, 
Cish, and Bcl6 transcription. Of particular interest would be depletion of Bcl6 or Stat5 in 
cells, followed by rescue with mutant forms of Bcl6 or Stat5 deficient in DNA binding 
activity or protein interaction with p300 or Hdac3. Similar experiments in which p300 and 
Hdac3 levels are depleted and rescued with mutant p300 and Hdac3 lacking catalytic 
activity would evaluate whether the catalytic activities of p300 and Hdac3 are crucial to 
regulation of Socs2, Cish, and Bcl6 expression, or if p300 and Hdac3 may be primarily 
functioning as scaffold proteins for Bcl6, Stat5, or other proteins, similar to the CSL 
(CBF1/Suppressor of Hairless/Lag1) DNA-binding protein, which functions as a 
constitutively present tether at the Hes1 (hairy and enchancer of split-1) promoter for both 
corepressor and coactivator complexes (34, 35). ChIP experiments showing Stat5 
occupancy in liver from mice deficient in Bcl6 have demonstrated that Stat5 occupancy of 
the Socs2 promoter is not dependent on the previous occupancy of Bcl6, and co-
immunoprecipitation experiments have not detected protein-protein interactions between 
Bcl6 and Stat5 under experimental conditions currently tested. Therefore, it would also be 
interesting to observe if the presence of p300 or Hdac3 at the Socs2, Cish, or Bcl6 
promoters is required for the recruitment of or switch in occupancy between Bcl6 and 
Stat5 in response to GH, similar to the coregulator FOG1 (friend of GATA 1), which 




Identifying potential post-translational modifications on Bcl6, Stat5, p300 or Hdac3 in 
response to activation of GH signaling pathways, and the downstream effects these post-
translational modifications have on protein-protein interactions, transcriptional regulatory 
complex recruitment, and chromatin modification would also be of interest. For example, 
phosphorylation of murine C/EBP! at T188 in response to GH signaling is known to 
recruit p300 to C/EBP!, resulting in and activation of c-fos transcription (37). Similarly, 
the identification of other proteins involved in the Bcl6- or Stat5-mediated regulation of 
Socs2, Cish, or Bcl6 expression in response to GH, and how these proteins would function 
in the context of a Bcl6 or Stat5 transcriptional regulatory complex in association with 
p300 or Hdac3 would provide insight into the molecular mechanisms of gene regulation. 
 
Characterization of the multiple regulatory elements that appear to be present on the Bcl6 
promoter would provide insight into how multiple regulatory regions and their associated 
nuclear proteins coordinate to recruit RNA pol II and/or the basal transcriptional 
machinery to the gene promoter or remodel the surrounding chromatin to promote or 
inhibit transcription. Genomatix analysis of the Socs2, Cish, and Bcl6 promoters also 
revealed potential binding sites for other transcription factors, including the well-
characterized GH-regulated transcription factor C/EBP! (8). The Bcl6 corepressor ETO 
has been shown to interact with C/EBP! in preadipocytes and adipocytes and play a role 
in adipogenesis (38, 39). This suggests another mechanism by which GH can repress gene 
transcription. Potential interactions between Bcl6, ETO, and C/EBP! also suggest that 
Bcl6 could function as a cofactor instead of a direct transcription factor when regulating 
expression of GH target genes, similar to what is seen when Bcl6 represses the expression 
of CDKN1A (cyclin dependent kinase inhibitor 1A, p21) in germinal centers through its 
interaction with the transcriptional activator Miz1 (Myc-interacting zinc finger protein 1) 
(40). Results from future experiments examining the expanded mechanisms of Bcl6 and 
Stat5 action in regulation of GH target genes will provide insight into basic mechanisms 
of transcription, reciprocal regulation of transcription by a transcriptional activator and a 
transcriptional repressor, and mechanisms by which GH represses gene transcription. 
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Further considerations on the complexity of transcriptional regulation: Chromatin 
acetylation, transcription, and adaptability of gene regulation 
 
Proposed mechanisms of p300 and Hdac3 action on reciprocal regulation of Socs2, Cish, 
and Bcl6 expression by Bcl6 and Stat5 
 
P300 and Hdac3 have been identified in these studies as coregulatory factors that 
participate in Bcl6- and Stat5-mediated regulation of Socs2, Cish, and Bcl6 expression in 
response to GH (Figure 5.1). One mechanism by which these coregulators may be 
influencing the activity of Bcl6 or Stat5 may be through their enzymatic activities on 
Bcl6 or Stat5. Acetylation is known to play a role in regulating the activity of both Bcl6 
and Stat5. Acetylation of Bcl6 inhibits the ability of Bcl6 to recruit some corepressors 
and inhibit transcription (30), and a lysine deacetylase activity is necessary for Stat5 
transcriptional activity on some target genes, including Cish (41). Another possibility is 
that p300 and Hdac3 are serving as scaffold proteins in multi-protein transcription 
complexes, and it is the recruitment and interaction of other proteins to this complex that 
mediate the regulatory effects p300 and Hdac3 have on Bcl6, Stat5, and gene expression. 
Co-immunoprecipitation experiments suggest that Bcl6 and Stat5 do not reside in the 
same protein complex when regulating expression of Socs2, Cish, and Bcl6. However, it 
appears that p300 and Hdac3 occupy the promoters of these genes both in the absence 
and presence of GH and may interact with both Bcl6 and Stat5 when the transcription 
factors are recruited. Therefore, Bcl6 and Stat5 may be the changing components in a 
promoter-associated transcriptional regulatory complex where p300 and Hdac3 act 
selectively depending on the identity of the transcription factor occupying the promoter 
(Figure 5.1). A third possibility is that p300 and Hdac3, as a lysine acetyltransferase and 
lysine deacetylase, respectively, may function at the promoters of these Bcl6/Stat5 target 
genes to modify the chromatin state of these genes as dynamic cycle of histone 




P300 and Hdac3 may function to regulation histone acetylation at the Socs2, Cish, and 
Bcl6 promoters 
 
ChIP for general activating histone marks showed that acetylated histone H3 and 
acetylated histone H4 signal increased from 2 to 5 fold on the Socs2 and Cish promoters 
in response to GH in adipocytes, correlating with induction of gene expression upon 
treatment. Acetylation of histones is indicative of open chromatin, which is conducive to 
active transcription (31), and the actions of p300 on the Socs2 and Cish promoters may 
be to acetylate histones and remodel the surrounding chromatin. Enrichment of acetylated 
histones near the Bcl6 promoter increased as well, but to a much lesser extent, suggesting 
that the chromatin needs to remain accessible to the transcriptional machinery, as changes 
in the transcription level of Bcl6 may need to be modulated at any time. Similarly, the 
role of Hdac3 may be to inhibit or balance the extent of histone acetylation at the Bcl6 
promoter, and may also function to downregulate Socs2 and Cish expression at later time 
points, or upon the loss of GH signal, by compressing the chromatin structure to render it 
temporarily inaccessible or less available for transcription factor binding. 
 
While the enrichment patterns of acetylated histone marks supports potential roles for 
p300 and Hdac3 in regulating transcription by remodeling the chromatin at these gene 
promoters, recent studies suggest that the relationship between the chromatin structure 
and gene transcription is even more complex than previously thought. Using mutant 
mouse fibroblasts with both p300 and CBP knocked out, it was demonstrated that 
p300/CBP are chiefly responsible for global acetylation of histone H3, and the p300/CBP 
knock out cells exhibited strongly attenuated histone H4 acetylation at CREB target 
genes in response to cyclic-AMP. However, transcription at these genes was not 
uniformly inhibited, and results suggested that the recruitment of p300/CBP to a genomic 
location, and the associated histone acetylation marks being present at this site, do not 
absolutely correlate as a requirement of gene activation. Target gene context, such as the 
DNA sequence, appeared to influence the extent to which p300 and CBP were necessary 
for transcription at target genes.  Transcription in the absence of p300/CBP correlated 
with genes having more cyclic AMP response elements, more bound CREB (cyclic AMP 
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response element binding protein) transcription factor, and more CRTC2 (cAMP-
response element binding protein-regulated transcription coactivator 2, a non-histone 
acetyltransferase CREB coactivator). The results suggested that genes with a greater local 
concentration and diversity of coregulators had more resilient-inducible expression, and 
regulation of these genes was less dependent on the presence of any one cofactor or 
cofactor-induced chromatin remodeling (42, 43).  
 
The Bcl6 promoter likely contains multiple regulatory sequences to coordinate complex 
transcriptional regulatory input factors 
 
As p300 and Hdac3 appear to interact with both Bcl6 and Stat5 on the Bcl6 promoter, 
and differences are observed in coregulator and transcription factor interactions when 
Bcl6 promoter sequences located adjacent to or more distal from the Bcl6/Stat5 
occupancy site are tested in promoter activation assays (Chapter 4, Figure 4.10), there 
appear to be multiple regulatory sequences in the Bcl6 promoter and multiple 
coregulators providing transcriptional input. It is appealing to hypothesize that Bcl6 
transcription is being regulated by multiple cofactors and nucleoprotein interactions using 
a variety of highly adaptive mechanisms. Promoter reporter gene assays suggest that 
p300 and Hdac3 do not greatly alter Bcl6-mediated repression of Socs2 and Cish 
expression, and full induction of Socs2 and Cish transcription in response to GH is 
dependent on the presence of both activated Stat5 and p300, suggesting that regulation of 
Socs2 and Cish transcription is highly dependent on Bcl6, Stat5, and p300, and loss of 
any one factor would cause a larger perturbance to gene expression levels of Socs2 and 
Cish, compared to Bcl6. This is supported by the observation that basal Socs2 mRNA 
levels increase in livers of Bcl6 knock out mice (Figure 3.2), but a corresponding increase 
in Stat5 occupancy was not observed at the Socs2 promoter (Figure 3.3A).  
 
During initial screens to identify potential coregulator candidates involved in the 
mechanism of reciprocally mediated Bcl6/Stat5 transcription, the occupancy of several 
other corepressor molecules reported to interact with Bcl6 in immune cells, such as CtBP 
(44) and the Bcl6 specific corepressor BCoR (45), were also probed for by ChIP in 
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adipocytes (data not shown). In particular, the Bcl6 corepressor ETO (46) had been shown 
previously to interact with C/EBP! in adipocytes and preadipocytes, and participate in 
adipogenesis (39). However, occupancy signals for all of the corepressors tested were 
extremely low and subsequent experiments focused on characterizing p300 and Hdac3 
action on Bcl6- or Stat5-mediated transcription. Concerns with antibody quality aside, 
these results would once again support the hypothesis that occupancy of Bcl6 and Stat5, 
rather than coregulators, are major determinants of transcriptional output for Socs2, Cish, 
and Bcl6, and the regulatory input provided by coregulators is likely for the purposes of 
fine-tuning expression levels. However, of the three genes tested, ChIP signals for several 
of the known Bcl6 corepressors were higher for the Bcl6/Stat5 regulatory region of the 
Bcl6 promoter compared to Socs2 and Cish, suggesting that these coregulators may also 
play a role in regulation of Bcl6 expression in adipocytes, and regulation of Bcl6 
expression may be fine tuned by the input of multiple coregulatory molecules. If 
regulation of Bcl6 transcription is indeed influenced by input from multiple coregulatory 
molecules in addition to p300 and Hdac3, this could be another difference in mechanisms 
by which Bcl6 and Stat5 are regulating Bcl6 expression in response to GH, in contrast to 
the regulation of Socs2 and Cish, which could be more dependent on p300, Hdac3, and 
chromatin acetylation than Bcl6.  
 
On a last note, Bcl6 and Stat5 are both transcription factors strongly regulated in response 
to GH signaling. It is interesting that of the current genes known to be regulated by both 
Bcl6 and Stat5 in response to GH using a Bcl6/Stat5 dual regulatory region, Socs2 and 
Cish are negative regulators of cytokine and GH signaling (47, 48), while Bcl6 is 
predicted to be a major repressor of GH target genes (8, 24, 49). Speculation would infer 
that genes strongly regulated by both Bcl6 and Stat5 in response to GH may be genes that 
enhance or suppress the GH signal in the cell and provide feedback on the status of 
hormone stimulation. Analysis of high throughput ChIP-Sequencing results and GH 
microarray data will provide more candidate Bcl6 target genes and candidate Bcl6/Stat5 
reciprocally regulated genes to help us further understand this repressor-activator 





In summary, through the work in this thesis, we have expanded our understanding of 
mechanisms by which GH can repress transcription of target genes, identified regulatory 
roles that the novel GH-regulated transcriptional repressor Bcl6 might be playing in GH 
action, and characterized the molecular mechanisms underlying differential 
transcriptional regulation of GH target genes by reciprocal occupancy of Bcl6 and Stat5. 
Future work characterizing novel Bcl6 target genes in GH action and the mechanism of 
reciprocal Bcl6- and Stat5-mediated transcriptional regulation will continue to provide 
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